

Supplemental Online Content

Sung H, Hyun N, Leach CR, Yabroff KR, Jemal A. Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States. *JAMA*. doi:10.1001/jama.2020.23130

eFigure 1A. Excess Absolute Risk of Developing Subsequent Primary Cancers Among 5-Year Cancer Survivors by Sex

eFigure 1B. Excess Absolute Risk of Dying From Subsequent Primary Cancers Among 5-Year Cancer Survivors by Sex

eFigure 2. Standardized Incidence Ratios for the Risk of Subsequent Primary Cancer (A, B) and Standardized Mortality Ratios for the Risk of Dying From a Subsequent Primary Cancer (C, D) With Statistically Significant Lower-Than-Expected Values by Sex

eFigure 3. Risk of Developing Any Alcohol- or Infection-Related Subsequent Primary Cancers Among Survivors of Prior Alcohol- or Infection-Related Cancers

eFigure 4. Ratios of Standardized Incidence Ratios for Select Subsequent Primary Cancer Types Among 5-Year Cancer Survivors by First Primary Cancer Diagnosis Year (1975-1989, 1990-1999, 2000-2011) in 9 SEER Registries

eTable 1. Characteristics Of The Survivors Who Were Diagnosed With An Invasive First Primary Cancer From 1975-2011 At Ages 20-84 And Who Survived For 5 Years Or Longer in 9 SEER registries

eTable 2. Classification Of Cancer Types Based on ICD-O-3 Site and Type Code and Definitions of The Same-Type Cancers

eTable 3. Definitions and Classification of Smoking-, Obesity-, Alcohol-, and Infection-Related Cancers

eTable 4. Number of Survivors and Person-Years of Follow-Up Included in the Mortality Analysis by First Primary Cancer Sites and Sex

eTable 5. Risks of Developing or Dying from Subsequent Primary Cancers Among 5-Year Survivors of Other and Unspecified Primary Cancer Sites by Sex

eTable 6. Risks of Developing Specific Type of Subsequent Primary Cancer Among 5-Year Cancer Survivors in 12 SEER Registries: Incidence, Percent Contribution to the Total Incidence, Standardized Incidence Ratio by First Primary Cancer Types and Sex

eTable 7. Risks of Dying from a Specific Type of Subsequent Primary Cancer Among 5-Year Cancer Survivors in 12 SEER Registries: Mortality, Percent Contribution to the Total Mortality, Standardized Mortality Ratio by First Primary Cancer Types and Sex

eTable 8. Percentage Contribution of Each Subsequent Primary Cancer Types to the Total Incidence of Subsequent Primary Cancer and to the Total Subsequent Primary Cancer Mortality Among All 5-Year Cancer Survivors by Sex in 12 SEER Registries

eTable 9. Risk of Developing Any Smoking- or Any Obesity-Related Subsequent Primary Cancers Among Smoking or Obesity-Related Cancer Survivors

eTable 10. Standardized Incidence Ratios and Ratios of Standardized Ratios by Diagnosis Year (1975-1989, 1990-1999, 2000-2011) for the Risk of Select 6 Subsequent Primary Cancers Among 5-Year Survivors of 16 First Primary Cancer Types in 9 SEER Registries

eTable 11. Results Based on a Single Outcome Analysis for the Risk of Developing Subsequent Primary Cancer Overall Among 5-Year Cancer Survivors in 12 SEER Program Registries

eTable 12. Results Based on the Earlier Start of Follow-Up (Since 1 Year From First Primary Cancer Diagnosis) for the Risk of Developing Subsequent Primary Cancer Overall Among 1-Year Cancer Survivors in the 12 SEER Registries

eReferences.

This supplemental material has been provided by the authors to give readers additional information about their work.

eMethods

The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program¹

Data for cancer incidence and mortality were obtained from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program, which includes population-based cancer registries that capture information by law on all cancer diagnoses occurring among residents within a geographically defined area. The SEER Program registries routinely collect data on patient demographics, primary tumor site, tumor morphology and stage at diagnosis, first course of treatment, and follow-up for vital status. The mortality data reported by SEER are provided by the National Center for Health Statistics. The population data used in calculating cancer rates is obtained periodically from the Census Bureau.

Race determination in the SEER Program

Race determination in the SEER Program is based on all resources in the facility, including the medical record, face sheet, physician and nursing notes, photographs, electronic data, and any other sources. When race is not stated but other information is provided in the medical record, Race Coding is based on Appendix D, Race And Nationality Descriptions From the 2000 U.S. Census Bureau and National Center for Health Statistics.² SEER race fields makes it possible to code multiple races for one person, consistent with the 2000 Census.³ In this study, race was classified as 5 groups: White, Black, American Indian/Alaska Native (AI/AN), Asian/Pacific Islander (API), and unknown. For incidence analysis, persons with AI/AN and API were combined as a group, and persons with unknown race were combined with White so this group can be matched with racial groups in the incidence reference file. For mortality analysis, AI/AN and API were combined as a group, and persons with unknown race (n=14,947; 1%) were excluded from the analysis for the compatibility in the race matching with the reference mortality file.

Study population

To examine the recent pattern of the risk for developing and dying from new malignancies among cancer survivors, we identified survivors who were diagnosed with an invasive first primary cancer at ages 20-84, excluding non-melanoma skin cancer, during 1992-2011 and who survived 5 years or more, from the 12 SEER registries (Atlanta (Metropolitan), Connecticut, Detroit (Metropolitan), Hawaii, Iowa, Los Angeles, New Mexico, Rural Georgia, San Francisco-Oakland SMSA, San Jose-Monterey, Seattle (Puget Sound), Utah, covering approximately 13%

of the US population.^{4,5} Alaska registry, in the SEER 13 Program, was excluded because of incompatibility of the reference file in the race matching. We excluded survivors with cancer diagnosis based only on autopsy reports or death certificates. Cancers were classified according to the tenth *International Classification of Diseases for Oncology 3rd edition* (ICD-O-3) (30 types in men and 31 types in women; **eTable 2**) and categorized according to SEER site groups.⁶ Chronic lymphocytic leukemia was classified into a subtype of non-Hodgkin lymphoma according to the 2001 WHO classification of lymphoid neoplasms.⁷

To examine long-term temporal trend in the risk of developing new malignancies, we identified 5-year survivors whose first primary cancers were diagnosed during 1975-2011 from the 9 SEER registries (Atlanta (Metropolitan), Connecticut, Detroit (Metropolitan), Hawaii, Iowa, New Mexico, San Francisco-Oakland SMSA, Seattle (Puget Sound), Utah), using the aforementioned method.⁸

Primary outcomes

The primary outcomes were incidence (per 10,000 person-years) and relative risk of developing SPCs among 5-year survivors of FPCs (standardized incidence ratio [SIR]). The secondary outcomes were mortality and relative risk of dying from a SPC (death from non-index cancer) among survivors (standardized mortality ratios [SMR]).

Follow-up and ascertainment of subsequent primary cancers

Survivors were followed from 5 years since FPC diagnosis until death, loss to follow-up (n=61,153, 4.0% in the 12 SEER registries; 22,472, 3.0% in the 9 SEER registries), attaining age at 89 (due to concerns regarding under-ascertainment in elderly population)⁹, or December 31, 2017, whichever came first. SPCs were ascertained following the SEER rules for Determining Multiple Primaries, considering the type of organ, date of diagnosis, histology, tumor behavior, and laterality of paired organ.¹⁰ “Overall SPCs” included all new primary cancers except same-type cancer (to minimize bias due to misclassification of recurrence) and non-melanoma skin cancer (definitions of same-type cancer in **eTable 2**). Further, for some organs, we extended definitions of same-type cancers to the anatomical types close to FPCs to reduce bias due to heightened medical surveillance of adjacent regions as well as artifactually decreased risks when surgery for the initial tumor often removes one or more closely located organs from risk. To take into account SPCs that take years of latency (e.g., radiotherapy-induced cancer)¹¹ and/or occur relatively in older ages, multiple events in a survivor were

allowed; therefore, survivors remained in the study after experiencing prior SPCs before censoring.

Cause of death was based on death certificate information reported to state vital statistics offices and compiled into a national file through CDC's National Center for Health Statistics' National Vital Statistics System.¹² The underlying causes of death were selected according to ICD-10 and then categorized according to SEER site groups.

Statistical analysis

We quantified the risk of developing SPCs among cancer survivors using incidence per 10,000 person-years and SIRs for overall and type-specific (organ-specific) SPCs in each of survivor groups of FPC and all survivors combined. For type-specific risks, analyses were limited to SPCs with 5 or more observed number of cases. The risk of dying from any type of SPCs (non-index cancers) among cancer survivors were measured using mortality per 10,000 person-years and standardized mortality ratios (SMR) in each of survivor groups of FPCs, using the same approach for incidence delineated below.

We define the following notation:

- (1) PY_i denotes the person-years at risk since the development of FPC i .
- (2) O_{ij} denotes the observed number of cases for SPC j during PY_i .
- (3) E_{ij} denotes the expected number of SPC j among survivors of FPC i and is calculated by $\sum_{s \in S} PY_{is} \times \lambda_{js}$, where S is the list of strata determined by race (white/unknown, Black, AI/AN/API), sex, age (5-year) and calendar year (1992-1994, 1995-1999, 2000-2004, 2005-2009, 2010-2014, 2015-2017) and λ_{js} is the incidence rate for cancer j in the general population within stratum s .

Incidence per 10,000 person-years and percentage contribution to the total incidence

Incidence of SPCs per 10,000 person-years among each survivor group of FPCs and all survivors combined were obtained by $O_{ij} \times 10,000/PY_i$ and $\sum_i O_{ij} \times 10,000/PY$, respectively. Note that $PY = \sum_i PY_i$. The confidence intervals were calculated under the assumption that the occurrence of subsequent cancers follows a Poisson distribution with the calculated incidence as a mean. The percentage contribution of each FPC-SPC combination to the overall absolute

risk of all SPCs among all survivors was calculated by $(O_{ij}/PY)/(\sum_{ij} O_{ij}/PY)$, that is $O_{ij}/\sum_{ij} O_{ij}$.

Standardized incidence ratio (SIR) and excess absolute incidence per 10,000 person-years

The SIR was calculated as the ratio of the observed-to-expected number of SPCs, that is, O_{ij}/E_{ij} and $\sum_j O_{ij}/\sum_j E_{ij}$ for type-specific SIR and SIR for all types of SPCs by FPCs, respectively.⁹ The corresponding excess absolute incidence per 10,000 person-years for type-specific SIR was obtained by $(O_{ij} - E_{ij}) \times 10,000/PY_i$.

Risk of developing any type of smoking-, obesity-, alcohol-, or infection-related cancer among survivors of first primary cancers associated with each of risk factors

Among each of survivor groups of 12 smoking-related cancers¹³, incidence per 10,000 person-years and SIRs (95% CIs) were estimated to quantify the risk of developing any types of smoking-related SPCs except for SPCs that occurred at the same site as the FPC. The same approach was used to quantify the risk of developing any types of obesity-¹⁴, alcohol-¹⁵, and infection-related¹⁶ cancers. The definitions of cancer groups according to risk factors were presented in **eTable3**.

Temporal trend analysis

For the select 6 SPCs for EAR, SIRs were calculated for each of the 16 top FPC survivors in men and women combined by diagnosis years (1975-1989, 1990-1999, 2000-2011) based on data from the 9 SEER registries. We used a multi-covariate Poisson regression model to test the trend in SIRs (ratio of SIR, RR) over diagnosis years. The model included the observed number of cases as the outcome, the log of expected number of cases as an offset to indirectly adjust for attained age and attained year of SPCs, and age at first cancer diagnosis (20-39, 40-64, 65-84 years), sex, and time since first cancer diagnosis (60-119, 120-179, 180+ months) as covariables.^{17,18}

We tested the linear term for the three periods in the regression model by using likelihood ratio test. It was assessed the goodness-of-fit of the model by using Chi-square test based on deviance. The model reasonably explained most the select FPC-SPC combinations (lack-of-fit results in 10 p-values<0.05 in total and 4 p-values<0.05 in men/women). The goodness-of-fit

test is sensitive to observed number of cases. Thus, we reported p-values as those were unless point estimates for the regression coefficients and standard errors seem reliable according to the empirical distributions for point estimates and standard errors. To quantify change rates in SIRs, we calculated the ratio of SIRs by using the fitted model and letting 1975-1989 SIR be the reference.

Sensitivity analyses



Sensitivity analyses were performed to determine whether the overall risks of developing SPCs are affected by restricting the risk of SPCs to only the first SPC (disallowing multiple events in an individual) or by starting follow-up for occurrence of SPCs 1 year since FPC diagnosis (without change in allowing multiple events in an individual). In the analysis restricted to the first SPC, survivors were censored at diagnosis of the first SPC, death, loss to follow-up, attaining age at 89, or December 31, 2017, whichever came first.

All analyses were stratified by sex except the trend analysis. Statistical significances were two-sided, p-values less than <0.05 . The tests, however, did not consider multiple comparison correction as this analysis was exploratory. All analyses were performed using the “MP-SIR” session of SEER*Stat 8.3.6,¹⁹ SAS 9.4, and Microsoft Excel Office 365 ProPlus.

eFigure 1A. Excess absolute incidence per 10,000 person-years for subsequent primary cancers (A, C) and corresponding percentage contributions of any given first primary cancer-subsequent primary cancer combination to the total excess absolute incidence (B, D) by sex among 5-year cancer survivors



(A) Men, Excess Absolute Incidence per 10,000 Person-years

(B) Men, Percentage Contribution to the Total Excess Absolute Incidence



(C) Women, Excess Absolute Incidence per 10,000 Person-years


(D) Women, Percentage Contribution to the Total Excess Absolute Incidence



eFigure 1B. Excess absolute mortality per 10,000 person-years for subsequent primary cancers (A, C) and corresponding percentage contributions of any given first primary cancer-subsequent primary cancer combination to the total excess absolute mortality (B, D) by sex among 5-year cancer survivors



(A) Men, Excess Absolute Mortality per 10,000 Person-years

(B) Men, Percentage Contribution to the Total Excess Absolute Mortality



(C) Women, Excess Absolute Mortality per 10,000 Person-years



(D) Women, Percentage Contribution to the Total Excess Absolute Mortality




eFigure 2. Standardized incidence ratios for the risk of subsequent primary cancer (A, B) and standardized mortality ratios for the risk of dying from a subsequent primary cancer (C, D) with statistically significant lower-than-expected values by sex

(A) Men, Standardized Incidence Ratio


(B) Women, Standardized Incidence Ratio



(C) Men, Standardized Mortality Ratio




(D) Women, Standardized Mortality Ratio




eFigure 3. Risk of developing any alcohol- or infection-related subsequent primary cancers among survivors of prior alcohol- or infection-related cancers

(A) The risk of developing any subsequent alcohol-related cancers among survivors of alcohol-related first primary cancers




(B) The risk of developing any subsequent infection-related cancers among survivors of infection-related first primary cancers



NOTE: Among each group of survivors of 7 alcohol-related cancers¹⁵, incidence per 10,000 person-years and SIRs were estimated to quantify the risk of developing any alcohol-related SPCs (except for SPCs that occurred at the same site as the FPC). Similarly, among each group of survivors of 10 infection-related cancers¹⁶, incidence per 10,000 person-years and SIRs were estimated for the risk of developing any infection-related SPCs. The risk of developing subsequent alcohol- or infection-related cancer after each of FPCs cannot be entirely attributable to alcohol or infection because of other risk factors. Refer to **eTable3** for definitions and classifications of alcohol- and infection-related cancers.

eFigure 4. Ratios of standardized incidence ratios for select subsequent primary cancer types among 5-year cancer survivors by first primary cancer diagnosis year (1975-1989, 1990-1999, 2000-2011) in 9 SEER registries



Abbreviations: CI, confidence interval; NOS, not otherwise specified; SEER, Surveillance, Epidemiology and End Results

Note: P_{trend} in the SIRs were tested using the likelihood ratio test for the linear diagnosis year term in a multi-covariate Poisson regression model. The model included the observed number of cases as an outcome, calendar year of (1975-1989 [reference], 1990-1999, 2000-2011), age at (20-39, 40-64, 66-84 years), and time since first cancer diagnosis (60-119, 120-179, 180+ months) and sex as covariables, and the log of the expected number of cases as an offset to indirectly adjust for attained age and attained year of SPCs. The linear trend for same-site subsequent primary cancer among survivors were not tested. All point estimates (95% CI) can be found in **eTable10**.

eTable 1. Characteristics of the survivors who were diagnosed with an invasive first primary cancer from 1975-2011 at ages 20-84 and who survived for 5 years or longer in 9 SEER registries

	Survivors		Person-years of follow-up since 5 years from first primary cancer	
	N	%	Total	Mean
Total	1669351	100	15030109	9.0
Sex				
Male	819,290	49.1	6612348	8.1
Female	850,061	50.9	8417762	9.9
Age at first primary cancer diagnosis				
20-39 years	152,374	9.1	2232405	14.7
40-64 years	820,822	49.2	8558360	10.4
65-84 years	696,155	41.7	4239344	6.1
Calendar year of first primary cancer diagnosis				
1975-1989	448,868	26.9	5776238	12.9
1990-1999	483,349	29.0	5186392	10.7
2000-2011	737,134	44.2	4067479	5.5
Survivors entering follow-up interval				
60-119 months	1,669,351	100.0	6776988	4.1
120-179 months	1,045,405	62.6	4019931	3.8
180+ months	599,016	35.9	4233190	7.1
Race				
White	1,418,216	85.0	12950609	9.1
Black	134,445	8.1	1070739	8.0
Asian or Pacific Islander	98,589	5.9	855902	8.7
Unknown	10,250	0.6	86490	8.4
American Indian/Alaska Native	7,851	0.5	66368	8.5
SEER registry recoded for first primary cancer				
Detroit (Metropolitan)	277,604	16.6	2484292	8.9
Seattle (Puget Sound)	262,233	15.7	2348222	9.0
San Francisco-Oakland SMSA	259,800	15.6	2403567	9.3
Connecticut	255,991	15.3	2316091	9.0
Iowa	207,143	12.4	1839226	8.9
Atlanta (Metropolitan)	139,871	8.4	1268111	9.1
Utah	101,270	6.1	898511	8.9
New Mexico	93,741	5.6	812214	8.7
Hawaii	71,698	4.3	659877	9.2
SEER Historic Stage				
Localized	761,926	45.6	7738233	10.2
Localized/regional (Prostate cases)	241,012	14.4	1602269	6.6
Regional	296,621	17.8	2634122	8.9
Distant	88,703	5.3	592378	6.7
Unstaged	143,041	8.6	1316253	9.2
Blank(s)	138,048	8.3	1146854	8.3
Reasons for exit of the current study				
End of Study	538,898	73.1	-	-
Death	175,764	23.8	-	-
Lost to Follow-up	22,472	3.0	-	-

eTable 2. Classification of cancer types based on ICD-O-3 Site and Type code and definitions of the same-type cancers

Cancer Types	ICD-O-3 Site	ICD-O-3 Histology	Definitions of same-site subsequent cancer ^a
Oral Cavity and Pharynx	C000-C009, C019-C029, C079-C089, C040-C049, C030-C039, C050-C059, C060-C069, C110-C119, C090-C099, C100-C109, C129, C130-C139, C140, C142, C148	Any histologies excluding 9050-9055, 9140, 9590-9992	-
Esophagus	C150-C159		-
Stomach	C160-C169		-
Small Intestine	C170-C179		-
Colon and Rectum	C180, C181, C182, C183, C184, C185, C186, C187, C188-C189, C260, C199, C209		Colon and Rectum, Anus, Anal Canal and Anorectum
Anus (and Anal Canal and Anorectum)	C210-C212, C218		-
Liver (and Intrahepatic Bile Duct)	C220, C221, C239		-
Gallbladder (and Other Biliary)	C239, C240-C249		-
Pancreas	C250-C259		-
Other Digestive Organs (including Retroperitoneum, Peritoneum, Omentum and Mesentery) ^b	C480, C481-C482, C268-C269, C488		-
Larynx	C320-C329		-
Lung (and Bronchus)	C340-C349		-
Other Respiratory Organs (including Nose, Nasal Cavity and Middle Ear, Pleura, Trachea, and Mediastinum) ^b	C300-C301, C310-C319 (Nose, Nasal Cavity and Middle Ear), C384 (Pleura), C339, C381-C383, C388, C390, C398, C399 (Trachea, Mediastinum and Other Respiratory Organs)		-
Bones and Joints	C400-C419		-
Soft Tissue including Heart	C380, C470-C479, C490-C499		-
Melanoma of the Skin	C440-C449	8720-8790	-
Breast	C500-C509	Any histologies excluding 9050-9055, 9140, 9590-9992	-
Cervix Uteri	C530-C539		-
Corpus and Uterus, Not Otherwise Specified	C540-C549, C559		Corpus and Uterus, NOS, Cervix Uteri, Ovary, and all Other Female Genital Organs
Ovary	C569		Corpus and Uterus, NOS, Cervix Uteri, Ovary, and all Other Female Genital Organs

Cancer Types	ICD-O-3 Site	ICD-O-3 Histology	Definitions of same-site subsequent cancer ^a
Vulva and Other Genital Organs	C529, C510-C519, C570-C579, C589		-
Prostate	C619		-
Testis	C620-C629		-
Penis and Other Genital Organs	C600-C609, C630-C639		-
Kidney and Renal Pelvis	C649, C659		-
Urinary Bladder	C670-C679		Urinary Bladder, Ureter, and Other Urinary Organs
Other Urinary Organs (including Ureter) ^b	C669, C680-C689		Urinary Bladder, Ureter, and Other Urinary Organs
Eye and Orbit	C690-C699		-
Brain and Other Nervous System	C710-C719, C700-C709, C720-C729		-
Thyroid	C739		-
Other Endocrine Organs (including Thymus) ^b	C379, C740-C749, C750-C759		-
Hodgkin Lymphoma			-
<i>Hodgkin – Nodal</i>	C024, C098-C099, C111, C142, C379, C422, C770-C779	9650-9667	
<i>Hodgkin - Extranodal</i>	Any sites		
Non-Hodgkin Lymphoma			-
<i>Non-Hodgkin Lymphoma – Nodal</i>	C024, C098, C099, C111, C142, C379, C422, C770-C779	9590-9597, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687-9691, 9695, 9698-9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735, 9737-9738, 9811-9818, 9823, 9827, 9837	
<i>Non-Hodgkin Lymphoma – Extranodal</i>	All sites except C024, C098-C099, C111, C142, C379, C422, C770-C779	9590-9597, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687, 9688, 9689-9691, 9695, 9698-9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735, 9737, 9738	
	All sites except C024, C098-C099, C111, C142, C379, C420-C422, C424, C770-C779	9811-9818, 9823, 9827, 9837	
<i>Chronic Lymphocytic Leukemia</i>	C420, C421, C424	9823	
Myeloma	Any sites	9731-9732, 9734	-
Acute Non-Lymphocytic Leukemia			-

Cancer Types	ICD-O-3 Site	ICD-O-3 Histology	Definitions of same-site subsequent cancer ^a
<i>Acute Myeloid Leukemia</i>	Any sites	9840, 9861, 9865-9867, 9869, 9871-9874, 9895-9897, 9898, 9910-9911, 9920	Acute Non-Lymphocytic Leukemia; <i>Chronic Myeloid Leukemia</i>
<i>Acute Monocytic Leukemia</i>	Any sites	9891	
<i>Other Acute Leukemia</i>	Any sites	9801, 9805-9809, 9931	
<i>Acute Lymphocytic Leukemia</i>	Any sites	9826, 9835-9836	-
	C420, C421, C424	9811-9818, 9837	-
<i>Chronic Myeloid Leukemia</i>	Any sites	9863, 9875-9876, 9945-9946	<i>Chronic Myeloid Leukemia</i> ; Acute Non-Lymphocytic Leukemia
Other Leukemia ^b			-
<i>Other Lymphocytic Leukemia</i>	Any sites	9820, 9832-9834, 9940	-
<i>Other Myeloid/Monocytic Leukemia</i>	Any sites	9860, 9930	-
<i>Aleukemic, subleukemic and Not Otherwise Specified</i>	Any sites	9733, 9742, 9800, 9831, 9870, 9948, 9963-9964	-
	C420, C421, C424	9827	-
Mesothelioma ^b		9050-9055	-
Kaposi Sarcoma		9140	
Miscellaneous ^b		9740-9741, 9750-9769, 9950, 9960-9962, 9965-9967, 9970-9971, 9975, 9980, 9982-9987, 9989, 9991-9992	-
	C760-C768, C809, C420-C424, C770-C779	All histologies excluding 9050-9055, 9140, 9590-9992	-

NOTE Modified from the Site Recode ICD-O-3/WHO 2008 Definition by SEER program (https://seer.cancer.gov/siterecode/icdo3_dwhohome/index.html).

^aIndicated only when it is different from the first primary cancer

^bCombined as a group, "Other and unspecified primary sites", in the main analysis.

eTable3. Cancers grouped by risk factors including smoking, obesity, infection, and alcohol consumption

<i>Smoking-associated cancers</i> ¹³	<i>Classification</i>
Oral Cavity and Pharynx	eTable2
Esophagus	eTable2
Stomach	eTable2
Colon and Rectum	eTable2
Liver and Intrahepatic Bile Duct	eTable2
Pancreas	eTable2
Larynx	eTable2
Lung and Bronchus	eTable2
Cervix Uteri	eTable2
Kidney and Renal Pelvis	eTable2
Urinary Bladder	eTable2
Acute Non-Lymphocytic Leukemia	eTable2
<i>Obesity-associated cancers</i> ¹⁴	<i>Classification</i>
Gallbladder and Other Biliary	eTable2
Pancreas	eTable2
Stomach Cardia	{Site and Morphology.Site recode ICD-O-3/WHO 2008} = ' Stomach' AND {Site and Morphology.Primary Site - labeled} = 'C16.0-Cardia, NOS'
Thyroid	eTable2
Kidney and Renal Pelvis	eTable2
Esophageal Adenocarcinoma	{Site and Morphology.Site recode ICD-O-3/WHO 2008} = ' Esophagus' AND {Site and Morphology.ICD-O-3 Hist/behav, malignant} = '8140/3: Adenocarcinoma, NOS','8141/3: Scirrhus adenocarcinoma','8143/3: Superficial spreading adenocarcinoma','8144/3: Adenocarcinoma, intestinal type','8145/3: Carcinoma, diffuse type','8190/3: Trabecular adenocarcinoma','8200/3: Adenoid cystic carcinoma','8201/3: Cribriform carcinoma, NOS','8210/3: Adenocarcinoma in adenomatous polyp','8211/3: Tubular adenocarcinoma','8213/3: Serrated adenocarcinoma','8214/3: Parietal cell carcinoma','8215/3: Adenocarcinoma of anal glands','8220/3: Adenocarcinoma in adenomatous polyposis coli','8221/3: Adenocarcinoma in multiple adenomatous polyps','8230/3: Solid carcinoma, NOS','8231/3: Carcinoma simplex','8260/3: Papillary adenocarcinoma, NOS','8261/3: Adenocarcinoma in villous adenoma','8262/3: Villous adenocarcinoma','8263/3: Adenocarcinoma in tubulovillous adenoma','8310/3: Clear cell adenocarcinoma, NOS','8401/3: Apocrine adenocarcinoma','8480/3: Mucinous adenocarcinoma','8481/3: Mucin-producing adenocarcinoma','8482/3: Mucinous adenocarcinoma, endocervical type','8490/3: Signet ring cell carcinoma','8550/3: Acinar cell carcinoma','8551/3: Acinar cell cystadenocarcinoma','8570/3: Adenocarcinoma with squamous metaplasia','8571/3: Adenocarcinoma with cartilaginous and osseous metaplasia','8572/3: Adenocarcinoma with spindle cell metaplasia','8573/3: Adenocarcinoma with apocrine metaplasia','8574/3: Adenocarcinoma with neuroendocrine differentiation','8576/3: Hepatoid adenocarcinoma'
Colon and Rectum	eTable2
Corpus and Uterus, NOS	eTable2
Breast	eTable2
Ovary	eTable2
Multiple Myeloma	{Site and Morphology.Site recode ICD-O-3/WHO 2008} = ' Myeloma' AND {Site and Morphology.ICD-O-3 Hist/behavior, labeled} = '9732/3: Plasma cell (multiple) myeloma'
Liver and Intrahepatic Bile Duct	eTable2
<i>Infection-associated cancers</i> ¹⁶	<i>Classification</i>
Oral Cavity and Pharynx (only HPV associated)	{Site and Morphology.Site recode ICD-O-3/WHO 2008} = ' Oral Cavity and Pharynx' AND {Site and Morphology.Primary Site - labeled} = 'C01.9-Base of tongue, NOS','C02.4-Lingual tonsil','C09.0-Tonsillar fossa','C09.1-Tonsillar pillar','C09.8-Overlapping lesion of tonsil','C09.9-Tonsil, NOS','C10.0-Vallecula','C10.1-Anterior

Stomach Non-cardia	surface of epiglottis','C10.2-Lateral wall of oropharynx','C10.3-Posterior wall of oropharynx','C10.4-Branchial cleft','C10.8-Overlapping lesion of oropharynx','C10.9-Oropharynx, NOS','C14.2-Waldeyers ring' {Site and Morphology.Site recode ICD-O-3/WHO 2008} = ' Stomach' AND {Site and Morphology.Primary Site - labeled} = 'C16.1-Fundus of stomach','C16.2-Body of stomach','C16.3-Gastric antrum','C16.4-Pylorus','C16.5-Lesser curvature of stomach NOS','C16.6-Greater curvature of stomach NOS','C16.8-Overlapping lesion of stomach','C16.9-Stomach, NOS'
Liver and Intrahepatic Bile Duct	eTable2
Anus, Anal Canal and Anorectum	eTable2
Cervix	eTable2
Vulva and vagina	C529, C510-C519
Penis	C600-C609
Hodgkin Lymphoma	eTable2
Non-Hodgkin Lymphoma	eTable2
Kaposi Sarcoma	eTable2
<hr/>	
<i>Alcohol-associated cancers¹⁵</i>	<i>Classification</i>
Oral Cavity and Pharynx	eTable2
Esophageal Squamous Cell Carcinoma	{Site and Morphology.Site recode ICD-O-3/WHO 2008} = ' Esophagus' AND {Site and Morphology.ICD-O-3 Hist/behavior, malig, labeled}2 = '8050/3: Papillary carcinoma, NOS','8051/3: Verrucous carcinoma, NOS','8052/3: Papillary squamous cell carcinoma','8053/3: Papillary squamous cell carcinoma, inverted','8070/3: Squamous cell carcinoma, NOS','8071/3: Squamous cell carcinoma, keratinizing, NOS','8072/3: Squamous cell ca., large cell, nonkeratinizing','8073/3: Squamous cell ca., small cell, nonkeratinizing','8074/3: Squamous cell carcinoma, spindle cell','8075/3: Squamous cell carcinoma, adenoid','8076/3: Squamous cell carcinoma, micro-invasive','8077/3: Squamous cell ca. & Grade III','8078/3: Squamous cell carcinoma with horn formation','8080/3: Queyrat erythroplasia, malignant','8081/3: Bowen disease, malignant','8082/3: Lymphoepithelial carcinoma'
Stomach	eTable2
Colon and Rectum	eTable2
Liver and Intrahepatic Bile Duct	eTable2
Larynx	eTable2
Female Breast	eTable2
<hr/>	

eTable 4. Number of survivors and person-years of follow-up included in the mortality analysis by first primary cancer sites and sex

Sex	First Primary Cancer	Survivors, n (%)	Follow-up Years since 5 years from First Primary Cancer, Total (Mean)
Men	Total	776604 (100)	5436148 (7)
Men	Total (excluding prostate cancer)	391951 (50.5)	2736027 (7)
Men	Larynx	9081 (1.2)	60506 (6.7)
Men	Hodgkin Lymphoma	7211 (0.9)	64585 (9)
Men	Kaposi Sarcoma	3836 (0.5)	34522 (9)
Men	Pancreas	1667 (0.2)	7811 (4.7)
Men	Esophagus	2736 (0.4)	15162 (5.5)
Men	Oral Cavity and Pharynx	22743 (2.9)	153869 (6.8)
Men	Acute Lymphocytic Leukemia	608 (0.1)	4663 (7.7)
Men	Gallbladder and Other Biliary	1005 (0.1)	5784 (5.8)
Men	Breast	1861 (0.2)	12005 (6.5)
Men	Lung and Bronchus	20842 (2.7)	109376 (5.2)
Men	Penis and Other Genital Organs	1566 (0.2)	10744 (6.9)
Men	Chronic Myeloid Leukemia	2726 (0.4)	17187 (6.3)
Men	Anus, Anal Canal and Anorectum	1945 (0.3)	13265 (6.8)
Men	Non-Hodgkin Lymphoma	44041 (5.7)	289499 (6.6)
Men	Thyroid	12333 (1.6)	97849 (7.9)
Men	Acute Non-Lymphocytic Leukemia	1900 (0.2)	14037 (7.4)
Men	Stomach	6114 (0.8)	37157 (6.1)
Men	Eye and Orbit	1609 (0.2)	11679 (7.3)
Men	Soft Tissue including Heart	5080 (0.7)	39141 (7.7)
Men	Urinary Bladder	51094 (6.6)	346728 (6.8)
Men	Kidney and Renal Pelvis	25791 (3.3)	167127 (6.5)
Men	Testis	17695 (2.3)	177622 (10)
Men	Small Intestine	2755 (0.4)	16957 (6.2)
Men	Brain and Other Nervous System	4776 (0.6)	34058 (7.1)
Men	Bones and Joints	1382 (0.2)	11644 (8.4)
Men	Myeloma	6683 (0.9)	29865 (4.5)
Men	Colon and Rectum	74184 (9.6)	507279 (6.8)
Men	Liver and Intrahepatic Bile Duct	3613 (0.5)	16194 (4.5)
Men	Melanoma of the Skin	44828 (5.8)	358549 (8)
Men	Prostate	384653 (49.5)	2700121 (7)
Men	Remaining values	10246 (1.3)	71166 (6.9)
Women	Total	745550 (100)	5658681 (7.6)
Women	Larynx	2087 (0.3)	13691 (6.6)
Women	Esophagus	845 (0.1)	4615 (5.5)
Women	Hodgkin Lymphoma	6223 (0.8)	58530 (9.4)
Women	Acute Lymphocytic Leukemia	483 (0.1)	3566 (7.4)
Women	Anus, Anal Canal and Anorectum	3027 (0.4)	20608 (6.8)
Women	Oral Cavity and Pharynx	10680 (1.4)	76049 (7.1)
Women	Pancreas	1665 (0.2)	8728 (5.2)
Women	Kaposi Sarcoma	164 (0)	1012 (6.2)

Women	Urinary Bladder	15578 (2.1)	109135 (7)
Women	Liver and Intrahepatic Bile Duct	1454 (0.2)	6823 (4.7)
Women	Non-Hodgkin Lymphoma	36978 (5)	247631 (6.7)
Women	Vulva and Other Genital Organs	6035 (0.8)	43476 (7.2)
Women	Gallbladder and Other Biliary	1308 (0.2)	8126 (6.2)
Women	Small Intestine	2493 (0.3)	15123 (6.1)
Women	Acute Non-Lymphocytic Leukemia	1850 (0.2)	14578 (7.9)
Women	Lung and Bronchus	24018 (3.2)	131531 (5.5)
Women	Kidney and Renal Pelvis	15880 (2.1)	105282 (6.6)
Women	Soft Tissue including Heart	4197 (0.6)	33529 (8)
Women	Ovary	18095 (2.4)	130615 (7.2)
Women	Cervix Uteri	19943 (2.7)	187717 (9.4)
Women	Eye and Orbit	1349 (0.2)	9970 (7.4)
Women	Thyroid	43042 (5.8)	348802 (8.1)
Women	Breast	332998 (44.7)	2628867 (7.9)
Women	Colon and Rectum	68385 (9.2)	467675 (6.8)
Women	Chronic Myeloid Leukemia	1930 (0.3)	12403 (6.4)
Women	Corpus and Uterus, NOS	62541 (8.4)	492687 (7.9)
Women	Myeloma	5549 (0.7)	24066 (4.3)
Women	Stomach	4496 (0.6)	27637 (6.1)
Women	Melanoma of the Skin	39213 (5.3)	334637 (8.5)
Women	Brain and Other Nervous System	4105 (0.6)	30842 (7.5)
Women	Bones and Joints	1237 (0.2)	10830 (8.8)
Women	Remaining values	7702 (1)	49899 (6.5)

eTable 5. Risks of developing or dying from subsequent primary cancers among 5-year survivors of other and unspecified primary cancer sites by sex

Outcome	Sex	First Primary Cancer	Survivors, No.	Observed number of subsequent primary cancer cases or deaths	Incidence or Mortality per 10,000 person-years	Expected number of Subsequent Primary Cancer Cases or Deaths	Standardized Incidence Ratio or Standardized Mortality Ratio (95% CI)	Mean Age at First Primary Cancer	Mean Age at Subsequent Primary Cancer Diagnosis or Death from Subsequent Primary Cancer	Total Person-years at Risk	Mean Person-Years at Risk
Incidence	Men	Mesothelioma	213	16	169	18	0.9 (0.52 to 1.47)	61.8	74.4	944	4.4
Mortality	Men	Mesothelioma	213	99	1048	8	12.26 (9.97 to 14.93)	61.8	72.2	944	4.4
Incidence	Men	Miscellaneous	4126	623	233	476	1.31 (1.21 to 1.42)	60.2	72.0	26684	6.5
Mortality	Men	Miscellaneous	4078	501	190	190	2.64 (2.42 to 2.89)	60.2	72.2	26406	6.5
Incidence	Men	Nose and Other Respiratory Organs	1438	198	185	147	1.35 (1.17 to 1.56)	53.2	70.5	10693	7.4
Mortality	Men	Nose and Other Respiratory Organs	1424	224	211	60	3.73 (3.26 to 4.26)	53.2	69.1	10605	7.4
Incidence	Men	Other Leukemia	1951	301	192	247	1.22 (1.09 to 1.37)	55.9	70.3	15716	8.1
Mortality	Men	Other Leukemia	1915	190	123	99	1.91 (1.65 to 2.21)	56.0	72.0	15483	8.1
Incidence	Men	Peritoneum and Other Digestive Organs	667	75	176	59	1.26 (1 to 1.59)	55.4	68.9	4256	6.4
Mortality	Men	Peritoneum and Other Digestive Organs	666	156	367	25	6.31 (5.36 to 7.39)	55.4	65.6	4255	6.4
Incidence	Men	Thymus and Other Endocrine Organs	1064	126	169	89	1.42 (1.18 to 1.69)	51.2	68.1	7471	7.0
Mortality	Men	Thymus and Other Endocrine Organs	1058	85	115	35	2.4 (1.92 to 2.98)	51.2	67.3	7415	7.0
Incidence	Men	Ureter and Other Urinary Organs	904	149	241	124	1.2 (1.02 to 1.41)	65.1	74.5	6174	6.8
Mortality	Men	Ureter and Other Urinary Organs	892	103	170	62	1.67 (1.37 to 2.03)	65.2	77.4	6058	6.8
Incidence	Women	Mesothelioma	178	7	63	12	0.59 (0.24 to 1.22)	56.9	64.0	1115	6.3
Mortality	Women	Mesothelioma	175	71	662	5	15.0 (11.8 to 19.0)	57.1	70.1	1072	6.1
Incidence	Women	Miscellaneous	2931	356	187	243	1.47 (1.32 to 1.63)	61.4	71.9	19036	6.5
Mortality	Women	Miscellaneous	2895	384	204	101	3.79 (3.43 to 4.2)	61.5	72.6	18783	6.5
Incidence	Women	Nose and Other Respiratory Organs	902	103	159	75	1.38 (1.13 to 1.68)	57.4	67.5	6472	7.2
Mortality	Women	Nose and Other Respiratory Organs	894	134	208	31	4.26 (3.58 to 5.05)	57.5	67.6	6430	7.2
Incidence	Women	Other Leukemia	789	80	132	71	1.12 (0.89 to 1.4)	57.2	70.8	6072	7.7
Mortality	Women	Other Leukemia	778	81	135	30	2.74 (2.18 to 3.41)	57.4	74.4	5995	7.7
Incidence	Women	Peritoneum and Other Digestive Organs	1506	102	124	99	1.03 (0.84 to 1.25)	59.6	70.6	8249	5.5
Mortality	Women	Peritoneum and Other Digestive Organs	1502	486	590	42	11.71 (10.69 to 12.8)	59.6	69.3	8238	5.5
Incidence	Women	Thymus and Other Endocrine Organs	915	76	124	60	1.26 (1 to 1.58)	53.1	66.4	6119	6.7
Mortality	Women	Thymus and Other Endocrine Organs	911	58	95	22	2.59 (1.97 to 3.35)	53.1	67.5	6091	6.7
Incidence	Women	Ureter and Other Urinary Organs	552	71	212	48	1.47 (1.15 to 1.85)	67.7	77.1	3342	6.1
Mortality	Women	Ureter and Other Urinary Organs	547	52	158	24	2.2 (1.65 to 2.89)	67.8	78.8	3289	6.0

eTable 6. Risks of developing specific type of subsequent primary cancer among 5-year cancer survivors in 12 SEER registries: incidence, percent contribution to the total incidence, standardized incidence ratio by first primary cancer types and sex

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Acute Lymphocytic Leukemia	Oral Cavity and Pharynx	612	10	21.2	0.01	1.0	9.71 (4.66 to 17.85)	38.7	58.7
M	Acute Non-Lymphocytic Leukemia	Colon and Rectum	1907	13	9.2	0.01	12.7	1.02 (0.54 to 1.75)	47.5	70.0
M	Acute Non-Lymphocytic Leukemia	Kidney and Renal Pelvis	1907	6	4.3	0.01	5.9	1.02 (0.37 to 2.22)	47.5	63.9
M	Acute Non-Lymphocytic Leukemia	Lung and Bronchus	1907	19	13.5	0.02	17.2	1.11 (0.67 to 1.73)	47.5	70.4
M	Acute Non-Lymphocytic Leukemia	Melanoma of the Skin	1907	7	5.0	0.01	7.9	0.88 (0.36 to 1.82)	47.5	67.8
M	Acute Non-Lymphocytic Leukemia	Non-Hodgkin Lymphoma	1907	5	3.5	0.01	8.4	0.6 (0.19 to 1.39)	47.5	72.5
M	Acute Non-Lymphocytic Leukemia	Oral Cavity and Pharynx	1907	21	14.9	0.02	4.8	4.35 (2.69 to 6.65)	47.5	53.0
M	Acute Non-Lymphocytic Leukemia	Prostate	1907	28	19.9	0.03	41.1	0.68 (0.45 to 0.98)	47.5	64.9
M	Acute Non-Lymphocytic Leukemia	Urinary Bladder	1907	15	10.6	0.02	9.3	1.61 (0.9 to 2.65)	47.5	74.4
M	Anus, Anal Canal and Anorectum	Colon and Rectum	1956	21	15.7	0.02	19.2	1.09 (0.68 to 1.67)	55.8	67.8
M	Anus, Anal Canal and Anorectum	Esophagus	1956	5	3.7	0.01	3.2	1.54 (0.5 to 3.6)	55.8	64.6
M	Anus, Anal Canal and Anorectum	Larynx	1956	7	5.2	0.01	2.3	3.03 (1.22 to 6.23)	55.8	71.0
M	Anus, Anal Canal and Anorectum	Liver and Intrahepatic Bile Duct	1956	7	5.2	0.01	5.3	1.33 (0.53 to 2.73)	55.8	66.8
M	Anus, Anal Canal and Anorectum	Lung and Bronchus	1956	65	48.7	0.07	28.4	2.29 (1.77 to 2.92)	55.8	67.0
M	Anus, Anal Canal and Anorectum	Melanoma of the Skin	1956	9	6.7	0.01	11.3	0.8 (0.37 to 1.52)	55.8	72.1
M	Anus, Anal Canal and Anorectum	Non-Hodgkin Lymphoma	1956	24	18.0	0.03	12.5	1.93 (1.23 to 2.87)	55.8	70.2
M	Anus, Anal Canal and Anorectum	Oral Cavity and Pharynx	1956	17	12.7	0.02	6.4	2.64 (1.54 to 4.23)	55.8	65.2
M	Anus, Anal Canal and Anorectum	Pancreas	1956	6	4.5	0.01	6.2	0.97 (0.36 to 2.12)	55.8	65.0
M	Anus, Anal Canal and Anorectum	Prostate	1956	25	18.7	0.03	63.6	0.39 (0.25 to 0.58)	55.8	74.5
M	Anus, Anal Canal and Anorectum	Stomach	1956	5	3.7	0.01	4.1	1.21 (0.39 to 2.82)	55.8	75.1
M	Anus, Anal Canal and Anorectum	Urinary Bladder	1956	23	17.2	0.03	15.7	1.47 (0.93 to 2.2)	55.8	68.9
M	Bones and Joints	Acute Non-Lymphocytic Leukemia	1402	7	5.9	0.01	1.1	6.61 (2.66 to 13.61)	44.5	60.6
M	Bones and Joints	Colon and Rectum	1402	9	7.6	0.01	10.1	0.89 (0.41 to 1.69)	44.5	61.1
M	Bones and Joints	Lung and Bronchus	1402	11	9.3	0.01	13.5	0.81 (0.41 to 1.45)	44.5	71.0
M	Bones and Joints	Non-Hodgkin Lymphoma	1402	5	4.2	0.01	6.5	0.76 (0.25 to 1.78)	44.5	70.0
M	Bones and Joints	Oral Cavity and Pharynx	1402	5	4.2	0.01	3.6	1.39 (0.45 to 3.24)	44.5	50.8
M	Bones and Joints	Prostate	1402	29	24.5	0.03	31.2	0.93 (0.62 to 1.33)	44.5	68.2
M	Bones and Joints	Soft Tissue including Heart	1402	5	4.2	0.01	0.7	6.76 (2.19 to 15.77)	44.5	57.5
M	Brain and Other Nervous System	Acute Non-Lymphocytic Leukemia	4817	11	3.2	0.01	2.3	4.87 (2.43 to 8.71)	42.0	51.1

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Brain and Other Nervous System	Colon and Rectum	4817	25	7.3	0.03	22.6	1.11 (0.72 to 1.63)	42.0	60.6
M	Brain and Other Nervous System	Esophagus	4817	7	2.0	0.01	3.7	1.91 (0.77 to 3.94)	42.0	61.3
M	Brain and Other Nervous System	Kidney and Renal Pelvis	4817	15	4.4	0.02	10.8	1.38 (0.78 to 2.28)	42.0	60.7
M	Brain and Other Nervous System	Lung and Bronchus	4817	27	7.9	0.03	27.2	0.99 (0.66 to 1.45)	42.0	63.0
M	Brain and Other Nervous System	Melanoma of the Skin	4817	18	5.2	0.02	15.3	1.18 (0.7 to 1.86)	42.0	61.8
M	Brain and Other Nervous System	Non-Hodgkin Lymphoma	4817	20	5.8	0.02	15.0	1.33 (0.81 to 2.06)	42.0	64.1
M	Brain and Other Nervous System	Oral Cavity and Pharynx	4817	8	2.3	0.01	9.3	0.86 (0.37 to 1.69)	42.0	51.1
M	Brain and Other Nervous System	Prostate	4817	64	18.6	0.07	69.4	0.92 (0.71 to 1.18)	42.0	62.9
M	Brain and Other Nervous System	Stomach	4817	5	1.5	0.01	4.6	1.1 (0.36 to 2.56)	42.0	62.8
M	Brain and Other Nervous System	Thyroid	4817	8	2.3	0.01	3.8	2.13 (0.92 to 4.19)	42.0	56.1
M	Brain and Other Nervous System	Urinary Bladder	4817	9	2.6	0.01	15.0	0.6 (0.27 to 1.14)	42.0	68.5
M	Breast	Acute Non-Lymphocytic Leukemia	1878	5	4.1	0.01	2.8	1.8 (0.58 to 4.19)	63.1	69.7
M	Breast	Brain and Other Nervous System	1878	5	4.1	0.01	2.6	1.95 (0.64 to 4.56)	63.1	72.4
M	Breast	Colon and Rectum	1878	27	22.2	0.03	24.4	1.11 (0.73 to 1.61)	63.1	75.0
M	Breast	Kidney and Renal Pelvis	1878	7	5.7	0.01	9.3	0.75 (0.3 to 1.55)	63.1	77.9
M	Breast	Larynx	1878	5	4.1	0.01	2.7	1.86 (0.61 to 4.35)	63.1	74.6
M	Breast	Liver and Intrahepatic Bile Duct	1878	10	8.2	0.01	5.6	1.78 (0.86 to 3.28)	63.1	75.8
M	Breast	Lung and Bronchus	1878	45	37.0	0.05	37.6	1.2 (0.87 to 1.6)	63.1	76.3
M	Breast	Melanoma of the Skin	1878	12	9.9	0.01	13.5	0.89 (0.46 to 1.55)	63.1	77.9
M	Breast	Non-Hodgkin Lymphoma	1878	22	18.1	0.02	15.6	1.41 (0.88 to 2.13)	63.1	77.9
M	Breast	Oral Cavity and Pharynx	1878	11	9.0	0.01	6.8	1.61 (0.81 to 2.89)	63.1	74.4
M	Breast	Pancreas	1878	14	11.5	0.02	7.8	1.78 (0.98 to 2.99)	63.1	76.7
M	Breast	Prostate	1878	88	72.3	0.10	73.8	1.19 (0.96 to 1.47)	63.1	72.6
M	Breast	Stomach	1878	6	4.9	0.01	5.5	1.1 (0.4 to 2.39)	63.1	80.0
M	Breast	Urinary Bladder	1878	21	17.2	0.02	21.7	0.97 (0.6 to 1.48)	63.1	77.4
M	Chronic Myeloid Leukemia	Acute Lymphocytic Leukemia	2772	10	5.7	0.01	0.2	45.56 (21.85 to 83.79)	51.6	54.9
M	Chronic Myeloid Leukemia	Colon and Rectum	2772	20	11.4	0.02	18.2	1.1 (0.67 to 1.69)	51.6	65.4
M	Chronic Myeloid Leukemia	Kidney and Renal Pelvis	2772	6	3.4	0.01	8.2	0.74 (0.27 to 1.6)	51.6	55.8
M	Chronic Myeloid Leukemia	Lung and Bronchus	2772	26	14.9	0.03	25.4	1.03 (0.67 to 1.5)	51.6	69.4
M	Chronic Myeloid Leukemia	Melanoma of the Skin	2772	11	6.3	0.01	11.0	1 (0.5 to 1.79)	51.6	60.0
M	Chronic Myeloid Leukemia	Non-Hodgkin Lymphoma	2772	17	9.7	0.02	11.9	1.43 (0.84 to 2.3)	51.6	65.6
M	Chronic Myeloid Leukemia	Oral Cavity and Pharynx	2772	27	15.4	0.03	6.5	4.13 (2.73 to 6.02)	51.6	56.6

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Chronic Myeloid Leukemia	Prostate	2772	51	29.2	0.06	57.3	0.89 (0.66 to 1.17)	51.6	65.9
M	Chronic Myeloid Leukemia	Thyroid	2772	7	4.0	0.01	2.2	3.21 (1.29 to 6.61)	51.6	60.2
M	Chronic Myeloid Leukemia	Urinary Bladder	2772	12	6.9	0.01	13.9	0.86 (0.45 to 1.51)	51.6	70.7
M	Colon and Rectum	Acute Lymphocytic Leukemia	74722	13	0.3	0.01	8.6	1.52 (0.81 to 2.6)	63.3	68.9
M	Colon and Rectum	Acute Non-Lymphocytic Leukemia	74722	163	3.2	0.18	119.5	1.36 (1.16 to 1.59)	63.3	76.4
M	Colon and Rectum	Bones and Joints	74722	11	0.2	0.01	9.9	1.11 (0.56 to 1.99)	63.3	63.2
M	Colon and Rectum	Brain and Other Nervous System	74722	98	1.9	0.11	106.4	0.92 (0.75 to 1.12)	63.3	72.1
M	Colon and Rectum	Breast	74722	33	0.6	0.04	26.5	1.25 (0.86 to 1.75)	63.3	75.2
M	Colon and Rectum	Chronic Myeloid Leukemia	74722	54	1.1	0.06	45.2	1.2 (0.9 to 1.56)	63.3	77.0
M	Colon and Rectum	Esophagus	74722	177	3.5	0.20	165.3	1.07 (0.92 to 1.24)	63.3	75.6
M	Colon and Rectum	Eye and Orbit	74722	14	0.3	0.02	16.8	0.83 (0.46 to 1.4)	63.3	75.2
M	Colon and Rectum	Gallbladder and Other Biliary	74722	102	2.0	0.11	78.9	1.29 (1.06 to 1.57)	63.3	73.6
M	Colon and Rectum	Hodgkin Lymphoma	74722	15	0.3	0.02	22.8	0.66 (0.37 to 1.09)	63.3	72.9
M	Colon and Rectum	Kaposi Sarcoma	74722	10	0.2	0.01	9.1	1.1 (0.53 to 2.02)	63.3	72.5
M	Colon and Rectum	Kidney and Renal Pelvis	74722	412	8.1	0.46	383.7	1.07 (0.97 to 1.18)	63.3	73.7
M	Colon and Rectum	Larynx	74722	110	2.2	0.12	110.3	1 (0.82 to 1.2)	63.3	75.4
M	Colon and Rectum	Liver and Intrahepatic Bile Duct	74722	233	4.6	0.26	244.2	0.95 (0.84 to 1.09)	63.3	72.6
M	Colon and Rectum	Lung and Bronchus	74722	1706	33.4	1.92	1610.9	1.06 (1.01 to 1.11)	63.3	76.1
M	Colon and Rectum	Melanoma of the Skin	74722	449	8.8	0.51	550.3	0.82 (0.74 to 0.9)	63.3	76.5
M	Colon and Rectum	Myeloma	74722	183	3.6	0.21	190.9	0.96 (0.83 to 1.11)	63.3	75.8
M	Colon and Rectum	Non-Hodgkin Lymphoma	74722	603	11.8	0.68	659.8	0.91 (0.84 to 0.99)	63.3	76.0
M	Colon and Rectum	Oral Cavity and Pharynx	74722	309	6.1	0.35	281.4	1.1 (0.98 to 1.23)	63.3	72.9
M	Colon and Rectum	Pancreas	74722	400	7.8	0.45	334.4	1.2 (1.08 to 1.32)	63.3	74.9
M	Colon and Rectum	Penis and Other Genital Organs	74722	33	0.6	0.04	25.8	1.28 (0.88 to 1.8)	63.3	76.0
M	Colon and Rectum	Prostate	74722	2688	52.6	3.03	3042.2	0.88 (0.85 to 0.92)	63.3	73.5
M	Colon and Rectum	Small Intestine	74722	121	2.4	0.14	53.2	2.27 (1.89 to 2.72)	63.3	70.1
M	Colon and Rectum	Soft Tissue including Heart	74722	72	1.4	0.08	65.7	1.1 (0.86 to 1.38)	63.3	73.3
M	Colon and Rectum	Stomach	74722	273	5.3	0.31	245.4	1.11 (0.99 to 1.25)	63.3	75.2
M	Colon and Rectum	Thyroid	74722	71	1.4	0.08	72.2	0.98 (0.77 to 1.24)	63.3	69.2
M	Colon and Rectum	Urinary Bladder	74722	991	19.4	1.12	925.3	1.07 (1.01 to 1.14)	63.3	77.1
M	Esophagus	Acute Non-Lymphocytic Leukemia	2746	6	3.9	0.01	3.3	1.8 (0.66 to 3.92)	62.8	68.9
M	Esophagus	Colon and Rectum	2746	25	16.4	0.03	28.4	0.88 (0.57 to 1.3)	62.8	74.9

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Esophagus	Kidney and Renal Pelvis	2746	12	7.9	0.01	11.5	1.04 (0.54 to 1.82)	62.8	69.1
M	Esophagus	Larynx	2746	8	5.3	0.01	3.2	2.47 (1.06 to 4.86)	62.8	64.0
M	Esophagus	Liver and Intrahepatic Bile Duct	2746	8	5.3	0.01	7.0	1.15 (0.5 to 2.26)	62.8	74.8
M	Esophagus	Lung and Bronchus	2746	86	56.5	0.10	44.7	1.93 (1.54 to 2.38)	62.8	71.9
M	Esophagus	Melanoma of the Skin	2746	15	9.9	0.02	17.3	0.87 (0.49 to 1.43)	62.8	71.2
M	Esophagus	Non-Hodgkin Lymphoma	2746	22	14.4	0.02	19.0	1.16 (0.73 to 1.75)	62.8	75.2
M	Esophagus	Oral Cavity and Pharynx	2746	41	26.9	0.05	8.6	4.75 (3.41 to 6.44)	62.8	68.9
M	Esophagus	Pancreas	2746	12	7.9	0.01	9.4	1.27 (0.66 to 2.22)	62.8	72.6
M	Esophagus	Prostate	2746	96	63.0	0.11	90.4	1.06 (0.86 to 1.3)	62.8	72.2
M	Esophagus	Stomach	2746	20	13.1	0.02	6.4	3.12 (1.9 to 4.81)	62.8	71.7
M	Esophagus	Urinary Bladder	2746	33	21.7	0.04	25.8	1.28 (0.88 to 1.79)	62.8	76.4
M	Eye and Orbit	Colon and Rectum	1645	25	20.8	0.03	18.7	1.34 (0.87 to 1.98)	57.9	77.0
M	Eye and Orbit	Kidney and Renal Pelvis	1645	9	7.5	0.01	7.7	1.17 (0.54 to 2.23)	57.9	65.4
M	Eye and Orbit	Lung and Bronchus	1645	39	32.5	0.04	27.6	1.41 (1 to 1.93)	57.9	73.8
M	Eye and Orbit	Melanoma of the Skin	1645	23	19.2	0.03	12.3	1.87 (1.18 to 2.8)	57.9	73.1
M	Eye and Orbit	Non-Hodgkin Lymphoma	1645	17	14.2	0.02	12.8	1.33 (0.78 to 2.13)	57.9	75.0
M	Eye and Orbit	Pancreas	1645	8	6.7	0.01	6.0	1.34 (0.58 to 2.65)	57.9	75.0
M	Eye and Orbit	Prostate	1645	47	39.1	0.05	58.0	0.81 (0.6 to 1.08)	57.9	71.8
M	Eye and Orbit	Urinary Bladder	1645	20	16.7	0.02	17.0	1.18 (0.72 to 1.82)	57.9	75.9
M	Gallbladder and Other Biliary	Colon and Rectum	1010	27	46.5	0.03	11.0	2.46 (1.62 to 3.57)	62.6	72.2
M	Gallbladder and Other Biliary	Liver and Intrahepatic Bile Duct	1010	9	15.5	0.01	2.8	3.24 (1.48 to 6.14)	62.6	68.1
M	Gallbladder and Other Biliary	Lung and Bronchus	1010	17	29.2	0.02	16.6	1.02 (0.6 to 1.64)	62.6	76.2
M	Gallbladder and Other Biliary	Melanoma of the Skin	1010	5	8.6	0.01	5.7	0.87 (0.28 to 2.03)	62.6	74.5
M	Gallbladder and Other Biliary	Non-Hodgkin Lymphoma	1010	6	10.3	0.01	6.9	0.87 (0.32 to 1.9)	62.6	71.8
M	Gallbladder and Other Biliary	Pancreas	1010	12	20.6	0.01	3.5	3.44 (1.78 to 6)	62.6	68.9
M	Gallbladder and Other Biliary	Prostate	1010	18	31.0	0.02	31.6	0.57 (0.34 to 0.9)	62.6	72.8
M	Gallbladder and Other Biliary	Stomach	1010	8	13.8	0.01	2.6	3.04 (1.31 to 5.98)	62.6	72.4
M	Gallbladder and Other Biliary	Urinary Bladder	1010	14	24.1	0.02	9.4	1.48 (0.81 to 2.49)	62.6	72.8
M	Hodgkin Lymphoma	Acute Non-Lymphocytic Leukemia	7278	28	4.3	0.03	4.0	7.04 (4.68 to 10.17)	40.1	53.8
M	Hodgkin Lymphoma	Anus, Anal Canal and Anorectum	7278	10	1.5	0.01	1.6	6.11 (2.93 to 11.24)	40.1	50.4
M	Hodgkin Lymphoma	Brain and Other Nervous System	7278	5	0.8	0.01	6.3	0.8 (0.26 to 1.86)	40.1	53.7
M	Hodgkin Lymphoma	Chronic Myeloid Leukemia	7278	5	0.8	0.01	1.9	2.63 (0.85 to 6.13)	40.1	59.4

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Hodgkin Lymphoma	Colon and Rectum	7278	45	6.9	0.05	39.2	1.15 (0.84 to 1.54)	40.1	60.4
M	Hodgkin Lymphoma	Esophagus	7278	12	1.8	0.01	6.2	1.94 (1 to 3.39)	40.1	61.0
M	Hodgkin Lymphoma	Kidney and Renal Pelvis	7278	17	2.6	0.02	18.9	0.9 (0.53 to 1.44)	40.1	63.3
M	Hodgkin Lymphoma	Larynx	7278	8	1.2	0.01	4.6	1.75 (0.75 to 3.44)	40.1	70.6
M	Hodgkin Lymphoma	Liver and Intrahepatic Bile Duct	7278	10	1.5	0.01	11.2	0.89 (0.43 to 1.64)	40.1	64.7
M	Hodgkin Lymphoma	Lung and Bronchus	7278	104	16.0	0.12	46.8	2.22 (1.82 to 2.69)	40.1	63.8
M	Hodgkin Lymphoma	Melanoma of the Skin	7278	36	5.5	0.04	26.1	1.38 (0.97 to 1.91)	40.1	57.9
M	Hodgkin Lymphoma	Myeloma	7278	5	0.8	0.01	6.7	0.74 (0.24 to 1.74)	40.1	64.8
M	Hodgkin Lymphoma	Non-Hodgkin Lymphoma	7278	110	16.9	0.12	26.0	4.24 (3.48 to 5.11)	40.1	59.9
M	Hodgkin Lymphoma	Oral Cavity and Pharynx	7278	43	6.6	0.05	15.7	2.74 (1.99 to 3.7)	40.1	56.7
M	Hodgkin Lymphoma	Pancreas	7278	10	1.5	0.01	11.1	0.9 (0.43 to 1.65)	40.1	69.7
M	Hodgkin Lymphoma	Prostate	7278	99	15.2	0.11	117.8	0.84 (0.68 to 1.02)	40.1	63.0
M	Hodgkin Lymphoma	Small Intestine	7278	5	0.8	0.01	2.3	2.17 (0.7 to 5.06)	40.1	63.1
M	Hodgkin Lymphoma	Soft Tissue including Heart	7278	6	0.9	0.01	3.2	1.86 (0.68 to 4.04)	40.1	59.5
M	Hodgkin Lymphoma	Stomach	7278	8	1.2	0.01	7.9	1.02 (0.44 to 2.01)	40.1	69.5
M	Hodgkin Lymphoma	Thyroid	7278	17	2.6	0.02	6.7	2.54 (1.48 to 4.06)	40.1	47.8
M	Hodgkin Lymphoma	Urinary Bladder	7278	35	5.4	0.04	25.6	1.37 (0.95 to 1.9)	40.1	67.8
M	Kaposi Sarcoma	Anus, Anal Canal and Anorectum	3962	83	23.2	0.09	1.2	71.33 (56.81 to 88.42)	43.4	52.0
M	Kaposi Sarcoma	Colon and Rectum	3962	24	6.7	0.03	26.7	0.9 (0.58 to 1.34)	43.4	61.7
M	Kaposi Sarcoma	Esophagus	3962	6	1.7	0.01	4.1	1.46 (0.54 to 3.17)	43.4	62.4
M	Kaposi Sarcoma	Gallbladder and Other Biliary	3962	6	1.7	0.01	1.5	3.89 (1.43 to 8.46)	43.4	64.2
M	Kaposi Sarcoma	Hodgkin Lymphoma	3962	12	3.4	0.01	1.3	9.15 (4.73 to 15.99)	43.4	51.7
M	Kaposi Sarcoma	Kidney and Renal Pelvis	3962	7	2.0	0.01	12.5	0.56 (0.23 to 1.16)	43.4	57.3
M	Kaposi Sarcoma	Liver and Intrahepatic Bile Duct	3962	22	6.2	0.02	8.0	2.74 (1.72 to 4.15)	43.4	55.7
M	Kaposi Sarcoma	Lung and Bronchus	3962	23	6.4	0.03	31.3	0.74 (0.47 to 1.1)	43.4	63.4
M	Kaposi Sarcoma	Melanoma of the Skin	3962	14	3.9	0.02	16.3	0.86 (0.47 to 1.45)	43.4	65.6
M	Kaposi Sarcoma	Non-Hodgkin Lymphoma	3962	62	17.3	0.07	17.0	3.65 (2.8 to 4.68)	43.4	52.8
M	Kaposi Sarcoma	Oral Cavity and Pharynx	3962	36	10.1	0.04	10.7	3.36 (2.35 to 4.65)	43.4	56.8
M	Kaposi Sarcoma	Pancreas	3962	9	2.5	0.01	7.5	1.2 (0.55 to 2.27)	43.4	59.2
M	Kaposi Sarcoma	Penis and Other Genital Organs	3962	9	2.5	0.01	0.6	14.72 (6.73 to 27.95)	43.4	52.3
M	Kaposi Sarcoma	Prostate	3962	52	14.5	0.06	79.0	0.66 (0.49 to 0.86)	43.4	67.4
M	Kaposi Sarcoma	Urinary Bladder	3962	20	5.6	0.02	17.0	1.18 (0.72 to 1.82)	43.4	69.2

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Kidney and Renal Pelvis	Acute Lymphocytic Leukemia	25977	7	0.4	0.01	2.6	2.71 (1.09 to 5.57)	59.5	68.5
M	Kidney and Renal Pelvis	Acute Non-Lymphocytic Leukemia	25977	32	1.9	0.04	31.9	1 (0.69 to 1.42)	59.5	73.4
M	Kidney and Renal Pelvis	Brain and Other Nervous System	25977	38	2.3	0.04	32.1	1.19 (0.84 to 1.63)	59.5	68.7
M	Kidney and Renal Pelvis	Breast	25977	9	0.5	0.01	7.5	1.2 (0.55 to 2.28)	59.5	70.5
M	Kidney and Renal Pelvis	Chronic Myeloid Leukemia	25977	17	1.0	0.02	12.3	1.38 (0.81 to 2.22)	59.5	68.0
M	Kidney and Renal Pelvis	Colon and Rectum	25977	239	14.2	0.27	282.0	0.85 (0.74 to 0.96)	59.5	72.1
M	Kidney and Renal Pelvis	Esophagus	25977	45	2.7	0.05	47.5	0.95 (0.69 to 1.27)	59.5	73.9
M	Kidney and Renal Pelvis	Gallbladder and Other Biliary	25977	15	0.9	0.02	20.5	0.73 (0.41 to 1.21)	59.5	73.1
M	Kidney and Renal Pelvis	Kaposi Sarcoma	25977	6	0.4	0.01	2.8	2.16 (0.79 to 4.7)	59.5	73.0
M	Kidney and Renal Pelvis	Larynx	25977	32	1.9	0.04	32.5	0.98 (0.67 to 1.39)	59.5	68.9
M	Kidney and Renal Pelvis	Liver and Intrahepatic Bile Duct	25977	89	5.3	0.10	74.0	1.2 (0.97 to 1.48)	59.5	67.6
M	Kidney and Renal Pelvis	Lung and Bronchus	25977	487	28.9	0.55	430.6	1.13 (1.03 to 1.24)	59.5	73.8
M	Kidney and Renal Pelvis	Melanoma of the Skin	25977	161	9.6	0.18	164.1	0.98 (0.84 to 1.15)	59.5	71.1
M	Kidney and Renal Pelvis	Myeloma	25977	59	3.5	0.07	53.8	1.1 (0.84 to 1.42)	59.5	73.3
M	Kidney and Renal Pelvis	Non-Hodgkin Lymphoma	25977	178	10.6	0.20	183.9	0.97 (0.83 to 1.12)	59.5	73.9
M	Kidney and Renal Pelvis	Oral Cavity and Pharynx	25977	82	4.9	0.09	88.0	0.93 (0.74 to 1.16)	59.5	68.0
M	Kidney and Renal Pelvis	Pancreas	25977	113	6.7	0.13	92.2	1.23 (1.01 to 1.47)	59.5	73.1
M	Kidney and Renal Pelvis	Prostate	25977	943	56.1	1.06	899.1	1.05 (0.98 to 1.12)	59.5	70.5
M	Kidney and Renal Pelvis	Small Intestine	25977	27	1.6	0.03	15.6	1.73 (1.14 to 2.52)	59.5	75.0
M	Kidney and Renal Pelvis	Soft Tissue including Heart	25977	25	1.5	0.03	18.4	1.36 (0.88 to 2)	59.5	65.8
M	Kidney and Renal Pelvis	Stomach	25977	73	4.3	0.08	63.2	1.15 (0.91 to 1.45)	59.5	73.0
M	Kidney and Renal Pelvis	Thyroid	25977	56	3.3	0.06	24.3	2.31 (1.74 to 3)	59.5	67.6
M	Kidney and Renal Pelvis	Urinary Bladder	25977	316	18.8	0.36	242.6	1.3 (1.16 to 1.46)	59.5	74.4
M	Larynx	Acute Non-Lymphocytic Leukemia	9107	19	3.1	0.02	13.3	1.43 (0.86 to 2.24)	62.5	75.3
M	Larynx	Anus, Anal Canal and Anorectum	9107	6	1.0	0.01	2.9	2.11 (0.77 to 4.58)	62.5	67.2
M	Larynx	Brain and Other Nervous System	9107	7	1.2	0.01	12.7	0.55 (0.22 to 1.13)	62.5	76.4
M	Larynx	Breast	9107	5	0.8	0.01	3.1	1.59 (0.52 to 3.72)	62.5	72.2
M	Larynx	Chronic Myeloid Leukemia	9107	7	1.2	0.01	5.1	1.38 (0.55 to 2.84)	62.5	79.0
M	Larynx	Colon and Rectum	9107	153	25.2	0.17	123.2	1.24 (1.05 to 1.46)	62.5	73.6
M	Larynx	Esophagus	9107	79	13.0	0.09	19.8	3.99 (3.16 to 4.97)	62.5	70.6
M	Larynx	Gallbladder and Other Biliary	9107	10	1.6	0.01	8.6	1.17 (0.56 to 2.15)	62.5	71.8
M	Larynx	Kidney and Renal Pelvis	9107	48	7.9	0.05	46.5	1.03 (0.76 to 1.37)	62.5	72.2

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Larynx	Liver and Intrahepatic Bile Duct	9107	55	9.1	0.06	27.8	1.98 (1.49 to 2.57)	62.5	71.0
M	Larynx	Lung and Bronchus	9107	757	124.7	0.85	190.5	3.97 (3.7 to 4.27)	62.5	72.5
M	Larynx	Melanoma of the Skin	9107	44	7.2	0.05	63.6	0.69 (0.5 to 0.93)	62.5	74.8
M	Larynx	Myeloma	9107	22	3.6	0.02	22.8	0.97 (0.61 to 1.46)	62.5	78.7
M	Larynx	Non-Hodgkin Lymphoma	9107	86	14.2	0.10	75.7	1.14 (0.91 to 1.4)	62.5	74.9
M	Larynx	Oral Cavity and Pharynx	9107	247	40.7	0.28	34.1	7.24 (6.36 to 8.2)	62.5	69.1
M	Larynx	Pancreas	9107	36	5.9	0.04	38.4	0.94 (0.66 to 1.3)	62.5	73.9
M	Larynx	Prostate	9107	356	58.7	0.40	393.5	0.91 (0.81 to 1)	62.5	73.0
M	Larynx	Small Intestine	9107	8	1.3	0.01	6.4	1.25 (0.54 to 2.47)	62.5	71.1
M	Larynx	Soft Tissue including Heart	9107	16	2.6	0.02	7.4	2.17 (1.24 to 3.52)	62.5	74.3
M	Larynx	Stomach	9107	35	5.8	0.04	27.3	1.28 (0.89 to 1.78)	62.5	74.7
M	Larynx	Thyroid	9107	11	1.8	0.01	8.6	1.27 (0.64 to 2.28)	62.5	70.9
M	Larynx	Urinary Bladder	9107	174	28.7	0.20	103.7	1.68 (1.44 to 1.95)	62.5	75.6
M	Liver and Intrahepatic Bile Duct	Acute Non-Lymphocytic Leukemia	3629	8	4.9	0.01	2.4	3.31 (1.43 to 6.52)	58.9	72.8
M	Liver and Intrahepatic Bile Duct	Colon and Rectum	3629	18	11.1	0.02	22.6	0.8 (0.47 to 1.26)	58.9	67.9
M	Liver and Intrahepatic Bile Duct	Esophagus	3629	5	3.1	0.01	3.6	1.4 (0.45 to 3.26)	58.9	65.3
M	Liver and Intrahepatic Bile Duct	Kidney and Renal Pelvis	3629	9	5.5	0.01	9.7	0.93 (0.43 to 1.77)	58.9	61.2
M	Liver and Intrahepatic Bile Duct	Lung and Bronchus	3629	37	22.7	0.04	33.0	1.12 (0.79 to 1.55)	58.9	67.5
M	Liver and Intrahepatic Bile Duct	Melanoma of the Skin	3629	7	4.3	0.01	10.3	0.68 (0.27 to 1.4)	58.9	66.4
M	Liver and Intrahepatic Bile Duct	Non-Hodgkin Lymphoma	3629	19	11.7	0.02	13.6	1.4 (0.84 to 2.18)	58.9	64.1
M	Liver and Intrahepatic Bile Duct	Oral Cavity and Pharynx	3629	12	7.4	0.01	7.6	1.58 (0.82 to 2.76)	58.9	63.4
M	Liver and Intrahepatic Bile Duct	Pancreas	3629	5	3.1	0.01	7.5	0.67 (0.22 to 1.56)	58.9	76.2
M	Liver and Intrahepatic Bile Duct	Prostate	3629	52	31.9	0.06	70.7	0.74 (0.55 to 0.97)	58.9	70.3
M	Liver and Intrahepatic Bile Duct	Stomach	3629	5	3.1	0.01	6.1	0.81 (0.26 to 1.9)	58.9	69.0
M	Liver and Intrahepatic Bile Duct	Thyroid	3629	5	3.1	0.01	2.4	2.09 (0.68 to 4.88)	58.9	66.3
M	Liver and Intrahepatic Bile Duct	Urinary Bladder	3629	7	4.3	0.01	15.8	0.44 (0.18 to 0.91)	58.9	72.6
M	Lung and Bronchus	Acute Non-Lymphocytic Leukemia	20874	47	4.3	0.05	25.1	1.87 (1.38 to 2.49)	64.3	74.5
M	Lung and Bronchus	Anus, Anal Canal and Anorectum	20874	9	0.8	0.01	5.1	1.76 (0.81 to 3.34)	64.3	68.9
M	Lung and Bronchus	Bones and Joints	20874	5	0.5	0.01	2.1	2.37 (0.77 to 5.52)	64.3	71.9
M	Lung and Bronchus	Brain and Other Nervous System	20874	19	1.7	0.02	23.2	0.82 (0.49 to 1.28)	64.3	73.6
M	Lung and Bronchus	Breast	20874	7	0.6	0.01	5.7	1.22 (0.49 to 2.52)	64.3	70.7
M	Lung and Bronchus	Chronic Myeloid Leukemia	20874	17	1.6	0.02	9.5	1.78 (1.04 to 2.86)	64.3	71.2

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Lung and Bronchus	Colon and Rectum	20874	301	27.5	0.34	228.3	1.32 (1.17 to 1.48)	64.3	74.3
M	Lung and Bronchus	Esophagus	20874	103	9.4	0.12	36.1	2.85 (2.33 to 3.46)	64.3	70.9
M	Lung and Bronchus	Eye and Orbit	20874	5	0.5	0.01	3.6	1.39 (0.45 to 3.24)	64.3	73.6
M	Lung and Bronchus	Gallbladder and Other Biliary	20874	18	1.6	0.02	16.4	1.1 (0.65 to 1.73)	64.3	75.4
M	Lung and Bronchus	Kidney and Renal Pelvis	20874	89	8.1	0.10	83.9	1.06 (0.85 to 1.31)	64.3	73.9
M	Lung and Bronchus	Larynx	20874	81	7.4	0.09	24.9	3.25 (2.58 to 4.04)	64.3	72.6
M	Lung and Bronchus	Liver and Intrahepatic Bile Duct	20874	57	5.2	0.06	51.7	1.1 (0.84 to 1.43)	64.3	73.7
M	Lung and Bronchus	Melanoma of the Skin	20874	103	9.4	0.12	116.6	0.88 (0.72 to 1.07)	64.3	74.8
M	Lung and Bronchus	Myeloma	20874	30	2.7	0.03	41.4	0.72 (0.49 to 1.03)	64.3	75.4
M	Lung and Bronchus	Non-Hodgkin Lymphoma	20874	156	14.2	0.18	140.6	1.11 (0.94 to 1.3)	64.3	74.9
M	Lung and Bronchus	Oral Cavity and Pharynx	20874	124	11.3	0.14	61.2	2.03 (1.69 to 2.42)	64.3	71.6
M	Lung and Bronchus	Pancreas	20874	97	8.9	0.11	71.3	1.36 (1.1 to 1.66)	64.3	74.0
M	Lung and Bronchus	Penis and Other Genital Organs	20874	6	0.5	0.01	5.4	1.11 (0.41 to 2.41)	64.3	73.7
M	Lung and Bronchus	Prostate	20874	588	53.7	0.66	700.6	0.84 (0.77 to 0.91)	64.3	72.8
M	Lung and Bronchus	Small Intestine	20874	10	0.9	0.01	11.6	0.87 (0.42 to 1.59)	64.3	74.1
M	Lung and Bronchus	Soft Tissue including Heart	20874	23	2.1	0.03	13.8	1.67 (1.06 to 2.51)	64.3	72.8
M	Lung and Bronchus	Stomach	20874	81	7.4	0.09	52.1	1.56 (1.24 to 1.93)	64.3	73.5
M	Lung and Bronchus	Thyroid	20874	23	2.1	0.03	15.5	1.48 (0.94 to 2.22)	64.3	70.8
M	Lung and Bronchus	Urinary Bladder	20874	329	30.0	0.37	194.9	1.69 (1.51 to 1.88)	64.3	75.5
M	Melanoma of the Skin	Acute Lymphocytic Leukemia	46007	6	0.2	0.01	5.6	1.08 (0.4 to 2.35)	56.3	64.5
M	Melanoma of the Skin	Acute Non-Lymphocytic Leukemia	46007	64	1.7	0.07	62.7	1.02 (0.79 to 1.3)	56.3	72.4
M	Melanoma of the Skin	Anus, Anal Canal and Anorectum	46007	8	0.2	0.01	15.7	0.51 (0.22 to 1)	56.3	74.7
M	Melanoma of the Skin	Bones and Joints	46007	7	0.2	0.01	6.4	1.09 (0.44 to 2.25)	56.3	71.8
M	Melanoma of the Skin	Brain and Other Nervous System	46007	90	2.4	0.10	68.7	1.31 (1.05 to 1.61)	56.3	69.6
M	Melanoma of the Skin	Breast	46007	19	0.5	0.02	14.1	1.34 (0.81 to 2.1)	56.3	71.1
M	Melanoma of the Skin	Chronic Myeloid Leukemia	46007	23	0.6	0.03	24.6	0.94 (0.59 to 1.4)	56.3	72.8
M	Melanoma of the Skin	Colon and Rectum	46007	412	11.2	0.46	531.0	0.78 (0.7 to 0.86)	56.3	72.2
M	Melanoma of the Skin	Esophagus	46007	73	2.0	0.08	94.4	0.77 (0.61 to 0.97)	56.3	72.2
M	Melanoma of the Skin	Eye and Orbit	46007	23	0.6	0.03	11.1	2.08 (1.32 to 3.12)	56.3	65.1
M	Melanoma of the Skin	Gallbladder and Other Biliary	46007	23	0.6	0.03	37.5	0.61 (0.39 to 0.92)	56.3	76.1
M	Melanoma of the Skin	Hodgkin Lymphoma	46007	10	0.3	0.01	15.9	0.63 (0.3 to 1.16)	56.3	63.6
M	Melanoma of the Skin	Kidney and Renal Pelvis	46007	256	6.9	0.29	228.2	1.12 (0.99 to 1.27)	56.3	70.0

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Melanoma of the Skin	Larynx	46007	27	0.7	0.03	61.2	0.44 (0.29 to 0.64)	56.3	74.1
M	Melanoma of the Skin	Liver and Intrahepatic Bile Duct	46007	70	1.9	0.08	129.4	0.54 (0.42 to 0.68)	56.3	70.5
M	Melanoma of the Skin	Lung and Bronchus	46007	533	14.4	0.60	793.8	0.67 (0.62 to 0.73)	56.3	74.4
M	Melanoma of the Skin	Myeloma	46007	86	2.3	0.10	96.5	0.89 (0.71 to 1.1)	56.3	72.8
M	Melanoma of the Skin	Non-Hodgkin Lymphoma	46007	414	11.2	0.47	375.2	1.1 (1 to 1.22)	56.3	73.1
M	Melanoma of the Skin	Oral Cavity and Pharynx	46007	137	3.7	0.15	180.5	0.76 (0.64 to 0.9)	56.3	69.8
M	Melanoma of the Skin	Pancreas	46007	155	4.2	0.17	174.1	0.89 (0.76 to 1.04)	56.3	73.6
M	Melanoma of the Skin	Penis and Other Genital Organs	46007	16	0.4	0.02	13.5	1.18 (0.68 to 1.92)	56.3	73.8
M	Melanoma of the Skin	Prostate	46007	1794	48.6	2.02	1674.9	1.07 (1.02 to 1.12)	56.3	70.1
M	Melanoma of the Skin	Small Intestine	46007	28	0.8	0.03	29.3	0.96 (0.64 to 1.38)	56.3	68.0
M	Melanoma of the Skin	Soft Tissue including Heart	46007	75	2.0	0.08	37.7	1.99 (1.57 to 2.5)	56.3	70.8
M	Melanoma of the Skin	Stomach	46007	69	1.9	0.08	110.1	0.63 (0.49 to 0.79)	56.3	72.2
M	Melanoma of the Skin	Testis	46007	11	0.3	0.01	13.3	0.83 (0.41 to 1.48)	56.3	52.5
M	Melanoma of the Skin	Thyroid	46007	75	2.0	0.08	52.8	1.42 (1.12 to 1.78)	56.3	62.6
M	Melanoma of the Skin	Urinary Bladder	46007	400	10.8	0.45	491.8	0.81 (0.74 to 0.9)	56.3	75.0
M	Myeloma	Acute Lymphocytic Leukemia	6728	9	3.0	0.01	0.4	20.07 (9.18 to 38.09)	61.1	65.7
M	Myeloma	Acute Non-Lymphocytic Leukemia	6728	41	13.6	0.05	5.6	7.36 (5.28 to 9.99)	61.1	67.7
M	Myeloma	Colon and Rectum	6728	55	18.3	0.06	51.4	1.07 (0.81 to 1.39)	61.1	71.6
M	Myeloma	Esophagus	6728	8	2.7	0.01	8.5	0.94 (0.41 to 1.85)	61.1	75.7
M	Myeloma	Hodgkin Lymphoma	6728	5	1.7	0.01	1.3	3.94 (1.28 to 9.2)	61.1	69.5
M	Myeloma	Kidney and Renal Pelvis	6728	26	8.6	0.03	21.2	1.22 (0.8 to 1.79)	61.1	67.1
M	Myeloma	Liver and Intrahepatic Bile Duct	6728	8	2.7	0.01	13.7	0.59 (0.25 to 1.15)	61.1	71.8
M	Myeloma	Lung and Bronchus	6728	61	20.3	0.07	79.3	0.77 (0.59 to 0.99)	61.1	72.7
M	Myeloma	Melanoma of the Skin	6728	34	11.3	0.04	27.2	1.25 (0.87 to 1.75)	61.1	73.5
M	Myeloma	Non-Hodgkin Lymphoma	6728	38	12.6	0.04	32.0	1.19 (0.84 to 1.63)	61.1	71.1
M	Myeloma	Oral Cavity and Pharynx	6728	20	6.6	0.02	15.7	1.27 (0.78 to 1.96)	61.1	69.3
M	Myeloma	Pancreas	6728	13	4.3	0.01	16.7	0.78 (0.42 to 1.33)	61.1	71.8
M	Myeloma	Prostate	6728	130	43.2	0.15	171.2	0.76 (0.64 to 0.9)	61.1	70.1
M	Myeloma	Soft Tissue including Heart	6728	6	2.0	0.01	3.2	1.87 (0.69 to 4.07)	61.1	64.9
M	Myeloma	Stomach	6728	13	4.3	0.01	11.7	1.11 (0.59 to 1.9)	61.1	65.9
M	Myeloma	Thyroid	6728	6	2.0	0.01	4.3	1.41 (0.52 to 3.07)	61.1	55.6
M	Myeloma	Urinary Bladder	6728	39	13.0	0.04	41.7	0.94 (0.67 to 1.28)	61.1	72.7

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Non-Hodgkin Lymphoma	Acute Lymphocytic Leukemia	44576	14	0.5	0.02	4.5	3.14 (1.72 to 5.27)	59.1	72.3
M	Non-Hodgkin Lymphoma	Acute Non-Lymphocytic Leukemia	44576	223	7.6	0.25	53.9	4.14 (3.62 to 4.72)	59.1	70.4
M	Non-Hodgkin Lymphoma	Anus, Anal Canal and Anorectum	44576	56	1.9	0.06	12.6	4.44 (3.35 to 5.76)	59.1	60.6
M	Non-Hodgkin Lymphoma	Bones and Joints	44576	7	0.2	0.01	5.1	1.37 (0.55 to 2.82)	59.1	66.5
M	Non-Hodgkin Lymphoma	Brain and Other Nervous System	44576	49	1.7	0.06	54.5	0.9 (0.67 to 1.19)	59.1	67.5
M	Non-Hodgkin Lymphoma	Breast	44576	21	0.7	0.02	12.2	1.72 (1.06 to 2.62)	59.1	70.0
M	Non-Hodgkin Lymphoma	Chronic Myeloid Leukemia	44576	45	1.5	0.05	20.8	2.16 (1.57 to 2.89)	59.1	68.9
M	Non-Hodgkin Lymphoma	Colon and Rectum	44576	424	14.5	0.48	468.0	0.91 (0.82 to 1)	59.1	74.8
M	Non-Hodgkin Lymphoma	Esophagus	44576	82	2.8	0.09	78.7	1.04 (0.83 to 1.29)	59.1	72.3
M	Non-Hodgkin Lymphoma	Eye and Orbit	44576	13	0.4	0.01	8.6	1.52 (0.81 to 2.6)	59.1	72.4
M	Non-Hodgkin Lymphoma	Gallbladder and Other Biliary	44576	41	1.4	0.05	33.9	1.21 (0.87 to 1.64)	59.1	72.2
M	Non-Hodgkin Lymphoma	Hodgkin Lymphoma	44576	126	4.3	0.14	12.5	10.09 (8.4 to 12.01)	59.1	63.3
M	Non-Hodgkin Lymphoma	Kaposi Sarcoma	44576	13	0.4	0.01	5.2	2.51 (1.33 to 4.28)	59.1	52.1
M	Non-Hodgkin Lymphoma	Kidney and Renal Pelvis	44576	219	7.5	0.25	190.4	1.15 (1 to 1.31)	59.1	69.2
M	Non-Hodgkin Lymphoma	Larynx	44576	63	2.2	0.07	52.4	1.2 (0.92 to 1.54)	59.1	71.3
M	Non-Hodgkin Lymphoma	Liver and Intrahepatic Bile Duct	44576	107	3.7	0.12	116.9	0.92 (0.75 to 1.11)	59.1	68.5
M	Non-Hodgkin Lymphoma	Lung and Bronchus	44576	854	29.2	0.96	706.0	1.21 (1.13 to 1.29)	59.1	73.1
M	Non-Hodgkin Lymphoma	Melanoma of the Skin	44576	386	13.2	0.44	285.0	1.35 (1.22 to 1.5)	59.1	73.1
M	Non-Hodgkin Lymphoma	Myeloma	44576	71	2.4	0.08	86.1	0.82 (0.64 to 1.04)	59.1	72.1
M	Non-Hodgkin Lymphoma	Oral Cavity and Pharynx	44576	219	7.5	0.25	145.6	1.5 (1.31 to 1.72)	59.1	69.2
M	Non-Hodgkin Lymphoma	Pancreas	44576	158	5.4	0.18	151.6	1.04 (0.89 to 1.22)	59.1	74.3
M	Non-Hodgkin Lymphoma	Penis and Other Genital Organs	44576	18	0.6	0.02	11.6	1.55 (0.92 to 2.45)	59.1	70.0
M	Non-Hodgkin Lymphoma	Prostate	44576	1352	46.2	1.52	1439.5	0.94 (0.89 to 0.99)	59.1	71.8
M	Non-Hodgkin Lymphoma	Small Intestine	44576	29	1.0	0.03	25.2	1.15 (0.77 to 1.65)	59.1	69.4
M	Non-Hodgkin Lymphoma	Soft Tissue including Heart	44576	48	1.6	0.05	31.4	1.53 (1.13 to 2.03)	59.1	72.3
M	Non-Hodgkin Lymphoma	Stomach	44576	113	3.9	0.13	103.0	1.1 (0.9 to 1.32)	59.1	73.6
M	Non-Hodgkin Lymphoma	Testis	44576	7	0.2	0.01	8.6	0.82 (0.33 to 1.68)	59.1	55.9
M	Non-Hodgkin Lymphoma	Thyroid	44576	59	2.0	0.07	40.9	1.44 (1.1 to 1.86)	59.1	65.1
M	Non-Hodgkin Lymphoma	Urinary Bladder	44576	487	16.6	0.55	414.3	1.18 (1.07 to 1.29)	59.1	75.0
M	Oral Cavity and Pharynx	Acute Non-Lymphocytic Leukemia	22937	31	2.0	0.03	25.6	1.21 (0.82 to 1.72)	57.5	69.5
M	Oral Cavity and Pharynx	Anus, Anal Canal and Anorectum	22937	7	0.5	0.01	6.5	1.08 (0.44 to 2.23)	57.5	64.7
M	Oral Cavity and Pharynx	Bones and Joints	22937	13	0.8	0.01	2.6	5.05 (2.69 to 8.64)	57.5	61.4

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Oral Cavity and Pharynx	Brain and Other Nervous System	22937	28	1.8	0.03	27.8	1.01 (0.67 to 1.45)	57.5	67.7
M	Oral Cavity and Pharynx	Chronic Myeloid Leukemia	22937	13	0.8	0.01	10.0	1.3 (0.69 to 2.22)	57.5	68.7
M	Oral Cavity and Pharynx	Colon and Rectum	22937	254	16.4	0.29	236.9	1.07 (0.94 to 1.21)	57.5	72.4
M	Oral Cavity and Pharynx	Esophagus	22937	168	10.8	0.19	39.9	4.21 (3.6 to 4.9)	57.5	67.1
M	Oral Cavity and Pharynx	Gallbladder and Other Biliary	22937	27	1.7	0.03	16.6	1.63 (1.07 to 2.37)	57.5	74.5
M	Oral Cavity and Pharynx	Hodgkin Lymphoma	22937	6	0.4	0.01	6.3	0.95 (0.35 to 2.07)	57.5	69.4
M	Oral Cavity and Pharynx	Kidney and Renal Pelvis	22937	99	6.4	0.11	98.6	1 (0.82 to 1.22)	57.5	68.7
M	Oral Cavity and Pharynx	Larynx	22937	138	8.9	0.16	27.4	5.03 (4.23 to 5.95)	57.5	66.5
M	Oral Cavity and Pharynx	Liver and Intrahepatic Bile Duct	22937	98	6.3	0.11	64.4	1.52 (1.24 to 1.86)	57.5	67.6
M	Oral Cavity and Pharynx	Lung and Bronchus	22937	866	55.8	0.98	351.0	2.47 (2.31 to 2.64)	57.5	70.4
M	Oral Cavity and Pharynx	Melanoma of the Skin	22937	170	11.0	0.19	138.0	1.23 (1.05 to 1.43)	57.5	71.9
M	Oral Cavity and Pharynx	Myeloma	22937	38	2.4	0.04	42.5	0.89 (0.63 to 1.23)	57.5	69.7
M	Oral Cavity and Pharynx	Non-Hodgkin Lymphoma	22937	144	9.3	0.16	153.0	0.94 (0.79 to 1.11)	57.5	71.5
M	Oral Cavity and Pharynx	Pancreas	22937	75	4.8	0.08	75.0	1 (0.79 to 1.25)	57.5	71.9
M	Oral Cavity and Pharynx	Penis and Other Genital Organs	22937	8	0.5	0.01	5.6	1.42 (0.61 to 2.8)	57.5	74.4
M	Oral Cavity and Pharynx	Prostate	22937	706	45.5	0.80	776.2	0.91 (0.84 to 0.98)	57.5	69.3
M	Oral Cavity and Pharynx	Small Intestine	22937	12	0.8	0.01	12.7	0.94 (0.49 to 1.65)	57.5	70.7
M	Oral Cavity and Pharynx	Soft Tissue including Heart	22937	33	2.1	0.04	15.4	2.15 (1.48 to 3.02)	57.5	67.3
M	Oral Cavity and Pharynx	Stomach	22937	65	4.2	0.07	52.2	1.25 (0.96 to 1.59)	57.5	71.7
M	Oral Cavity and Pharynx	Thyroid	22937	24	1.5	0.03	22.0	1.09 (0.7 to 1.62)	57.5	64.2
M	Oral Cavity and Pharynx	Urinary Bladder	22937	208	13.4	0.23	195.5	1.06 (0.92 to 1.22)	57.5	73.5
M	Pancreas	Colon and Rectum	1674	20	25.5	0.02	13.1	1.53 (0.93 to 2.36)	60.0	74.0
M	Pancreas	Kidney and Renal Pelvis	1674	5	6.4	0.01	5.3	0.95 (0.31 to 2.21)	60.0	71.2
M	Pancreas	Liver and Intrahepatic Bile Duct	1674	5	6.4	0.01	3.4	1.45 (0.47 to 3.38)	60.0	65.8
M	Pancreas	Lung and Bronchus	1674	28	35.7	0.03	19.9	1.41 (0.94 to 2.04)	60.0	70.1
M	Pancreas	Melanoma of the Skin	1674	11	14.0	0.01	7.4	1.48 (0.74 to 2.65)	60.0	71.1
M	Pancreas	Myeloma	1674	5	6.4	0.01	2.4	2.06 (0.67 to 4.82)	60.0	69.0
M	Pancreas	Non-Hodgkin Lymphoma	1674	13	16.6	0.01	8.5	1.54 (0.82 to 2.63)	60.0	72.1
M	Pancreas	Oral Cavity and Pharynx	1674	7	8.9	0.01	4.0	1.75 (0.7 to 3.61)	60.0	64.1
M	Pancreas	Prostate	1674	38	48.4	0.04	40.5	0.94 (0.67 to 1.29)	60.0	73.6
M	Pancreas	Stomach	1674	11	14.0	0.01	3.0	3.63 (1.81 to 6.49)	60.0	68.6
M	Pancreas	Thyroid	1674	7	8.9	0.01	1.1	6.28 (2.52 to 12.94)	60.0	62.6

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Pancreas	Urinary Bladder	1674	13	16.6	0.01	11.2	1.16 (0.62 to 1.99)	60.0	70.8
M	Penis and Other Genital Organs	Anus, Anal Canal and Anorectum	1592	5	4.6	0.01	0.5	10.31 (3.35 to 24.05)	61.5	67.5
M	Penis and Other Genital Organs	Colon and Rectum	1592	24	21.9	0.03	20.7	1.16 (0.74 to 1.73)	61.5	75.0
M	Penis and Other Genital Organs	Kidney and Renal Pelvis	1592	5	4.6	0.01	7.6	0.66 (0.21 to 1.54)	61.5	71.6
M	Penis and Other Genital Organs	Lung and Bronchus	1592	53	48.4	0.06	31.0	1.71 (1.28 to 2.23)	61.5	71.5
M	Penis and Other Genital Organs	Melanoma of the Skin	1592	6	5.5	0.01	11.0	0.55 (0.2 to 1.19)	61.5	72.6
M	Penis and Other Genital Organs	Non-Hodgkin Lymphoma	1592	18	16.5	0.02	13.0	1.39 (0.82 to 2.2)	61.5	71.4
M	Penis and Other Genital Organs	Oral Cavity and Pharynx	1592	8	7.3	0.01	5.7	1.41 (0.61 to 2.77)	61.5	67.4
M	Penis and Other Genital Organs	Pancreas	1592	6	5.5	0.01	6.5	0.93 (0.34 to 2.02)	61.5	74.0
M	Penis and Other Genital Organs	Prostate	1592	54	49.4	0.06	60.1	0.9 (0.68 to 1.17)	61.5	73.2
M	Penis and Other Genital Organs	Soft Tissue including Heart	1592	11	10.1	0.01	1.3	8.49 (4.24 to 15.19)	61.5	70.0
M	Penis and Other Genital Organs	Stomach	1592	7	6.4	0.01	4.8	1.45 (0.59 to 3)	61.5	80.2
M	Penis and Other Genital Organs	Urinary Bladder	1592	24	21.9	0.03	17.8	1.35 (0.86 to 2)	61.5	76.6
M	Prostate	Acute Lymphocytic Leukemia	390274	53	0.2	0.06	49.4	1.07 (0.8 to 1.4)	66.4	74.5
M	Prostate	Acute Non-Lymphocytic Leukemia	390274	779	2.9	0.88	762.3	1.02 (0.95 to 1.1)	66.4	78.5
M	Prostate	Anus, Anal Canal and Anorectum	390274	167	0.6	0.19	141.7	1.18 (1.01 to 1.37)	66.4	77.4
M	Prostate	Bones and Joints	390274	68	0.2	0.08	59.3	1.15 (0.89 to 1.45)	66.4	75.4
M	Prostate	Brain and Other Nervous System	390274	604	2.2	0.68	641.1	0.94 (0.87 to 1.02)	66.4	76.2
M	Prostate	Breast	390274	168	0.6	0.19	171.8	0.98 (0.84 to 1.14)	66.4	76.8
M	Prostate	Chronic Myeloid Leukemia	390274	258	0.9	0.29	285.8	0.9 (0.8 to 1.02)	66.4	78.3
M	Prostate	Colon and Rectum	390274	5799	21.2	6.54	6598.5	0.88 (0.86 to 0.9)	66.4	78.0
M	Prostate	Esophagus	390274	881	3.2	0.99	1036.5	0.85 (0.8 to 0.91)	66.4	77.0
M	Prostate	Eye and Orbit	390274	102	0.4	0.11	102.5	1 (0.81 to 1.21)	66.4	76.0
M	Prostate	Gallbladder and Other Biliary	390274	434	1.6	0.49	489.4	0.89 (0.81 to 0.97)	66.4	78.2
M	Prostate	Hodgkin Lymphoma	390274	111	0.4	0.13	132.3	0.84 (0.69 to 1.01)	66.4	76.3
M	Prostate	Kaposi Sarcoma	390274	31	0.1	0.03	51.0	0.61 (0.41 to 0.86)	66.4	77.3
M	Prostate	Kidney and Renal Pelvis	390274	2414	8.8	2.72	2360.7	1.02 (0.98 to 1.06)	66.4	75.4
M	Prostate	Larynx	390274	517	1.9	0.58	698.0	0.74 (0.68 to 0.81)	66.4	76.8
M	Prostate	Liver and Intrahepatic Bile Duct	390274	844	3.1	0.95	1378.2	0.61 (0.57 to 0.66)	66.4	76.2
M	Prostate	Lung and Bronchus	390274	8539	31.3	9.63	10380.0	0.82 (0.81 to 0.84)	66.4	77.5
M	Prostate	Melanoma of the Skin	390274	3476	12.7	3.92	3429.4	1.01 (0.98 to 1.05)	66.4	76.9
M	Prostate	Myeloma	390274	1306	4.8	1.47	1261.6	1.04 (0.98 to 1.09)	66.4	77.1

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Prostate	Non-Hodgkin Lymphoma	390274	4026	14.7	4.54	4119.7	0.98 (0.95 to 1.01)	66.4	77.5
M	Prostate	Oral Cavity and Pharynx	390274	1284	4.7	1.45	1654.8	0.78 (0.73 to 0.82)	66.4	75.5
M	Prostate	Pancreas	390274	1918	7.0	2.16	2121.6	0.9 (0.86 to 0.95)	66.4	77.2
M	Prostate	Penis and Other Genital Organs	390274	141	0.5	0.16	163.3	0.86 (0.73 to 1.02)	66.4	77.6
M	Prostate	Small Intestine	390274	406	1.5	0.46	341.7	1.19 (1.08 to 1.31)	66.4	76.8
M	Prostate	Soft Tissue including Heart	390274	445	1.6	0.50	404.0	1.1 (1 to 1.21)	66.4	77.7
M	Prostate	Stomach	390274	1290	4.7	1.45	1509.4	0.86 (0.81 to 0.9)	66.4	78.1
M	Prostate	Testis	390274	33	0.1	0.04	34.3	0.96 (0.66 to 1.35)	66.4	71.5
M	Prostate	Thyroid	390274	472	1.7	0.53	397.0	1.19 (1.08 to 1.3)	66.4	72.8
M	Prostate	Urinary Bladder	390274	6330	23.2	7.14	5964.0	1.06 (1.04 to 1.09)	66.4	78.6
M	Small Intestine	Colon and Rectum	2771	27	15.8	0.03	27.3	0.99 (0.65 to 1.44)	59.0	66.2
M	Small Intestine	Kidney and Renal Pelvis	2771	11	6.4	0.01	11.5	0.96 (0.48 to 1.71)	59.0	68.3
M	Small Intestine	Liver and Intrahepatic Bile Duct	2771	12	7.0	0.01	7.4	1.62 (0.84 to 2.83)	59.0	72.6
M	Small Intestine	Lung and Bronchus	2771	35	20.5	0.04	41.5	0.84 (0.59 to 1.17)	59.0	72.4
M	Small Intestine	Melanoma of the Skin	2771	15	8.8	0.02	15.7	0.96 (0.54 to 1.58)	59.0	71.8
M	Small Intestine	Myeloma	2771	5	2.9	0.01	5.3	0.94 (0.3 to 2.18)	59.0	72.2
M	Small Intestine	Non-Hodgkin Lymphoma	2771	25	14.7	0.03	17.7	1.42 (0.92 to 2.09)	59.0	75.0
M	Small Intestine	Oral Cavity and Pharynx	2771	10	5.9	0.01	8.7	1.15 (0.55 to 2.11)	59.0	71.1
M	Small Intestine	Pancreas	2771	15	8.8	0.02	9.0	1.67 (0.94 to 2.76)	59.0	68.6
M	Small Intestine	Prostate	2771	94	55.1	0.11	88.8	1.06 (0.86 to 1.3)	59.0	69.5
M	Small Intestine	Stomach	2771	8	4.7	0.01	6.1	1.3 (0.56 to 2.57)	59.0	70.9
M	Small Intestine	Thyroid	2771	5	2.9	0.01	2.4	2.07 (0.67 to 4.83)	59.0	70.8
M	Small Intestine	Urinary Bladder	2771	22	12.9	0.02	22.9	0.96 (0.6 to 1.45)	59.0	77.0
M	Soft Tissue including Heart	Acute Non-Lymphocytic Leukemia	5151	7	1.8	0.01	5.6	1.25 (0.5 to 2.57)	52.9	68.2
M	Soft Tissue including Heart	Bones and Joints	5151	6	1.5	0.01	0.6	10.02 (3.68 to 21.81)	52.9	55.1
M	Soft Tissue including Heart	Brain and Other Nervous System	5151	6	1.5	0.01	6.1	0.99 (0.36 to 2.15)	52.9	65.7
M	Soft Tissue including Heart	Colon and Rectum	5151	41	10.3	0.05	51.0	0.8 (0.58 to 1.09)	52.9	67.4
M	Soft Tissue including Heart	Esophagus	5151	6	1.5	0.01	8.3	0.72 (0.27 to 1.58)	52.9	78.5
M	Soft Tissue including Heart	Kidney and Renal Pelvis	5151	28	7.0	0.03	21.0	1.33 (0.89 to 1.93)	52.9	69.0
M	Soft Tissue including Heart	Liver and Intrahepatic Bile Duct	5151	9	2.3	0.01	13.4	0.67 (0.31 to 1.28)	52.9	65.8
M	Soft Tissue including Heart	Lung and Bronchus	5151	72	18.1	0.08	73.5	0.98 (0.77 to 1.23)	52.9	71.9
M	Soft Tissue including Heart	Melanoma of the Skin	5151	56	14.1	0.06	29.6	1.89 (1.43 to 2.46)	52.9	71.1

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Soft Tissue including Heart	Myeloma	5151	13	3.3	0.01	9.3	1.41 (0.75 to 2.4)	52.9	77.7
M	Soft Tissue including Heart	Non-Hodgkin Lymphoma	5151	30	7.5	0.03	32.9	0.91 (0.62 to 1.3)	52.9	71.8
M	Soft Tissue including Heart	Oral Cavity and Pharynx	5151	20	5.0	0.02	16.4	1.22 (0.75 to 1.89)	52.9	67.3
M	Soft Tissue including Heart	Pancreas	5151	19	4.8	0.02	16.0	1.19 (0.72 to 1.86)	52.9	73.1
M	Soft Tissue including Heart	Prostate	5151	160	40.2	0.18	154.9	1.03 (0.88 to 1.21)	52.9	70.5
M	Soft Tissue including Heart	Small Intestine	5151	6	1.5	0.01	2.8	2.17 (0.8 to 4.73)	52.9	67.6
M	Soft Tissue including Heart	Stomach	5151	11	2.8	0.01	11.2	0.98 (0.49 to 1.76)	52.9	69.8
M	Soft Tissue including Heart	Thyroid	5151	14	3.5	0.02	5.0	2.79 (1.53 to 4.69)	52.9	61.0
M	Soft Tissue including Heart	Urinary Bladder	5151	44	11.1	0.05	41.7	1.06 (0.77 to 1.42)	52.9	74.6
M	Stomach	Acute Non-Lymphocytic Leukemia	6149	13	3.5	0.01	8.0	1.63 (0.87 to 2.78)	63.1	75.3
M	Stomach	Brain and Other Nervous System	6149	7	1.9	0.01	6.8	1.03 (0.41 to 2.12)	63.1	71.6
M	Stomach	Chronic Myeloid Leukemia	6149	5	1.3	0.01	3.0	1.68 (0.55 to 3.93)	63.1	71.6
M	Stomach	Colon and Rectum	6149	92	24.6	0.10	73.0	1.26 (1.02 to 1.55)	63.1	73.9
M	Stomach	Esophagus	6149	18	4.8	0.02	10.7	1.68 (1 to 2.66)	63.1	72.8
M	Stomach	Gallbladder and Other Biliary	6149	8	2.1	0.01	5.9	1.36 (0.59 to 2.68)	63.1	73.4
M	Stomach	Kidney and Renal Pelvis	6149	24	6.4	0.03	25.7	0.94 (0.6 to 1.39)	63.1	71.6
M	Stomach	Larynx	6149	7	1.9	0.01	7.2	0.97 (0.39 to 2)	63.1	69.9
M	Stomach	Liver and Intrahepatic Bile Duct	6149	33	8.8	0.04	20.1	1.65 (1.13 to 2.31)	63.1	72.6
M	Stomach	Lung and Bronchus	6149	149	39.9	0.17	109.9	1.36 (1.15 to 1.59)	63.1	75.7
M	Stomach	Melanoma of the Skin	6149	27	7.2	0.03	31.1	0.87 (0.57 to 1.26)	63.1	72.5
M	Stomach	Myeloma	6149	14	3.7	0.02	12.8	1.1 (0.6 to 1.84)	63.1	78.4
M	Stomach	Non-Hodgkin Lymphoma	6149	42	11.2	0.05	42.4	0.99 (0.71 to 1.34)	63.1	74.0
M	Stomach	Oral Cavity and Pharynx	6149	16	4.3	0.02	18.9	0.85 (0.49 to 1.38)	63.1	70.6
M	Stomach	Pancreas	6149	36	9.6	0.04	23.0	1.56 (1.1 to 2.16)	63.1	74.4
M	Stomach	Prostate	6149	187	50.1	0.21	202.2	0.93 (0.8 to 1.07)	63.1	73.7
M	Stomach	Small Intestine	6149	5	1.3	0.01	3.5	1.41 (0.46 to 3.29)	63.1	71.9
M	Stomach	Soft Tissue including Heart	6149	5	1.3	0.01	4.4	1.14 (0.37 to 2.67)	63.1	78.5
M	Stomach	Thyroid	6149	9	2.4	0.01	5.1	1.76 (0.81 to 3.35)	63.1	65.0
M	Stomach	Urinary Bladder	6149	64	17.1	0.07	57.4	1.11 (0.86 to 1.42)	63.1	75.6
M	Testis	Acute Non-Lymphocytic Leukemia	17913	16	0.9	0.02	7.5	2.12 (1.21 to 3.44)	35.8	60.9
M	Testis	Brain and Other Nervous System	17913	12	0.7	0.01	15.2	0.79 (0.41 to 1.38)	35.8	47.4
M	Testis	Chronic Myeloid Leukemia	17913	9	0.5	0.01	4.1	2.22 (1.01 to 4.21)	35.8	40.6

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Testis	Colon and Rectum	17913	101	5.6	0.11	78.7	1.28 (1.05 to 1.56)	35.8	57.7
M	Testis	Esophagus	17913	8	0.4	0.01	11.9	0.67 (0.29 to 1.33)	35.8	56.6
M	Testis	Gallbladder and Other Biliary	17913	5	0.3	0.01	4.1	1.21 (0.39 to 2.83)	35.8	57.9
M	Testis	Hodgkin Lymphoma	17913	6	0.3	0.01	6.2	0.97 (0.36 to 2.12)	35.8	43.9
M	Testis	Kidney and Renal Pelvis	17913	40	2.2	0.05	41.0	0.98 (0.7 to 1.33)	35.8	55.2
M	Testis	Liver and Intrahepatic Bile Duct	17913	15	0.8	0.02	24.5	0.61 (0.34 to 1.01)	35.8	60.1
M	Testis	Lung and Bronchus	17913	79	4.4	0.09	74.3	1.06 (0.84 to 1.33)	35.8	62.0
M	Testis	Melanoma of the Skin	17913	68	3.8	0.08	60.4	1.13 (0.87 to 1.43)	35.8	54.8
M	Testis	Myeloma	17913	12	0.7	0.01	11.8	1.01 (0.52 to 1.77)	35.8	55.9
M	Testis	Non-Hodgkin Lymphoma	17913	50	2.8	0.06	53.3	0.94 (0.7 to 1.24)	35.8	58.5
M	Testis	Oral Cavity and Pharynx	17913	18	1.0	0.02	37.0	0.49 (0.29 to 0.77)	35.8	56.6
M	Testis	Pancreas	17913	36	2.0	0.04	20.3	1.77 (1.24 to 2.46)	35.8	59.5
M	Testis	Prostate	17913	170	9.5	0.19	207.7	0.82 (0.7 to 0.95)	35.8	59.6
M	Testis	Small Intestine	17913	8	0.4	0.01	4.7	1.72 (0.74 to 3.39)	35.8	57.9
M	Testis	Soft Tissue including Heart	17913	16	0.9	0.02	7.3	2.19 (1.25 to 3.55)	35.8	50.2
M	Testis	Stomach	17913	21	1.2	0.02	14.9	1.41 (0.87 to 2.16)	35.8	59.9
M	Testis	Thyroid	17913	31	1.7	0.03	18.5	1.68 (1.14 to 2.38)	35.8	45.3
M	Testis	Urinary Bladder	17913	69	3.8	0.08	42.2	1.64 (1.27 to 2.07)	35.8	59.0
M	Thyroid	Acute Lymphocytic Leukemia	12442	9	0.9	0.01	1.3	7.12 (3.26 to 13.52)	49.8	60.5
M	Thyroid	Acute Non-Lymphocytic Leukemia	12442	16	1.6	0.02	11.1	1.44 (0.82 to 2.33)	49.8	68.5
M	Thyroid	Brain and Other Nervous System	12442	14	1.4	0.02	13.9	1.01 (0.55 to 1.7)	49.8	60.7
M	Thyroid	Chronic Myeloid Leukemia	12442	7	0.7	0.01	4.6	1.52 (0.61 to 3.14)	49.8	66.7
M	Thyroid	Colon and Rectum	12442	97	9.8	0.11	103.2	0.94 (0.76 to 1.15)	49.8	69.0
M	Thyroid	Esophagus	12442	21	2.1	0.02	17.5	1.2 (0.74 to 1.83)	49.8	69.6
M	Thyroid	Gallbladder and Other Biliary	12442	14	1.4	0.02	7.1	1.97 (1.08 to 3.3)	49.8	72.8
M	Thyroid	Kidney and Renal Pelvis	12442	102	10.3	0.11	46.9	2.18 (1.77 to 2.64)	49.8	64.6
M	Thyroid	Larynx	12442	7	0.7	0.01	12.0	0.58 (0.23 to 1.2)	49.8	71.3
M	Thyroid	Liver and Intrahepatic Bile Duct	12442	14	1.4	0.02	31.2	0.45 (0.25 to 0.75)	49.8	69.3
M	Thyroid	Lung and Bronchus	12442	113	11.5	0.13	143.2	0.79 (0.65 to 0.95)	49.8	69.4
M	Thyroid	Melanoma of the Skin	12442	86	8.7	0.10	65.8	1.31 (1.05 to 1.62)	49.8	67.2
M	Thyroid	Myeloma	12442	22	2.2	0.02	18.5	1.19 (0.75 to 1.8)	49.8	72.9
M	Thyroid	Non-Hodgkin Lymphoma	12442	92	9.3	0.10	68.6	1.34 (1.08 to 1.65)	49.8	66.4

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Thyroid	Oral Cavity and Pharynx	12442	29	2.9	0.03	38.3	0.76 (0.51 to 1.09)	49.8	61.4
M	Thyroid	Pancreas	12442	37	3.8	0.04	32.6	1.14 (0.8 to 1.57)	49.8	67.8
M	Thyroid	Penis and Other Genital Organs	12442	5	0.5	0.01	2.5	2 (0.65 to 4.68)	49.8	69.4
M	Thyroid	Prostate	12442	385	39.0	0.43	329.6	1.17 (1.05 to 1.29)	49.8	66.6
M	Thyroid	Small Intestine	12442	12	1.2	0.01	5.8	2.06 (1.06 to 3.59)	49.8	71.3
M	Thyroid	Soft Tissue including Heart	12442	19	1.9	0.02	7.4	2.57 (1.55 to 4.02)	49.8	64.9
M	Thyroid	Stomach	12442	25	2.5	0.03	22.6	1.11 (0.72 to 1.63)	49.8	67.8
M	Thyroid	Urinary Bladder	12442	83	8.4	0.09	79.9	1.04 (0.83 to 1.29)	49.8	73.4
M	Urinary Bladder	Acute Lymphocytic Leukemia	51513	11	0.3	0.01	6.2	1.79 (0.89 to 3.2)	65.6	69.7
M	Urinary Bladder	Acute Non-Lymphocytic Leukemia	51513	101	2.9	0.11	89.5	1.13 (0.92 to 1.37)	65.6	77.5
M	Urinary Bladder	Anus, Anal Canal and Anorectum	51513	16	0.5	0.02	17.4	0.92 (0.53 to 1.5)	65.6	72.4
M	Urinary Bladder	Bones and Joints	51513	8	0.2	0.01	7.3	1.1 (0.47 to 2.16)	65.6	76.5
M	Urinary Bladder	Brain and Other Nervous System	51513	81	2.3	0.09	79.7	1.02 (0.81 to 1.26)	65.6	73.9
M	Urinary Bladder	Breast	51513	20	0.6	0.02	19.4	1.03 (0.63 to 1.59)	65.6	72.0
M	Urinary Bladder	Chronic Myeloid Leukemia	51513	32	0.9	0.04	33.8	0.95 (0.65 to 1.34)	65.6	76.7
M	Urinary Bladder	Colon and Rectum	51513	688	19.7	0.78	762.0	0.9 (0.84 to 0.97)	65.6	76.6
M	Urinary Bladder	Esophagus	51513	142	4.1	0.16	122.7	1.16 (0.98 to 1.36)	65.6	75.2
M	Urinary Bladder	Eye and Orbit	51513	11	0.3	0.01	13.2	0.84 (0.42 to 1.5)	65.6	76.0
M	Urinary Bladder	Gallbladder and Other Biliary	51513	48	1.4	0.05	55.9	0.86 (0.63 to 1.14)	65.6	78.3
M	Urinary Bladder	Hodgkin Lymphoma	51513	13	0.4	0.01	16.7	0.78 (0.41 to 1.33)	65.6	70.0
M	Urinary Bladder	Kidney and Renal Pelvis	51513	487	13.9	0.55	275.6	1.77 (1.61 to 1.93)	65.6	73.7
M	Urinary Bladder	Larynx	51513	111	3.2	0.13	78.7	1.41 (1.16 to 1.7)	65.6	73.7
M	Urinary Bladder	Liver and Intrahepatic Bile Duct	51513	187	5.3	0.21	157.0	1.19 (1.03 to 1.38)	65.6	74.7
M	Urinary Bladder	Lung and Bronchus	51513	2078	59.4	2.34	1166.1	1.78 (1.71 to 1.86)	65.6	76.4
M	Urinary Bladder	Melanoma of the Skin	51513	306	8.8	0.34	442.7	0.69 (0.62 to 0.77)	65.6	76.4
M	Urinary Bladder	Myeloma	51513	121	3.5	0.14	135.3	0.89 (0.74 to 1.07)	65.6	77.8
M	Urinary Bladder	Non-Hodgkin Lymphoma	51513	449	12.8	0.51	498.4	0.9 (0.82 to 0.99)	65.6	76.8
M	Urinary Bladder	Oral Cavity and Pharynx	51513	187	5.3	0.21	202.8	0.92 (0.8 to 1.06)	65.6	74.3
M	Urinary Bladder	Pancreas	51513	210	6.0	0.24	242.3	0.87 (0.75 to 0.99)	65.6	77.3
M	Urinary Bladder	Penis and Other Genital Organs	51513	20	0.6	0.02	18.9	1.06 (0.65 to 1.63)	65.6	75.4
M	Urinary Bladder	Prostate	51513	1818	52.0	2.05	2154.9	0.84 (0.81 to 0.88)	65.6	74.2
M	Urinary Bladder	Small Intestine	51513	48	1.4	0.05	37.9	1.27 (0.93 to 1.68)	65.6	76.3

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
M	Urinary Bladder	Soft Tissue including Heart	51513	44	1.3	0.05	48.9	0.9 (0.65 to 1.21)	65.6	73.8
M	Urinary Bladder	Stomach	51513	168	4.8	0.19	166.1	1.01 (0.86 to 1.18)	65.6	76.7
M	Urinary Bladder	Testis	51513	8	0.2	0.01	6.3	1.28 (0.55 to 2.52)	65.6	70.5
M	Urinary Bladder	Thyroid	51513	64	1.8	0.07	50.4	1.27 (0.98 to 1.62)	65.6	70.6
W	Acute Lymphocytic Leukemia	Breast	486	8	22.4	0.01	7.1	1.13 (0.49 to 2.23)	41.3	65.0
W	Acute Lymphocytic Leukemia	Lung and Bronchus	486	6	16.8	0.01	2.1	2.85 (1.05 to 6.21)	41.3	67.8
W	Acute Non-Lymphocytic Leukemia	Breast	1861	46	31.4	0.08	37.8	1.22 (0.89 to 1.62)	46.9	60.0
W	Acute Non-Lymphocytic Leukemia	Colon and Rectum	1861	7	4.8	0.01	10.0	0.7 (0.28 to 1.44)	46.9	76.3
W	Acute Non-Lymphocytic Leukemia	Corpus and Uterus, NOS	1861	8	5.5	0.01	8.5	0.95 (0.41 to 1.86)	46.9	67.0
W	Acute Non-Lymphocytic Leukemia	Lung and Bronchus	1861	14	9.6	0.02	13.9	1.01 (0.55 to 1.69)	46.9	67.7
W	Acute Non-Lymphocytic Leukemia	Melanoma of the Skin	1861	5	3.4	0.01	4.7	1.07 (0.35 to 2.49)	46.9	78.3
W	Acute Non-Lymphocytic Leukemia	Non-Hodgkin Lymphoma	1861	7	4.8	0.01	5.7	1.23 (0.49 to 2.52)	46.9	65.9
W	Acute Non-Lymphocytic Leukemia	Thyroid	1861	7	4.8	0.01	4.4	1.59 (0.64 to 3.27)	46.9	61.3
W	Acute Non-Lymphocytic Leukemia	Urinary Bladder	1861	6	4.1	0.01	2.4	2.46 (0.9 to 5.35)	46.9	73.9
W	Anus, Anal Canal and Anorectum	Acute Non-Lymphocytic Leukemia	3042	6	2.9	0.01	2.4	2.51 (0.92 to 5.46)	59.8	66.3
W	Anus, Anal Canal and Anorectum	Breast	3042	77	37.2	0.13	76.8	1 (0.79 to 1.25)	59.8	68.1
W	Anus, Anal Canal and Anorectum	Colon and Rectum	3042	38	18.4	0.06	26.9	1.41 (1 to 1.94)	59.8	73.9
W	Anus, Anal Canal and Anorectum	Corpus and Uterus, NOS	3042	39	18.8	0.07	17.6	2.21 (1.57 to 3.03)	59.8	68.7
W	Anus, Anal Canal and Anorectum	Lung and Bronchus	3042	80	38.6	0.14	37.9	2.11 (1.67 to 2.63)	59.8	70.3
W	Anus, Anal Canal and Anorectum	Melanoma of the Skin	3042	13	6.3	0.02	9.4	1.39 (0.74 to 2.37)	59.8	71.2
W	Anus, Anal Canal and Anorectum	Non-Hodgkin Lymphoma	3042	13	6.3	0.02	14.8	0.88 (0.47 to 1.51)	59.8	71.6
W	Anus, Anal Canal and Anorectum	Oral Cavity and Pharynx	3042	9	4.3	0.02	4.2	2.17 (0.99 to 4.12)	59.8	64.8
W	Anus, Anal Canal and Anorectum	Pancreas	3042	10	4.8	0.02	9.0	1.11 (0.53 to 2.04)	59.8	73.3
W	Anus, Anal Canal and Anorectum	Urinary Bladder	3042	14	6.8	0.02	7.2	1.94 (1.06 to 3.25)	59.8	65.8
W	Anus, Anal Canal and Anorectum	Vulva and Other Genital Organs	3042	24	11.6	0.04	3.2	7.55 (4.84 to 11.24)	59.8	65.5
W	Bones and Joints	Breast	1252	19	17.3	0.03	27.9	0.68 (0.41 to 1.06)	45.6	64.4
W	Bones and Joints	Liver and Intrahepatic Bile Duct	1252	5	4.6	0.01	0.9	5.36 (1.74 to 12.52)	45.6	53.9
W	Bones and Joints	Lung and Bronchus	1252	13	11.8	0.02	10.3	1.27 (0.67 to 2.16)	45.6	66.3
W	Bones and Joints	Melanoma of the Skin	1252	5	4.6	0.01	3.7	1.35 (0.44 to 3.14)	45.6	59.8
W	Bones and Joints	Non-Hodgkin Lymphoma	1252	5	4.6	0.01	4.3	1.15 (0.37 to 2.69)	45.6	68.8
W	Brain and Other Nervous System	Breast	4123	62	20.0	0.11	69.3	0.89 (0.69 to 1.15)	42.8	58.5
W	Brain and Other Nervous System	Colon and Rectum	4123	13	4.2	0.02	16.7	0.78 (0.42 to 1.33)	42.8	64.4

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Brain and Other Nervous System	Corpus and Uterus, NOS	4123	12	3.9	0.02	14.9	0.8 (0.42 to 1.4)	42.8	55.9
W	Brain and Other Nervous System	Kidney and Renal Pelvis	4123	6	1.9	0.01	5.0	1.2 (0.44 to 2.61)	42.8	60.8
W	Brain and Other Nervous System	Lung and Bronchus	4123	18	5.8	0.03	21.4	0.84 (0.5 to 1.33)	42.8	62.5
W	Brain and Other Nervous System	Melanoma of the Skin	4123	13	4.2	0.02	9.4	1.38 (0.73 to 2.36)	42.8	61.7
W	Brain and Other Nervous System	Non-Hodgkin Lymphoma	4123	9	2.9	0.02	9.5	0.95 (0.44 to 1.81)	42.8	67.0
W	Brain and Other Nervous System	Pancreas	4123	7	2.3	0.01	4.9	1.44 (0.58 to 2.96)	42.8	75.2
W	Brain and Other Nervous System	Soft Tissue including Heart	4123	7	2.3	0.01	1.2	5.79 (2.33 to 11.93)	42.8	56.3
W	Brain and Other Nervous System	Thyroid	4123	14	4.5	0.02	9.4	1.49 (0.81 to 2.49)	42.8	52.3
W	Breast	Acute Lymphocytic Leukemia	334273	57	0.2	0.10	30.9	1.85 (1.4 to 2.39)	58.8	69.0
W	Breast	Acute Non-Lymphocytic Leukemia	334273	455	1.7	0.77	301.9	1.51 (1.37 to 1.65)	58.8	71.9
W	Breast	Anus, Anal Canal and Anorectum	334273	156	0.6	0.26	158.0	0.99 (0.84 to 1.16)	58.8	68.2
W	Breast	Bones and Joints	334273	33	0.1	0.06	29.9	1.11 (0.76 to 1.55)	58.8	66.3
W	Breast	Brain and Other Nervous System	334273	258	1.0	0.44	327.9	0.79 (0.69 to 0.89)	58.8	70.9
W	Breast	Cervix Uteri	334273	150	0.6	0.25	293.5	0.51 (0.43 to 0.6)	58.8	67.4
W	Breast	Chronic Myeloid Leukemia	334273	119	0.5	0.20	106.9	1.11 (0.92 to 1.33)	58.8	72.1
W	Breast	Colon and Rectum	334273	3241	12.3	5.49	3401.6	0.95 (0.92 to 0.99)	58.8	74.8
W	Breast	Corpus and Uterus, NOS	334273	2782	10.5	4.71	2153.8	1.29 (1.24 to 1.34)	58.8	69.9
W	Breast	Esophagus	334273	194	0.7	0.33	181.8	1.07 (0.92 to 1.23)	58.8	74.2
W	Breast	Eye and Orbit	334273	47	0.2	0.08	52.8	0.89 (0.66 to 1.19)	58.8	69.5
W	Breast	Gallbladder and Other Biliary	334273	268	1.0	0.45	304.7	0.88 (0.78 to 0.99)	58.8	75.2
W	Breast	Hodgkin Lymphoma	334273	51	0.2	0.09	69.6	0.73 (0.55 to 0.96)	58.8	70.5
W	Breast	Kaposi Sarcoma	334273	7	0.0	0.01	8.5	0.82 (0.33 to 1.69)	58.8	77.4
W	Breast	Kidney and Renal Pelvis	334273	813	3.1	1.38	838.9	0.97 (0.9 to 1.04)	58.8	72.0
W	Breast	Larynx	334273	81	0.3	0.14	88.8	0.91 (0.72 to 1.13)	58.8	71.0
W	Breast	Liver and Intrahepatic Bile Duct	334273	373	1.4	0.63	425.0	0.88 (0.79 to 0.97)	58.8	73.5
W	Breast	Lung and Bronchus	334273	5409	20.5	9.16	4811.9	1.12 (1.09 to 1.15)	58.8	73.1
W	Breast	Melanoma of the Skin	334273	1167	4.4	1.98	1126.3	1.04 (0.98 to 1.1)	58.8	69.7
W	Breast	Myeloma	334273	406	1.5	0.69	497.9	0.82 (0.74 to 0.9)	58.8	73.1
W	Breast	Non-Hodgkin Lymphoma	334273	1710	6.5	2.90	1850.0	0.92 (0.88 to 0.97)	58.8	73.7
W	Breast	Oral Cavity and Pharynx	334273	702	2.7	1.19	519.9	1.35 (1.25 to 1.45)	58.8	69.6
W	Breast	Ovary	334273	1097	4.2	1.86	958.4	1.15 (1.08 to 1.21)	58.8	68.2
W	Breast	Pancreas	334273	1240	4.7	2.10	1134.3	1.09 (1.03 to 1.16)	58.8	74.4

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Breast	Small Intestine	334273	201	0.8	0.34	163.1	1.23 (1.07 to 1.42)	58.8	70.1
W	Breast	Soft Tissue including Heart	334273	322	1.2	0.55	178.4	1.81 (1.61 to 2.01)	58.8	68.5
W	Breast	Stomach	334273	507	1.9	0.86	488.7	1.04 (0.95 to 1.13)	58.8	72.9
W	Breast	Thyroid	334273	811	3.1	1.37	723.5	1.12 (1.05 to 1.2)	58.8	64.8
W	Breast	Urinary Bladder	334273	982	3.7	1.66	904.6	1.09 (1.02 to 1.16)	58.8	74.2
W	Breast	Vulva and Other Genital Organs	334273	413	1.6	0.70	389.5	1.06 (0.96 to 1.17)	58.8	71.5
W	Cervix Uteri	Acute Non-Lymphocytic Leukemia	20153	12	0.6	0.02	11.6	1.04 (0.54 to 1.81)	46.4	62.3
W	Cervix Uteri	Anus, Anal Canal and Anorectum	20153	14	0.7	0.02	7.6	1.83 (1 to 3.08)	46.4	61.7
W	Cervix Uteri	Brain and Other Nervous System	20153	14	0.7	0.02	15.1	0.93 (0.51 to 1.56)	46.4	61.1
W	Cervix Uteri	Breast	20153	380	20.0	0.64	493.4	0.77 (0.7 to 0.85)	46.4	60.0
W	Cervix Uteri	Chronic Myeloid Leukemia	20153	5	0.3	0.01	4.4	1.14 (0.37 to 2.66)	46.4	62.2
W	Cervix Uteri	Colon and Rectum	20153	176	9.3	0.30	132.2	1.33 (1.14 to 1.54)	46.4	65.7
W	Cervix Uteri	Corpus and Uterus, NOS	20153	57	3.0	0.10	107.5	0.53 (0.4 to 0.69)	46.4	63.1
W	Cervix Uteri	Gallbladder and Other Biliary	20153	17	0.9	0.03	11.1	1.53 (0.89 to 2.46)	46.4	68.2
W	Cervix Uteri	Hodgkin Lymphoma	20153	8	0.4	0.01	4.3	1.87 (0.81 to 3.69)	46.4	55.6
W	Cervix Uteri	Kidney and Renal Pelvis	20153	39	2.1	0.07	36.7	1.06 (0.76 to 1.45)	46.4	62.3
W	Cervix Uteri	Larynx	20153	8	0.4	0.01	4.0	1.99 (0.86 to 3.91)	46.4	60.3
W	Cervix Uteri	Liver and Intrahepatic Bile Duct	20153	21	1.1	0.04	18.3	1.15 (0.71 to 1.76)	46.4	71.4
W	Cervix Uteri	Lung and Bronchus	20153	322	17.0	0.55	169.1	1.9 (1.7 to 2.12)	46.4	66.7
W	Cervix Uteri	Melanoma of the Skin	20153	33	1.7	0.06	57.2	0.58 (0.4 to 0.81)	46.4	60.2
W	Cervix Uteri	Myeloma	20153	21	1.1	0.04	19.8	1.06 (0.66 to 1.62)	46.4	66.0
W	Cervix Uteri	Non-Hodgkin Lymphoma	20153	71	3.7	0.12	69.7	1.02 (0.8 to 1.29)	46.4	66.0
W	Cervix Uteri	Oral Cavity and Pharynx	20153	30	1.6	0.05	22.7	1.32 (0.89 to 1.89)	46.4	65.6
W	Cervix Uteri	Ovary	20153	32	1.7	0.05	45.2	0.71 (0.48 to 1)	46.4	60.8
W	Cervix Uteri	Pancreas	20153	35	1.8	0.06	39.8	0.88 (0.61 to 1.22)	46.4	66.8
W	Cervix Uteri	Small Intestine	20153	9	0.5	0.02	7.1	1.27 (0.58 to 2.41)	46.4	70.3
W	Cervix Uteri	Soft Tissue including Heart	20153	20	1.1	0.03	8.5	2.35 (1.44 to 3.63)	46.4	63.6
W	Cervix Uteri	Stomach	20153	32	1.7	0.05	20.7	1.55 (1.06 to 2.18)	46.4	69.0
W	Cervix Uteri	Thyroid	20153	51	2.7	0.09	56.8	0.9 (0.67 to 1.18)	46.4	55.7
W	Cervix Uteri	Urinary Bladder	20153	43	2.3	0.07	29.2	1.48 (1.07 to 1.99)	46.4	67.5
W	Cervix Uteri	Vulva and Other Genital Organs	20153	85	4.5	0.14	15.7	5.43 (4.34 to 6.71)	46.4	64.1
W	Chronic Myeloid Leukemia	Breast	1969	25	19.8	0.04	37.3	0.67 (0.43 to 0.99)	53.4	67.6

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Chronic Myeloid Leukemia	Colon and Rectum	1969	15	11.9	0.03	11.1	1.36 (0.76 to 2.24)	53.4	70.9
W	Chronic Myeloid Leukemia	Corpus and Uterus, NOS	1969	8	6.3	0.01	8.4	0.96 (0.41 to 1.88)	53.4	61.3
W	Chronic Myeloid Leukemia	Lung and Bronchus	1969	12	9.5	0.02	15.6	0.77 (0.4 to 1.34)	53.4	71.3
W	Chronic Myeloid Leukemia	Melanoma of the Skin	1969	7	5.5	0.01	4.6	1.52 (0.61 to 3.14)	53.4	66.3
W	Chronic Myeloid Leukemia	Non-Hodgkin Lymphoma	1969	8	6.3	0.01	6.3	1.28 (0.55 to 2.52)	53.4	73.9
W	Chronic Myeloid Leukemia	Oral Cavity and Pharynx	1969	10	7.9	0.02	1.9	5.34 (2.56 to 9.82)	53.4	65.4
W	Colon and Rectum	Acute Lymphocytic Leukemia	68770	5	0.1	0.01	5.8	0.86 (0.28 to 2.02)	65.1	72.2
W	Colon and Rectum	Acute Non-Lymphocytic Leukemia	68770	60	1.3	0.10	68.0	0.88 (0.67 to 1.14)	65.1	77.2
W	Colon and Rectum	Bones and Joints	68770	12	0.3	0.02	5.9	2.04 (1.05 to 3.56)	65.1	70.9
W	Colon and Rectum	Brain and Other Nervous System	68770	61	1.3	0.10	64.9	0.94 (0.72 to 1.21)	65.1	76.8
W	Colon and Rectum	Breast	68770	1768	37.6	2.99	1801.4	0.98 (0.94 to 1.03)	65.1	74.1
W	Colon and Rectum	Cervix Uteri	68770	49	1.0	0.08	51.9	0.94 (0.7 to 1.25)	65.1	71.3
W	Colon and Rectum	Chronic Myeloid Leukemia	68770	30	0.6	0.05	23.7	1.27 (0.86 to 1.81)	65.1	75.9
W	Colon and Rectum	Corpus and Uterus, NOS	68770	521	11.1	0.88	382.3	1.36 (1.25 to 1.49)	65.1	70.4
W	Colon and Rectum	Esophagus	68770	52	1.1	0.09	41.6	1.25 (0.93 to 1.64)	65.1	76.3
W	Colon and Rectum	Eye and Orbit	68770	12	0.3	0.02	10.0	1.2 (0.62 to 2.09)	65.1	73.9
W	Colon and Rectum	Gallbladder and Other Biliary	68770	66	1.4	0.11	71.6	0.92 (0.71 to 1.17)	65.1	75.9
W	Colon and Rectum	Hodgkin Lymphoma	68770	8	0.2	0.01	13.5	0.6 (0.26 to 1.17)	65.1	71.8
W	Colon and Rectum	Kidney and Renal Pelvis	68770	162	3.4	0.27	170.6	0.95 (0.81 to 1.11)	65.1	73.9
W	Colon and Rectum	Larynx	68770	18	0.4	0.03	17.1	1.05 (0.62 to 1.67)	65.1	77.6
W	Colon and Rectum	Liver and Intrahepatic Bile Duct	68770	90	1.9	0.15	94.2	0.96 (0.77 to 1.18)	65.1	75.5
W	Colon and Rectum	Lung and Bronchus	68770	1185	25.2	2.01	1047.3	1.13 (1.07 to 1.2)	65.1	76.6
W	Colon and Rectum	Melanoma of the Skin	68770	169	3.6	0.29	205.2	0.82 (0.7 to 0.96)	65.1	74.5
W	Colon and Rectum	Myeloma	68770	109	2.3	0.18	112.4	0.97 (0.8 to 1.17)	65.1	76.1
W	Colon and Rectum	Non-Hodgkin Lymphoma	68770	396	8.4	0.67	400.5	0.99 (0.89 to 1.09)	65.1	78.3
W	Colon and Rectum	Oral Cavity and Pharynx	68770	105	2.2	0.18	107.2	0.98 (0.8 to 1.19)	65.1	73.9
W	Colon and Rectum	Ovary	68770	151	3.2	0.26	190.5	0.79 (0.67 to 0.93)	65.1	74.5
W	Colon and Rectum	Pancreas	68770	271	5.8	0.46	267.4	1.01 (0.9 to 1.14)	65.1	77.7
W	Colon and Rectum	Small Intestine	68770	81	1.7	0.14	34.2	2.37 (1.88 to 2.94)	65.1	73.0
W	Colon and Rectum	Soft Tissue including Heart	68770	50	1.1	0.08	37.0	1.35 (1 to 1.78)	65.1	72.1
W	Colon and Rectum	Stomach	68770	153	3.3	0.26	119.6	1.28 (1.08 to 1.5)	65.1	76.1
W	Colon and Rectum	Thyroid	68770	134	2.9	0.23	113.2	1.18 (0.99 to 1.4)	65.1	69.6

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Colon and Rectum	Urinary Bladder	68770	253	5.4	0.43	209.8	1.21 (1.06 to 1.36)	65.1	77.1
W	Colon and Rectum	Vulva and Other Genital Organs	68770	86	1.8	0.15	82.0	1.05 (0.84 to 1.3)	65.1	75.5
W	Corpus and Uterus, NOS	Acute Lymphocytic Leukemia	62859	9	0.2	0.02	6.0	1.49 (0.68 to 2.83)	60.3	69.2
W	Corpus and Uterus, NOS	Acute Non-Lymphocytic Leukemia	62859	92	1.9	0.16	62.3	1.48 (1.19 to 1.81)	60.3	72.9
W	Corpus and Uterus, NOS	Anus, Anal Canal and Anorectum	62859	17	0.3	0.03	31.1	0.55 (0.32 to 0.88)	60.3	69.9
W	Corpus and Uterus, NOS	Bones and Joints	62859	9	0.2	0.02	5.8	1.55 (0.71 to 2.93)	60.3	66.9
W	Corpus and Uterus, NOS	Brain and Other Nervous System	62859	62	1.3	0.11	66.6	0.93 (0.71 to 1.19)	60.3	69.5
W	Corpus and Uterus, NOS	Breast	62859	1972	39.8	3.34	1904.0	1.04 (0.99 to 1.08)	60.3	72.1
W	Corpus and Uterus, NOS	Chronic Myeloid Leukemia	62859	22	0.4	0.04	21.8	1.01 (0.63 to 1.53)	60.3	74.1
W	Corpus and Uterus, NOS	Colon and Rectum	62859	970	19.6	1.64	693.8	1.4 (1.31 to 1.49)	60.3	71.9
W	Corpus and Uterus, NOS	Esophagus	62859	30	0.6	0.05	37.5	0.8 (0.54 to 1.14)	60.3	74.3
W	Corpus and Uterus, NOS	Eye and Orbit	62859	11	0.2	0.02	10.9	1.01 (0.51 to 1.81)	60.3	68.9
W	Corpus and Uterus, NOS	Gallbladder and Other Biliary	62859	59	1.2	0.10	62.7	0.94 (0.72 to 1.22)	60.3	73.2
W	Corpus and Uterus, NOS	Hodgkin Lymphoma	62859	21	0.4	0.04	13.8	1.53 (0.95 to 2.34)	60.3	71.2
W	Corpus and Uterus, NOS	Kidney and Renal Pelvis	62859	194	3.9	0.33	169.1	1.15 (0.99 to 1.32)	60.3	70.9
W	Corpus and Uterus, NOS	Larynx	62859	13	0.3	0.02	17.6	0.74 (0.39 to 1.26)	60.3	69.4
W	Corpus and Uterus, NOS	Liver and Intrahepatic Bile Duct	62859	77	1.6	0.13	84.8	0.91 (0.72 to 1.14)	60.3	71.7
W	Corpus and Uterus, NOS	Lung and Bronchus	62859	728	14.7	1.23	1005.7	0.72 (0.67 to 0.78)	60.3	74.1
W	Corpus and Uterus, NOS	Melanoma of the Skin	62859	222	4.5	0.38	227.4	0.98 (0.85 to 1.11)	60.3	72.2
W	Corpus and Uterus, NOS	Myeloma	62859	100	2.0	0.17	99.8	1 (0.82 to 1.22)	60.3	73.6
W	Corpus and Uterus, NOS	Non-Hodgkin Lymphoma	62859	356	7.2	0.60	383.8	0.93 (0.83 to 1.03)	60.3	73.3
W	Corpus and Uterus, NOS	Oral Cavity and Pharynx	62859	98	2.0	0.17	105.2	0.93 (0.76 to 1.14)	60.3	73.9
W	Corpus and Uterus, NOS	Pancreas	62859	236	4.8	0.40	233.2	1.01 (0.89 to 1.15)	60.3	74.5
W	Corpus and Uterus, NOS	Small Intestine	62859	41	0.8	0.07	32.5	1.26 (0.91 to 1.71)	60.3	67.4
W	Corpus and Uterus, NOS	Soft Tissue including Heart	62859	52	1.1	0.09	35.6	1.46 (1.09 to 1.92)	60.3	69.4
W	Corpus and Uterus, NOS	Stomach	62859	89	1.8	0.15	97.3	0.92 (0.74 to 1.13)	60.3	72.6
W	Corpus and Uterus, NOS	Thyroid	62859	150	3.0	0.25	133.4	1.13 (0.95 to 1.32)	60.3	64.9
W	Corpus and Uterus, NOS	Urinary Bladder	62859	247	5.0	0.42	190.3	1.3 (1.14 to 1.47)	60.3	75.0
W	Esophagus	Breast	846	18	39.0	0.03	18.2	0.99 (0.59 to 1.56)	65.0	75.2
W	Esophagus	Colon and Rectum	846	14	30.3	0.02	7.5	1.87 (1.02 to 3.14)	65.0	73.3
W	Esophagus	Corpus and Uterus, NOS	846	5	10.8	0.01	4.0	1.26 (0.41 to 2.94)	65.0	72.2
W	Esophagus	Lung and Bronchus	846	40	86.7	0.07	10.6	3.78 (2.7 to 5.14)	65.0	71.5

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Esophagus	Oral Cavity and Pharynx	846	18	39.0	0.03	1.0	17.22 (10.2 to 27.21)	65.0	68.5
W	Esophagus	Stomach	846	6	13.0	0.01	1.1	5.47 (2.01 to 11.92)	65.0	73.9
W	Esophagus	Urinary Bladder	846	6	13.0	0.01	2.0	3.01 (1.1 to 6.54)	65.0	80.8
W	Eye and Orbit	Breast	1378	36	35.2	0.06	35.8	1.01 (0.7 to 1.39)	57.9	67.4
W	Eye and Orbit	Colon and Rectum	1378	11	10.8	0.02	12.3	0.9 (0.45 to 1.61)	57.9	74.4
W	Eye and Orbit	Corpus and Uterus, NOS	1378	5	4.9	0.01	7.9	0.64 (0.21 to 1.48)	57.9	62.3
W	Eye and Orbit	Lung and Bronchus	1378	22	21.5	0.04	17.7	1.24 (0.78 to 1.88)	57.9	70.7
W	Eye and Orbit	Melanoma of the Skin	1378	18	17.6	0.03	4.8	3.75 (2.22 to 5.92)	57.9	69.7
W	Eye and Orbit	Non-Hodgkin Lymphoma	1378	9	8.8	0.02	7.0	1.28 (0.58 to 2.43)	57.9	76.2
W	Eye and Orbit	Ovary	1378	5	4.9	0.01	3.6	1.38 (0.45 to 3.23)	57.9	64.9
W	Gallbladder and Other Biliary	Breast	1314	30	36.8	0.05	30.4	0.99 (0.67 to 1.41)	64.4	71.9
W	Gallbladder and Other Biliary	Colon and Rectum	1314	22	27.0	0.04	13.2	1.66 (1.04 to 2.52)	64.4	77.0
W	Gallbladder and Other Biliary	Lung and Bronchus	1314	31	38.0	0.05	17.6	1.76 (1.19 to 2.5)	64.4	75.5
W	Gallbladder and Other Biliary	Non-Hodgkin Lymphoma	1314	9	11.0	0.02	6.7	1.34 (0.61 to 2.54)	64.4	78.4
W	Gallbladder and Other Biliary	Ovary	1314	6	7.4	0.01	3.2	1.88 (0.69 to 4.08)	64.4	80.3
W	Gallbladder and Other Biliary	Pancreas	1314	9	11.0	0.02	4.4	2.03 (0.93 to 3.84)	64.4	73.0
W	Gallbladder and Other Biliary	Stomach	1314	7	8.6	0.01	2.1	3.36 (1.35 to 6.93)	64.4	63.4
W	Hodgkin Lymphoma	Acute Lymphocytic Leukemia	6263	5	0.8	0.01	0.5	10.52 (3.42 to 24.56)	38.5	47.7
W	Hodgkin Lymphoma	Acute Non-Lymphocytic Leukemia	6263	14	2.4	0.02	2.5	5.63 (3.08 to 9.45)	38.5	60.2
W	Hodgkin Lymphoma	Anus, Anal Canal and Anorectum	6263	5	0.8	0.01	1.7	2.99 (0.97 to 6.98)	38.5	54.3
W	Hodgkin Lymphoma	Brain and Other Nervous System	6263	5	0.8	0.01	3.7	1.36 (0.44 to 3.17)	38.5	56.2
W	Hodgkin Lymphoma	Breast	6263	157	26.7	0.27	109.0	1.44 (1.22 to 1.69)	38.5	52.6
W	Hodgkin Lymphoma	Cervix Uteri	6263	8	1.4	0.01	7.0	1.14 (0.49 to 2.25)	38.5	49.6
W	Hodgkin Lymphoma	Colon and Rectum	6263	46	7.8	0.08	25.5	1.8 (1.32 to 2.4)	38.5	62.6
W	Hodgkin Lymphoma	Corpus and Uterus, NOS	6263	24	4.1	0.04	22.0	1.09 (0.7 to 1.63)	38.5	60.4
W	Hodgkin Lymphoma	Esophagus	6263	5	0.8	0.01	1.2	4.21 (1.37 to 9.83)	38.5	56.1
W	Hodgkin Lymphoma	Kidney and Renal Pelvis	6263	6	1.0	0.01	7.8	0.77 (0.28 to 1.69)	38.5	69.1
W	Hodgkin Lymphoma	Lung and Bronchus	6263	77	13.1	0.13	31.0	2.48 (1.96 to 3.1)	38.5	67.5
W	Hodgkin Lymphoma	Melanoma of the Skin	6263	27	4.6	0.05	16.1	1.67 (1.1 to 2.44)	38.5	53.4
W	Hodgkin Lymphoma	Myeloma	6263	5	0.8	0.01	3.7	1.35 (0.44 to 3.16)	38.5	60.0
W	Hodgkin Lymphoma	Non-Hodgkin Lymphoma	6263	73	12.4	0.12	14.5	5.04 (3.95 to 6.34)	38.5	66.7
W	Hodgkin Lymphoma	Oral Cavity and Pharynx	6263	19	3.2	0.03	4.7	4 (2.41 to 6.25)	38.5	54.9

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Hodgkin Lymphoma	Ovary	6263	8	1.4	0.01	9.7	0.82 (0.36 to 1.62)	38.5	60.4
W	Hodgkin Lymphoma	Pancreas	6263	8	1.4	0.01	7.2	1.11 (0.48 to 2.18)	38.5	65.7
W	Hodgkin Lymphoma	Soft Tissue including Heart	6263	9	1.5	0.02	2.0	4.46 (2.04 to 8.46)	38.5	48.5
W	Hodgkin Lymphoma	Stomach	6263	7	1.2	0.01	3.6	1.93 (0.78 to 3.97)	38.5	61.1
W	Hodgkin Lymphoma	Thyroid	6263	35	5.9	0.06	17.4	2.01 (1.4 to 2.79)	38.5	42.0
W	Hodgkin Lymphoma	Urinary Bladder	6263	11	1.9	0.02	5.6	1.96 (0.98 to 3.52)	38.5	67.5
W	Hodgkin Lymphoma	Vulva and Other Genital Organs	6263	7	1.2	0.01	3.4	2.06 (0.83 to 4.24)	38.5	51.8
W	Kidney and Renal Pelvis	Acute Non-Lymphocytic Leukemia	15980	17	1.6	0.03	12.7	1.33 (0.78 to 2.14)	60.5	75.1
W	Kidney and Renal Pelvis	Anus, Anal Canal and Anorectum	15980	6	0.6	0.01	6.5	0.93 (0.34 to 2.02)	60.5	72.1
W	Kidney and Renal Pelvis	Brain and Other Nervous System	15980	13	1.2	0.02	13.4	0.97 (0.52 to 1.66)	60.5	67.8
W	Kidney and Renal Pelvis	Breast	15980	407	38.4	0.69	389.0	1.05 (0.95 to 1.15)	60.5	71.3
W	Kidney and Renal Pelvis	Cervix Uteri	15980	7	0.7	0.01	11.7	0.6 (0.24 to 1.23)	60.5	64.4
W	Kidney and Renal Pelvis	Chronic Myeloid Leukemia	15980	5	0.5	0.01	4.5	1.11 (0.36 to 2.6)	60.5	71.6
W	Kidney and Renal Pelvis	Colon and Rectum	15980	152	14.4	0.26	142.0	1.07 (0.91 to 1.26)	60.5	74.1
W	Kidney and Renal Pelvis	Corpus and Uterus, NOS	15980	92	8.7	0.16	86.4	1.06 (0.86 to 1.31)	60.5	68.7
W	Kidney and Renal Pelvis	Gallbladder and Other Biliary	15980	6	0.6	0.01	12.9	0.47 (0.17 to 1.02)	60.5	76.4
W	Kidney and Renal Pelvis	Larynx	15980	9	0.8	0.02	3.7	2.46 (1.12 to 4.66)	60.5	72.2
W	Kidney and Renal Pelvis	Liver and Intrahepatic Bile Duct	15980	21	2.0	0.04	17.7	1.19 (0.73 to 1.81)	60.5	71.8
W	Kidney and Renal Pelvis	Lung and Bronchus	15980	281	26.5	0.48	202.2	1.39 (1.23 to 1.56)	60.5	73.3
W	Kidney and Renal Pelvis	Melanoma of the Skin	15980	43	4.1	0.07	45.8	0.94 (0.68 to 1.26)	60.5	72.1
W	Kidney and Renal Pelvis	Myeloma	15980	30	2.8	0.05	21.7	1.38 (0.93 to 1.98)	60.5	72.3
W	Kidney and Renal Pelvis	Non-Hodgkin Lymphoma	15980	82	7.7	0.14	76.7	1.07 (0.85 to 1.33)	60.5	72.9
W	Kidney and Renal Pelvis	Oral Cavity and Pharynx	15980	24	2.3	0.04	21.3	1.13 (0.72 to 1.68)	60.5	74.1
W	Kidney and Renal Pelvis	Ovary	15980	20	1.9	0.03	38.6	0.52 (0.32 to 0.8)	60.5	74.5
W	Kidney and Renal Pelvis	Pancreas	15980	72	6.8	0.12	48.5	1.48 (1.16 to 1.87)	60.5	74.4
W	Kidney and Renal Pelvis	Small Intestine	15980	9	0.8	0.02	7.0	1.29 (0.59 to 2.45)	60.5	71.2
W	Kidney and Renal Pelvis	Soft Tissue including Heart	15980	6	0.6	0.01	7.4	0.81 (0.3 to 1.76)	60.5	72.0
W	Kidney and Renal Pelvis	Stomach	15980	25	2.4	0.04	20.7	1.21 (0.78 to 1.79)	60.5	75.5
W	Kidney and Renal Pelvis	Thyroid	15980	73	6.9	0.12	28.7	2.55 (2 to 3.2)	60.5	64.7
W	Kidney and Renal Pelvis	Urinary Bladder	15980	56	5.3	0.09	38.2	1.47 (1.11 to 1.9)	60.5	76.3
W	Kidney and Renal Pelvis	Vulva and Other Genital Organs	15980	16	1.5	0.03	16.3	0.98 (0.56 to 1.59)	60.5	74.9
W	Larynx	Breast	2096	40	29.1	0.07	52.7	0.76 (0.54 to 1.03)	60.9	70.6

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Larynx	Colon and Rectum	2096	36	26.1	0.06	20.0	1.8 (1.26 to 2.49)	60.9	74.6
W	Larynx	Corpus and Uterus, NOS	2096	7	5.1	0.01	11.7	0.6 (0.24 to 1.23)	60.9	72.0
W	Larynx	Esophagus	2096	13	9.4	0.02	1.1	11.98 (6.38 to 20.48)	60.9	67.4
W	Larynx	Kidney and Renal Pelvis	2096	7	5.1	0.01	4.8	1.47 (0.59 to 3.03)	60.9	73.8
W	Larynx	Liver and Intrahepatic Bile Duct	2096	6	4.4	0.01	2.3	2.66 (0.98 to 5.8)	60.9	64.9
W	Larynx	Lung and Bronchus	2096	231	167.8	0.39	28.6	8.09 (7.08 to 9.2)	60.9	71.4
W	Larynx	Non-Hodgkin Lymphoma	2096	12	8.7	0.02	10.4	1.15 (0.6 to 2.02)	60.9	71.7
W	Larynx	Oral Cavity and Pharynx	2096	55	39.9	0.09	2.9	19.29 (14.53 to 25.11)	60.9	69.4
W	Larynx	Ovary	2096	6	4.4	0.01	5.3	1.12 (0.41 to 2.44)	60.9	67.1
W	Larynx	Pancreas	2096	6	4.4	0.01	6.5	0.93 (0.34 to 2.02)	60.9	72.2
W	Larynx	Stomach	2096	5	3.6	0.01	2.8	1.82 (0.59 to 4.24)	60.9	72.3
W	Larynx	Urinary Bladder	2096	7	5.1	0.01	5.2	1.34 (0.54 to 2.76)	60.9	71.9
W	Liver and Intrahepatic Bile Duct	Breast	1458	13	19.0	0.02	22.7	0.57 (0.31 to 0.98)	60.4	69.2
W	Liver and Intrahepatic Bile Duct	Colon and Rectum	1458	9	13.1	0.02	7.8	1.15 (0.52 to 2.18)	60.4	69.9
W	Liver and Intrahepatic Bile Duct	Lung and Bronchus	1458	20	29.2	0.03	10.8	1.85 (1.13 to 2.85)	60.4	68.1
W	Liver and Intrahepatic Bile Duct	Non-Hodgkin Lymphoma	1458	13	19.0	0.02	4.0	3.22 (1.71 to 5.5)	60.4	69.0
W	Lung and Bronchus	Acute Non-Lymphocytic Leukemia	24065	32	2.4	0.05	18.5	1.73 (1.19 to 2.45)	64.8	75.5
W	Lung and Bronchus	Anus, Anal Canal and Anorectum	24065	8	0.6	0.01	8.5	0.94 (0.41 to 1.86)	64.8	71.2
W	Lung and Bronchus	Brain and Other Nervous System	24065	10	0.8	0.02	18.7	0.53 (0.26 to 0.98)	64.8	68.2
W	Lung and Bronchus	Breast	24065	533	40.4	0.90	523.5	1.02 (0.93 to 1.11)	64.8	72.9
W	Lung and Bronchus	Cervix Uteri	24065	8	0.6	0.01	14.5	0.55 (0.24 to 1.09)	64.8	68.1
W	Lung and Bronchus	Chronic Myeloid Leukemia	24065	13	1.0	0.02	6.4	2.02 (1.08 to 3.46)	64.8	69.4
W	Lung and Bronchus	Colon and Rectum	24065	278	21.1	0.47	210.9	1.32 (1.17 to 1.48)	64.8	75.7
W	Lung and Bronchus	Corpus and Uterus, NOS	24065	67	5.1	0.11	113.3	0.59 (0.46 to 0.75)	64.8	72.0
W	Lung and Bronchus	Esophagus	24065	41	3.1	0.07	11.4	3.6 (2.59 to 4.89)	64.8	72.8
W	Lung and Bronchus	Eye and Orbit	24065	6	0.5	0.01	3.0	2.01 (0.74 to 4.38)	64.8	73.1
W	Lung and Bronchus	Gallbladder and Other Biliary	24065	15	1.1	0.03	18.9	0.79 (0.44 to 1.31)	64.8	74.9
W	Lung and Bronchus	Kidney and Renal Pelvis	24065	68	5.2	0.12	48.6	1.4 (1.09 to 1.77)	64.8	73.3
W	Lung and Bronchus	Larynx	24065	36	2.7	0.06	5.1	7.03 (4.93 to 9.74)	64.8	70.6
W	Lung and Bronchus	Liver and Intrahepatic Bile Duct	24065	30	2.3	0.05	25.0	1.2 (0.81 to 1.71)	64.8	74.0
W	Lung and Bronchus	Melanoma of the Skin	24065	57	4.3	0.10	61.1	0.93 (0.71 to 1.21)	64.8	74.6
W	Lung and Bronchus	Myeloma	24065	29	2.2	0.05	30.6	0.95 (0.63 to 1.36)	64.8	75.4

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Lung and Bronchus	Non-Hodgkin Lymphoma	24065	147	11.2	0.25	112.0	1.31 (1.11 to 1.54)	64.8	76.3
W	Lung and Bronchus	Oral Cavity and Pharynx	24065	60	4.6	0.10	30.0	2 (1.53 to 2.58)	64.8	71.8
W	Lung and Bronchus	Ovary	24065	49	3.7	0.08	54.1	0.91 (0.67 to 1.2)	64.8	73.4
W	Lung and Bronchus	Pancreas	24065	84	6.4	0.14	71.0	1.18 (0.94 to 1.46)	64.8	75.2
W	Lung and Bronchus	Small Intestine	24065	6	0.5	0.01	9.6	0.63 (0.23 to 1.37)	64.8	77.8
W	Lung and Bronchus	Soft Tissue including Heart	24065	15	1.1	0.03	10.2	1.47 (0.82 to 2.43)	64.8	74.6
W	Lung and Bronchus	Stomach	24065	28	2.1	0.05	30.1	0.93 (0.62 to 1.34)	64.8	77.7
W	Lung and Bronchus	Thyroid	24065	44	3.3	0.07	33.1	1.33 (0.97 to 1.79)	64.8	66.9
W	Lung and Bronchus	Urinary Bladder	24065	124	9.4	0.21	57.3	2.17 (1.8 to 2.58)	64.8	75.6
W	Lung and Bronchus	Vulva and Other Genital Organs	24065	20	1.5	0.03	22.8	0.88 (0.54 to 1.36)	64.8	73.8
W	Melanoma of the Skin	Acute Non-Lymphocytic Leukemia	40414	24	0.7	0.04	28.8	0.83 (0.53 to 1.24)	51.3	71.5
W	Melanoma of the Skin	Anus, Anal Canal and Anorectum	40414	21	0.6	0.04	18.2	1.16 (0.72 to 1.77)	51.3	65.3
W	Melanoma of the Skin	Bones and Joints	40414	5	0.1	0.01	3.6	1.41 (0.46 to 3.29)	51.3	61.1
W	Melanoma of the Skin	Brain and Other Nervous System	40414	45	1.3	0.08	36.5	1.23 (0.9 to 1.65)	51.3	66.2
W	Melanoma of the Skin	Breast	40414	1067	30.9	1.81	1044.7	1.02 (0.96 to 1.09)	51.3	65.8
W	Melanoma of the Skin	Cervix Uteri	40414	17	0.5	0.03	38.8	0.44 (0.26 to 0.7)	51.3	59.2
W	Melanoma of the Skin	Chronic Myeloid Leukemia	40414	10	0.3	0.02	10.8	0.93 (0.45 to 1.71)	51.3	70.9
W	Melanoma of the Skin	Colon and Rectum	40414	252	7.3	0.43	305.0	0.83 (0.73 to 0.94)	51.3	72.0
W	Melanoma of the Skin	Corpus and Uterus, NOS	40414	193	5.6	0.33	232.2	0.83 (0.72 to 0.96)	51.3	66.4
W	Melanoma of the Skin	Esophagus	40414	6	0.2	0.01	16.2	0.37 (0.14 to 0.81)	51.3	71.8
W	Melanoma of the Skin	Eye and Orbit	40414	13	0.4	0.02	6.1	2.12 (1.13 to 3.63)	51.3	64.5
W	Melanoma of the Skin	Gallbladder and Other Biliary	40414	21	0.6	0.04	26.5	0.79 (0.49 to 1.21)	51.3	72.8
W	Melanoma of the Skin	Hodgkin Lymphoma	40414	9	0.3	0.02	9.0	1.01 (0.46 to 1.91)	51.3	50.0
W	Melanoma of the Skin	Kidney and Renal Pelvis	40414	85	2.5	0.14	84.1	1.01 (0.81 to 1.25)	51.3	67.5
W	Melanoma of the Skin	Liver and Intrahepatic Bile Duct	40414	20	0.6	0.03	35.8	0.56 (0.34 to 0.86)	51.3	71.2
W	Melanoma of the Skin	Lung and Bronchus	40414	372	10.8	0.63	435.0	0.86 (0.77 to 0.95)	51.3	72.2
W	Melanoma of the Skin	Myeloma	40414	53	1.5	0.09	42.6	1.25 (0.93 to 1.63)	51.3	69.9
W	Melanoma of the Skin	Non-Hodgkin Lymphoma	40414	227	6.6	0.38	181.8	1.25 (1.09 to 1.42)	51.3	69.7
W	Melanoma of the Skin	Oral Cavity and Pharynx	40414	50	1.4	0.08	52.7	0.95 (0.7 to 1.25)	51.3	67.9
W	Melanoma of the Skin	Ovary	40414	90	2.6	0.15	101.2	0.89 (0.72 to 1.09)	51.3	63.6
W	Melanoma of the Skin	Pancreas	40414	87	2.5	0.15	99.0	0.88 (0.7 to 1.08)	51.3	71.5
W	Melanoma of the Skin	Small Intestine	40414	21	0.6	0.04	15.7	1.33 (0.83 to 2.04)	51.3	63.5

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Melanoma of the Skin	Soft Tissue including Heart	40414	32	0.9	0.05	18.5	1.73 (1.18 to 2.44)	51.3	67.8
W	Melanoma of the Skin	Stomach	40414	31	0.9	0.05	40.2	0.77 (0.53 to 1.1)	51.3	74.8
W	Melanoma of the Skin	Thyroid	40414	139	4.0	0.24	105.0	1.32 (1.11 to 1.56)	51.3	57.2
W	Melanoma of the Skin	Urinary Bladder	40414	93	2.7	0.16	83.3	1.12 (0.9 to 1.37)	51.3	72.7
W	Melanoma of the Skin	Vulva and Other Genital Organs	40414	25	0.7	0.04	40.2	0.62 (0.4 to 0.92)	51.3	68.7
W	Myeloma	Acute Lymphocytic Leukemia	5578	5	2.1	0.01	0.3	17.67 (5.74 to 41.24)	63.0	62.4
W	Myeloma	Acute Non-Lymphocytic Leukemia	5578	16	6.6	0.03	2.9	5.48 (3.14 to 8.91)	63.0	68.5
W	Myeloma	Breast	5578	70	28.9	0.12	90.5	0.77 (0.6 to 0.98)	63.0	70.8
W	Myeloma	Colon and Rectum	5578	46	19.0	0.08	33.8	1.36 (1 to 1.82)	63.0	72.2
W	Myeloma	Corpus and Uterus, NOS	5578	22	9.1	0.04	20.6	1.07 (0.67 to 1.62)	63.0	72.4
W	Myeloma	Kidney and Renal Pelvis	5578	5	2.1	0.01	8.3	0.6 (0.2 to 1.4)	63.0	75.0
W	Myeloma	Lung and Bronchus	5578	43	17.8	0.07	47.2	0.91 (0.66 to 1.23)	63.0	72.2
W	Myeloma	Melanoma of the Skin	5578	16	6.6	0.03	9.2	1.74 (0.99 to 2.82)	63.0	72.9
W	Myeloma	Non-Hodgkin Lymphoma	5578	22	9.1	0.04	17.1	1.29 (0.81 to 1.95)	63.0	76.1
W	Myeloma	Oral Cavity and Pharynx	5578	12	5.0	0.02	4.8	2.48 (1.28 to 4.34)	63.0	61.3
W	Myeloma	Pancreas	5578	9	3.7	0.02	11.6	0.77 (0.35 to 1.47)	63.0	74.6
W	Myeloma	Thyroid	5578	5	2.1	0.01	6.4	0.78 (0.26 to 1.83)	63.0	57.8
W	Non-Hodgkin Lymphoma	Acute Lymphocytic Leukemia	37467	12	0.5	0.02	3.0	4.03 (2.08 to 7.04)	61.5	69.4
W	Non-Hodgkin Lymphoma	Acute Non-Lymphocytic Leukemia	37467	124	4.9	0.21	31.0	4 (3.33 to 4.77)	61.5	69.1
W	Non-Hodgkin Lymphoma	Anus, Anal Canal and Anorectum	37467	18	0.7	0.03	15.2	1.18 (0.7 to 1.87)	61.5	70.7
W	Non-Hodgkin Lymphoma	Bones and Joints	37467	5	0.2	0.01	2.9	1.71 (0.56 to 3.99)	61.5	70.5
W	Non-Hodgkin Lymphoma	Brain and Other Nervous System	37467	43	1.7	0.07	32.4	1.33 (0.96 to 1.79)	61.5	71.2
W	Non-Hodgkin Lymphoma	Breast	37467	892	35.6	1.51	912.6	0.98 (0.91 to 1.04)	61.5	70.8
W	Non-Hodgkin Lymphoma	Cervix Uteri	37467	21	0.8	0.04	27.2	0.77 (0.48 to 1.18)	61.5	62.6
W	Non-Hodgkin Lymphoma	Chronic Myeloid Leukemia	37467	25	1.0	0.04	11.0	2.28 (1.48 to 3.37)	61.5	72.3
W	Non-Hodgkin Lymphoma	Colon and Rectum	37467	402	16.0	0.68	345.6	1.16 (1.05 to 1.28)	61.5	76.3
W	Non-Hodgkin Lymphoma	Corpus and Uterus, NOS	37467	184	7.3	0.31	198.6	0.93 (0.8 to 1.07)	61.5	70.1
W	Non-Hodgkin Lymphoma	Esophagus	37467	22	0.9	0.04	18.5	1.19 (0.75 to 1.8)	61.5	74.1
W	Non-Hodgkin Lymphoma	Eye and Orbit	37467	5	0.2	0.01	5.2	0.95 (0.31 to 2.22)	61.5	72.9
W	Non-Hodgkin Lymphoma	Gallbladder and Other Biliary	37467	33	1.3	0.06	31.1	1.06 (0.73 to 1.49)	61.5	77.8
W	Non-Hodgkin Lymphoma	Hodgkin Lymphoma	37467	66	2.6	0.11	7.0	9.42 (7.29 to 11.99)	61.5	67.2
W	Non-Hodgkin Lymphoma	Kidney and Renal Pelvis	37467	102	4.1	0.17	81.9	1.25 (1.02 to 1.51)	61.5	74.9

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Non-Hodgkin Lymphoma	Larynx	37467	11	0.4	0.02	8.4	1.32 (0.66 to 2.35)	61.5	69.4
W	Non-Hodgkin Lymphoma	Liver and Intrahepatic Bile Duct	37467	51	2.0	0.09	41.3	1.24 (0.92 to 1.62)	61.5	74.0
W	Non-Hodgkin Lymphoma	Lung and Bronchus	37467	714	28.5	1.21	484.1	1.48 (1.37 to 1.59)	61.5	74.1
W	Non-Hodgkin Lymphoma	Melanoma of the Skin	37467	172	6.9	0.29	112.9	1.52 (1.3 to 1.77)	61.5	72.9
W	Non-Hodgkin Lymphoma	Myeloma	37467	52	2.1	0.09	49.3	1.05 (0.79 to 1.38)	61.5	75.5
W	Non-Hodgkin Lymphoma	Oral Cavity and Pharynx	37467	88	3.5	0.15	51.3	1.72 (1.38 to 2.11)	61.5	72.0
W	Non-Hodgkin Lymphoma	Ovary	37467	80	3.2	0.14	92.8	0.86 (0.68 to 1.07)	61.5	72.9
W	Non-Hodgkin Lymphoma	Pancreas	37467	116	4.6	0.20	116.4	1 (0.82 to 1.2)	61.5	76.6
W	Non-Hodgkin Lymphoma	Small Intestine	37467	13	0.5	0.02	16.0	0.81 (0.43 to 1.39)	61.5	71.3
W	Non-Hodgkin Lymphoma	Soft Tissue including Heart	37467	15	0.6	0.03	17.6	0.85 (0.48 to 1.4)	61.5	78.1
W	Non-Hodgkin Lymphoma	Stomach	37467	61	2.4	0.10	48.8	1.25 (0.96 to 1.61)	61.5	74.8
W	Non-Hodgkin Lymphoma	Thyroid	37467	97	3.9	0.16	66.5	1.46 (1.18 to 1.78)	61.5	64.1
W	Non-Hodgkin Lymphoma	Urinary Bladder	37467	108	4.3	0.18	94.2	1.15 (0.94 to 1.39)	61.5	75.0
W	Non-Hodgkin Lymphoma	Vulva and Other Genital Organs	37467	40	1.6	0.07	39.6	1.01 (0.72 to 1.38)	61.5	72.2
W	Oral Cavity and Pharynx	Acute Non-Lymphocytic Leukemia	10788	9	1.2	0.02	8.1	1.11 (0.51 to 2.11)	58.0	72.8
W	Oral Cavity and Pharynx	Anus, Anal Canal and Anorectum	10788	9	1.2	0.02	4.1	2.17 (0.99 to 4.12)	58.0	65.1
W	Oral Cavity and Pharynx	Bones and Joints	10788	9	1.2	0.02	0.8	10.9 (4.98 to 20.69)	58.0	64.0
W	Oral Cavity and Pharynx	Brain and Other Nervous System	10788	5	0.7	0.01	8.8	0.57 (0.18 to 1.33)	58.0	66.7
W	Oral Cavity and Pharynx	Breast	10788	227	29.6	0.38	260.0	0.87 (0.76 to 0.99)	58.0	69.1
W	Oral Cavity and Pharynx	Colon and Rectum	10788	99	12.9	0.17	92.6	1.07 (0.87 to 1.3)	58.0	73.4
W	Oral Cavity and Pharynx	Corpus and Uterus, NOS	10788	51	6.6	0.09	57.4	0.89 (0.66 to 1.17)	58.0	70.0
W	Oral Cavity and Pharynx	Esophagus	10788	58	7.6	0.10	4.8	12 (9.11 to 15.51)	58.0	67.9
W	Oral Cavity and Pharynx	Gallbladder and Other Biliary	10788	9	1.2	0.02	8.2	1.1 (0.5 to 2.09)	58.0	77.5
W	Oral Cavity and Pharynx	Kidney and Renal Pelvis	10788	20	2.6	0.03	22.3	0.9 (0.55 to 1.39)	58.0	70.3
W	Oral Cavity and Pharynx	Larynx	10788	22	2.9	0.04	2.4	9.34 (5.85 to 14.14)	58.0	69.5
W	Oral Cavity and Pharynx	Liver and Intrahepatic Bile Duct	10788	14	1.8	0.02	11.6	1.21 (0.66 to 2.03)	58.0	66.7
W	Oral Cavity and Pharynx	Lung and Bronchus	10788	357	46.5	0.60	127.0	2.81 (2.53 to 3.12)	58.0	71.7
W	Oral Cavity and Pharynx	Melanoma of the Skin	10788	30	3.9	0.05	29.8	1.01 (0.68 to 1.44)	58.0	69.7
W	Oral Cavity and Pharynx	Myeloma	10788	16	2.1	0.03	13.2	1.21 (0.69 to 1.97)	58.0	75.6
W	Oral Cavity and Pharynx	Non-Hodgkin Lymphoma	10788	57	7.4	0.10	49.1	1.16 (0.88 to 1.5)	58.0	73.6
W	Oral Cavity and Pharynx	Ovary	10788	23	3.0	0.04	25.9	0.89 (0.56 to 1.33)	58.0	71.2
W	Oral Cavity and Pharynx	Pancreas	10788	27	3.5	0.05	30.1	0.9 (0.59 to 1.31)	58.0	70.0

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Oral Cavity and Pharynx	Small Intestine	10788	6	0.8	0.01	4.3	1.39 (0.51 to 3.03)	58.0	68.4
W	Oral Cavity and Pharynx	Soft Tissue including Heart	10788	12	1.6	0.02	4.8	2.48 (1.28 to 4.34)	58.0	69.0
W	Oral Cavity and Pharynx	Stomach	10788	19	2.5	0.03	13.5	1.41 (0.85 to 2.2)	58.0	68.6
W	Oral Cavity and Pharynx	Thyroid	10788	19	2.5	0.03	20.9	0.91 (0.55 to 1.42)	58.0	58.2
W	Oral Cavity and Pharynx	Urinary Bladder	10788	30	3.9	0.05	23.8	1.26 (0.85 to 1.8)	58.0	76.2
W	Oral Cavity and Pharynx	Vulva and Other Genital Organs	10788	22	2.9	0.04	10.3	2.14 (1.34 to 3.24)	58.0	64.1
W	Ovary	Acute Lymphocytic Leukemia	18169	5	0.4	0.01	1.4	3.51 (1.14 to 8.19)	55.0	55.0
W	Ovary	Acute Non-Lymphocytic Leukemia	18169	46	3.5	0.08	12.3	3.76 (2.75 to 5.01)	55.0	65.0
W	Ovary	Brain and Other Nervous System	18169	12	0.9	0.02	14.3	0.84 (0.44 to 1.47)	55.0	67.1
W	Ovary	Breast	18169	485	37.0	0.82	428.6	1.13 (1.03 to 1.24)	55.0	67.0
W	Ovary	Chronic Myeloid Leukemia	18169	10	0.8	0.02	4.4	2.28 (1.09 to 4.19)	55.0	68.0
W	Ovary	Colon and Rectum	18169	162	12.3	0.27	136.5	1.19 (1.01 to 1.39)	55.0	70.4
W	Ovary	Gallbladder and Other Biliary	18169	5	0.4	0.01	12.1	0.41 (0.13 to 0.96)	55.0	69.6
W	Ovary	Kidney and Renal Pelvis	18169	37	2.8	0.06	35.3	1.05 (0.74 to 1.44)	55.0	66.7
W	Ovary	Liver and Intrahepatic Bile Duct	18169	14	1.1	0.02	17.7	0.79 (0.43 to 1.33)	55.0	68.1
W	Ovary	Lung and Bronchus	18169	179	13.6	0.30	192.9	0.93 (0.8 to 1.07)	55.0	69.8
W	Ovary	Melanoma of the Skin	18169	50	3.8	0.08	50.7	0.99 (0.73 to 1.3)	55.0	65.6
W	Ovary	Myeloma	18169	22	1.7	0.04	19.8	1.11 (0.7 to 1.69)	55.0	72.8
W	Ovary	Non-Hodgkin Lymphoma	18169	66	5.0	0.11	75.6	0.87 (0.68 to 1.11)	55.0	70.3
W	Ovary	Oral Cavity and Pharynx	18169	25	1.9	0.04	22.1	1.13 (0.73 to 1.67)	55.0	68.2
W	Ovary	Pancreas	18169	62	4.7	0.11	44.4	1.4 (1.07 to 1.79)	55.0	74.2
W	Ovary	Small Intestine	18169	12	0.9	0.02	6.7	1.78 (0.92 to 3.12)	55.0	69.8
W	Ovary	Soft Tissue including Heart	18169	10	0.8	0.02	7.7	1.31 (0.63 to 2.4)	55.0	65.9
W	Ovary	Stomach	18169	20	1.5	0.03	19.8	1.01 (0.62 to 1.56)	55.0	67.4
W	Ovary	Thyroid	18169	49	3.7	0.08	37.4	1.31 (0.97 to 1.73)	55.0	61.3
W	Ovary	Urinary Bladder	18169	45	3.4	0.08	35.4	1.27 (0.93 to 1.7)	55.0	69.3
W	Pancreas	Breast	1675	41	46.6	0.07	30.1	1.36 (0.98 to 1.85)	59.8	72.3
W	Pancreas	Colon and Rectum	1675	14	15.9	0.02	11.2	1.25 (0.68 to 2.09)	59.8	67.9
W	Pancreas	Corpus and Uterus, NOS	1675	5	5.7	0.01	6.6	0.76 (0.25 to 1.76)	59.8	70.5
W	Pancreas	Kidney and Renal Pelvis	1675	7	8.0	0.01	2.7	2.62 (1.05 to 5.4)	59.8	63.8
W	Pancreas	Lung and Bronchus	1675	34	38.7	0.06	15.3	2.23 (1.54 to 3.12)	59.8	69.7
W	Pancreas	Non-Hodgkin Lymphoma	1675	7	8.0	0.01	5.8	1.21 (0.49 to 2.48)	59.8	74.9

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Pancreas	Stomach	1675	5	5.7	0.01	1.7	2.9 (0.94 to 6.76)	59.8	72.9
W	Small Intestine	Breast	2506	68	44.7	0.12	55.6	1.22 (0.95 to 1.55)	60.4	70.0
W	Small Intestine	Colon and Rectum	2506	22	14.5	0.04	20.4	1.08 (0.68 to 1.63)	60.4	71.5
W	Small Intestine	Kidney and Renal Pelvis	2506	8	5.3	0.01	5.0	1.59 (0.68 to 3.12)	60.4	74.4
W	Small Intestine	Liver and Intrahepatic Bile Duct	2506	5	3.3	0.01	2.5	2.01 (0.65 to 4.69)	60.4	71.5
W	Small Intestine	Lung and Bronchus	2506	32	21.0	0.05	28.8	1.11 (0.76 to 1.57)	60.4	76.1
W	Small Intestine	Melanoma of the Skin	2506	8	5.3	0.01	6.4	1.25 (0.54 to 2.47)	60.4	69.8
W	Small Intestine	Non-Hodgkin Lymphoma	2506	14	9.2	0.02	10.8	1.29 (0.71 to 2.17)	60.4	76.8
W	Small Intestine	Ovary	2506	5	3.3	0.01	5.5	0.91 (0.3 to 2.12)	60.4	71.8
W	Small Intestine	Pancreas	2506	11	7.2	0.02	7.0	1.58 (0.79 to 2.82)	60.4	68.1
W	Small Intestine	Stomach	2506	5	3.3	0.01	2.9	1.72 (0.56 to 4)	60.4	69.6
W	Small Intestine	Urinary Bladder	2506	8	5.3	0.01	5.4	1.48 (0.64 to 2.91)	60.4	77.7
W	Soft Tissue including Heart	Acute Non-Lymphocytic Leukemia	4243	10	2.9	0.02	3.0	3.37 (1.62 to 6.2)	52.8	56.3
W	Soft Tissue including Heart	Anus, Anal Canal and Anorectum	4243	6	1.8	0.01	1.6	3.67 (1.35 to 7.98)	52.8	67.6
W	Soft Tissue including Heart	Bones and Joints	4243	5	1.5	0.01	0.3	14.69 (4.77 to 34.28)	52.8	56.9
W	Soft Tissue including Heart	Breast	4243	105	30.9	0.18	101.3	1.04 (0.85 to 1.26)	52.8	67.7
W	Soft Tissue including Heart	Colon and Rectum	4243	31	9.1	0.05	33.2	0.93 (0.63 to 1.32)	52.8	75.4
W	Soft Tissue including Heart	Corpus and Uterus, NOS	4243	18	5.3	0.03	22.3	0.81 (0.48 to 1.28)	52.8	65.2
W	Soft Tissue including Heart	Kidney and Renal Pelvis	4243	12	3.5	0.02	8.5	1.42 (0.73 to 2.48)	52.8	68.3
W	Soft Tissue including Heart	Lung and Bronchus	4243	45	13.2	0.08	45.1	1 (0.73 to 1.33)	52.8	72.7
W	Soft Tissue including Heart	Melanoma of the Skin	4243	15	4.4	0.03	12.1	1.24 (0.7 to 2.05)	52.8	71.4
W	Soft Tissue including Heart	Non-Hodgkin Lymphoma	4243	28	8.2	0.05	17.8	1.57 (1.05 to 2.27)	52.8	72.6
W	Soft Tissue including Heart	Ovary	4243	13	3.8	0.02	9.8	1.33 (0.71 to 2.28)	52.8	71.1
W	Soft Tissue including Heart	Pancreas	4243	13	3.8	0.02	10.9	1.2 (0.64 to 2.05)	52.8	70.9
W	Soft Tissue including Heart	Thyroid	4243	24	7.1	0.04	9.5	2.52 (1.62 to 3.76)	52.8	59.4
W	Soft Tissue including Heart	Urinary Bladder	4243	7	2.1	0.01	8.4	0.84 (0.34 to 1.72)	52.8	67.2
W	Stomach	Breast	4518	72	26.0	0.12	95.6	0.75 (0.59 to 0.95)	63.8	73.2
W	Stomach	Colon and Rectum	4518	59	21.3	0.10	42.6	1.39 (1.06 to 1.79)	63.8	79.0
W	Stomach	Corpus and Uterus, NOS	4518	14	5.0	0.02	20.2	0.69 (0.38 to 1.16)	63.8	69.0
W	Stomach	Esophagus	4518	6	2.2	0.01	2.1	2.85 (1.05 to 6.2)	63.8	72.9
W	Stomach	Gallbladder and Other Biliary	4518	5	1.8	0.01	4.1	1.23 (0.4 to 2.87)	63.8	81.7
W	Stomach	Kidney and Renal Pelvis	4518	6	2.2	0.01	8.9	0.67 (0.25 to 1.46)	63.8	76.6

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Stomach	Liver and Intrahepatic Bile Duct	4518	6	2.2	0.01	6.3	0.95 (0.35 to 2.07)	63.8	77.6
W	Stomach	Lung and Bronchus	4518	63	22.7	0.11	53.2	1.18 (0.91 to 1.52)	63.8	75.3
W	Stomach	Melanoma of the Skin	4518	6	2.2	0.01	9.2	0.65 (0.24 to 1.42)	63.8	83.8
W	Stomach	Myeloma	4518	8	2.9	0.01	6.1	1.32 (0.57 to 2.6)	63.8	75.7
W	Stomach	Non-Hodgkin Lymphoma	4518	21	7.6	0.04	20.0	1.05 (0.65 to 1.61)	63.8	73.6
W	Stomach	Ovary	4518	8	2.9	0.01	9.8	0.82 (0.35 to 1.61)	63.8	70.0
W	Stomach	Pancreas	4518	22	7.9	0.04	14.5	1.52 (0.95 to 2.3)	63.8	73.7
W	Stomach	Thyroid	4518	8	2.9	0.01	6.9	1.17 (0.5 to 2.3)	63.8	74.6
W	Stomach	Urinary Bladder	4518	5	1.8	0.01	10.2	0.49 (0.16 to 1.14)	63.8	75.3
W	Stomach	Vulva and Other Genital Organs	4518	9	3.2	0.02	4.1	2.2 (1.01 to 4.17)	63.8	78.7
W	Thyroid	Acute Lymphocytic Leukemia	43436	10	0.3	0.02	3.3	3.01 (1.44 to 5.53)	46.4	59.4
W	Thyroid	Acute Non-Lymphocytic Leukemia	43436	36	1.0	0.06	21.6	1.66 (1.17 to 2.3)	46.4	63.0
W	Thyroid	Anus, Anal Canal and Anorectum	43436	16	0.5	0.03	14.4	1.11 (0.64 to 1.81)	46.4	61.4
W	Thyroid	Bones and Joints	43436	10	0.3	0.02	3.1	3.24 (1.55 to 5.95)	46.4	56.5
W	Thyroid	Brain and Other Nervous System	43436	30	0.9	0.05	28.4	1.06 (0.71 to 1.51)	46.4	61.2
W	Thyroid	Breast	43436	1042	29.6	1.76	897.3	1.16 (1.09 to 1.23)	46.4	61.1
W	Thyroid	Cervix Uteri	43436	27	0.8	0.05	41.0	0.66 (0.43 to 0.96)	46.4	52.1
W	Thyroid	Chronic Myeloid Leukemia	43436	16	0.5	0.03	8.2	1.95 (1.12 to 3.17)	46.4	54.5
W	Thyroid	Colon and Rectum	43436	202	5.7	0.34	229.4	0.88 (0.76 to 1.01)	46.4	64.7
W	Thyroid	Corpus and Uterus, NOS	43436	201	5.7	0.34	200.4	1 (0.87 to 1.15)	46.4	61.3
W	Thyroid	Esophagus	43436	9	0.3	0.02	11.4	0.79 (0.36 to 1.5)	46.4	72.1
W	Thyroid	Eye and Orbit	43436	8	0.2	0.01	4.4	1.81 (0.78 to 3.57)	46.4	60.0
W	Thyroid	Gallbladder and Other Biliary	43436	19	0.5	0.03	20.0	0.95 (0.57 to 1.48)	46.4	67.8
W	Thyroid	Kidney and Renal Pelvis	43436	114	3.2	0.19	67.3	1.69 (1.4 to 2.04)	46.4	64.7
W	Thyroid	Larynx	43436	5	0.1	0.01	6.9	0.72 (0.24 to 1.69)	46.4	83.3
W	Thyroid	Liver and Intrahepatic Bile Duct	43436	34	1.0	0.06	32.5	1.05 (0.73 to 1.46)	46.4	65.4
W	Thyroid	Lung and Bronchus	43436	285	8.1	0.48	306.3	0.93 (0.83 to 1.05)	46.4	68.9
W	Thyroid	Melanoma of the Skin	43436	121	3.4	0.20	113.9	1.06 (0.88 to 1.27)	46.4	61.0
W	Thyroid	Myeloma	43436	53	1.5	0.09	34.3	1.55 (1.16 to 2.02)	46.4	70.5
W	Thyroid	Non-Hodgkin Lymphoma	43436	179	5.1	0.30	130.2	1.38 (1.18 to 1.59)	46.4	66.8
W	Thyroid	Oral Cavity and Pharynx	43436	58	1.6	0.10	41.9	1.38 (1.05 to 1.79)	46.4	58.8
W	Thyroid	Ovary	43436	83	2.4	0.14	81.7	1.02 (0.81 to 1.26)	46.4	63.5

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Thyroid	Pancreas	43436	73	2.1	0.12	72.2	1.01 (0.79 to 1.27)	46.4	68.7
W	Thyroid	Small Intestine	43436	14	0.4	0.02	12.8	1.09 (0.6 to 1.83)	46.4	66.2
W	Thyroid	Soft Tissue including Heart	43436	27	0.8	0.05	15.7	1.72 (1.14 to 2.51)	46.4	60.9
W	Thyroid	Stomach	43436	44	1.3	0.07	35.2	1.25 (0.91 to 1.68)	46.4	65.8
W	Thyroid	Urinary Bladder	43436	46	1.3	0.08	54.1	0.85 (0.62 to 1.13)	46.4	71.2
W	Thyroid	Vulva and Other Genital Organs	43436	18	0.5	0.03	30.1	0.6 (0.35 to 0.94)	46.4	63.1
W	Urinary Bladder	Acute Non-Lymphocytic Leukemia	15717	18	1.6	0.03	16.7	1.08 (0.64 to 1.7)	66.3	77.1
W	Urinary Bladder	Anus, Anal Canal and Anorectum	15717	7	0.6	0.01	7.4	0.95 (0.38 to 1.96)	66.3	62.6
W	Urinary Bladder	Brain and Other Nervous System	15717	10	0.9	0.02	16.6	0.6 (0.29 to 1.11)	66.3	76.0
W	Urinary Bladder	Breast	15717	435	39.5	0.74	441.1	0.99 (0.9 to 1.08)	66.3	73.6
W	Urinary Bladder	Cervix Uteri	15717	13	1.2	0.02	11.6	1.12 (0.6 to 1.92)	66.3	75.8
W	Urinary Bladder	Colon and Rectum	15717	168	15.3	0.28	191.4	0.88 (0.75 to 1.02)	66.3	78.0
W	Urinary Bladder	Corpus and Uterus, NOS	15717	81	7.4	0.14	92.8	0.87 (0.69 to 1.09)	66.3	71.4
W	Urinary Bladder	Esophagus	15717	13	1.2	0.02	10.2	1.28 (0.68 to 2.19)	66.3	77.4
W	Urinary Bladder	Gallbladder and Other Biliary	15717	15	1.4	0.03	17.0	0.88 (0.49 to 1.45)	66.3	79.5
W	Urinary Bladder	Hodgkin Lymphoma	15717	5	0.5	0.01	3.4	1.48 (0.48 to 3.46)	66.3	71.9
W	Urinary Bladder	Kidney and Renal Pelvis	15717	102	9.3	0.17	41.5	2.46 (2 to 2.98)	66.3	73.2
W	Urinary Bladder	Liver and Intrahepatic Bile Duct	15717	24	2.2	0.04	21.0	1.14 (0.73 to 1.7)	66.3	76.1
W	Urinary Bladder	Lung and Bronchus	15717	615	55.9	1.04	261.3	2.35 (2.17 to 2.55)	66.3	76.1
W	Urinary Bladder	Melanoma of the Skin	15717	47	4.3	0.08	55.7	0.84 (0.62 to 1.12)	66.3	74.2
W	Urinary Bladder	Myeloma	15717	23	2.1	0.04	25.8	0.89 (0.57 to 1.34)	66.3	78.6
W	Urinary Bladder	Non-Hodgkin Lymphoma	15717	99	9.0	0.17	101.2	0.98 (0.8 to 1.19)	66.3	76.9
W	Urinary Bladder	Oral Cavity and Pharynx	15717	33	3.0	0.06	26.5	1.25 (0.86 to 1.75)	66.3	75.7
W	Urinary Bladder	Ovary	15717	40	3.6	0.07	47.2	0.85 (0.61 to 1.15)	66.3	75.0
W	Urinary Bladder	Pancreas	15717	59	5.4	0.10	63.8	0.93 (0.7 to 1.19)	66.3	79.0
W	Urinary Bladder	Small Intestine	15717	13	1.2	0.02	8.1	1.61 (0.86 to 2.75)	66.3	77.5
W	Urinary Bladder	Soft Tissue including Heart	15717	7	0.6	0.01	8.9	0.79 (0.32 to 1.62)	66.3	77.7
W	Urinary Bladder	Stomach	15717	22	2.0	0.04	26.4	0.83 (0.52 to 1.26)	66.3	77.3
W	Urinary Bladder	Thyroid	15717	40	3.6	0.07	26.5	1.51 (1.08 to 2.06)	66.3	68.7
W	Urinary Bladder	Vulva and Other Genital Organs	15717	30	2.7	0.05	20.6	1.45 (0.98 to 2.07)	66.3	73.6
W	Vulva and Other Genital Organs	Acute Non-Lymphocytic Leukemia	6079	10	2.3	0.02	4.8	2.07 (0.99 to 3.8)	58.9	67.5
W	Vulva and Other Genital Organs	Anus, Anal Canal and Anorectum	6079	21	4.8	0.04	2.5	8.35 (5.17 to 12.76)	58.9	70.6

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC	Incidence per 10,000 Person-years	% Contribution to the Total Incidence	Expected Number of SPC	SIR (95% CI)	Mean Age at FPC	Mean Age at SPC
W	Vulva and Other Genital Organs	Breast	6079	144	32.8	0.24	150.8	0.96 (0.81 to 1.12)	58.9	71.1
W	Vulva and Other Genital Organs	Colon and Rectum	6079	61	13.9	0.10	55.4	1.1 (0.84 to 1.42)	58.9	71.9
W	Vulva and Other Genital Organs	Corpus and Uterus, NOS	6079	28	6.4	0.05	33.1	0.85 (0.56 to 1.22)	58.9	72.2
W	Vulva and Other Genital Organs	Gallbladder and Other Biliary	6079	5	1.1	0.01	4.8	1.04 (0.34 to 2.42)	58.9	80.1
W	Vulva and Other Genital Organs	Kidney and Renal Pelvis	6079	11	2.5	0.02	13.2	0.84 (0.42 to 1.49)	58.9	72.5
W	Vulva and Other Genital Organs	Liver and Intrahepatic Bile Duct	6079	8	1.8	0.01	6.5	1.23 (0.53 to 2.43)	58.9	67.8
W	Vulva and Other Genital Organs	Lung and Bronchus	6079	144	32.8	0.24	74.9	1.92 (1.62 to 2.26)	58.9	70.4
W	Vulva and Other Genital Organs	Melanoma of the Skin	6079	19	4.3	0.03	18.3	1.04 (0.63 to 1.62)	58.9	68.8
W	Vulva and Other Genital Organs	Myeloma	6079	13	3.0	0.02	7.9	1.66 (0.88 to 2.83)	58.9	71.6
W	Vulva and Other Genital Organs	Non-Hodgkin Lymphoma	6079	27	6.2	0.05	29.5	0.92 (0.6 to 1.33)	58.9	74.3
W	Vulva and Other Genital Organs	Oral Cavity and Pharynx	6079	25	5.7	0.04	8.2	3.03 (1.96 to 4.48)	58.9	67.5
W	Vulva and Other Genital Organs	Ovary	6079	9	2.1	0.02	15.2	0.59 (0.27 to 1.13)	58.9	69.5
W	Vulva and Other Genital Organs	Pancreas	6079	14	3.2	0.02	18.1	0.77 (0.42 to 1.3)	58.9	76.6
W	Vulva and Other Genital Organs	Soft Tissue including Heart	6079	7	1.6	0.01	2.9	2.45 (0.98 to 5.04)	58.9	66.3
W	Vulva and Other Genital Organs	Stomach	6079	7	1.6	0.01	7.8	0.9 (0.36 to 1.86)	58.9	76.2
W	Vulva and Other Genital Organs	Thyroid	6079	11	2.5	0.02	11.8	0.93 (0.47 to 1.67)	58.9	64.7
W	Vulva and Other Genital Organs	Urinary Bladder	6079	18	4.1	0.03	14.5	1.24 (0.74 to 1.96)	58.9	74.4

eTable 7. Risks of dying from a specific type of subsequent primary cancer among 5-year cancer survivors in 12 SEER registries: mortality, percent contribution to the total mortality, standardized mortality ratio by first primary cancer types and sex

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Acute Lymphocytic Leukemia	Non-Hodgkin Lymphoma	608	8	17.2	0.02	0.4	19.74 (8.52 to 38.89)	38.7	74.5
M	Acute Non-Lymphocytic Leukemia	Colon and Rectum	1900	5	3.6	0.01	4.5	1.1 (0.36 to 2.57)	47.6	62.1
M	Acute Non-Lymphocytic Leukemia	Lung and Bronchus	1900	9	6.4	0.02	15.2	0.59 (0.27 to 1.12)	47.6	64.0
M	Acute Non-Lymphocytic Leukemia	Non-Hodgkin Lymphoma	1900	9	6.4	0.02	2.3	3.95 (1.81 to 7.5)	47.6	72.0
M	Acute Non-Lymphocytic Leukemia	Urinary Bladder	1900	8	5.7	0.02	1.6	4.91 (2.12 to 9.67)	47.6	71.8
M	Anus, Anal Canal and Anorectum	Colon and Rectum	1945	78	58.8	0.18	7.7	10.18 (8.04 to 12.7)	55.8	67.9
M	Anus, Anal Canal and Anorectum	Esophagus	1945	5	3.8	0.01	3.2	1.58 (0.51 to 3.69)	55.8	69.1
M	Anus, Anal Canal and Anorectum	Lung and Bronchus	1945	44	33.2	0.10	25.7	1.71 (1.24 to 2.3)	55.8	67.9
M	Anus, Anal Canal and Anorectum	Non-Hodgkin Lymphoma	1945	7	5.3	0.02	4.0	1.73 (0.7 to 3.56)	55.8	79.5
M	Anus, Anal Canal and Anorectum	Oral Cavity and Pharynx	1945	6	4.5	0.01	1.6	3.7 (1.36 to 8.05)	55.8	60.5
M	Anus, Anal Canal and Anorectum	Pancreas	1945	7	5.3	0.02	5.4	1.29 (0.52 to 2.66)	55.8	63.6
M	Anus, Anal Canal and Anorectum	Prostate	1945	5	3.8	0.01	8.9	0.56 (0.18 to 1.31)	55.8	83.1
M	Anus, Anal Canal and Anorectum	Soft Tissue including Heart	1945	5	3.8	0.01	0.5	9.47 (3.07 to 22.09)	55.8	75.4
M	Anus, Anal Canal and Anorectum	Urinary Bladder	1945	7	5.3	0.02	3.2	2.21 (0.89 to 4.56)	55.8	74.2
M	Bones and Joints	Acute Non-lymphocytic Leukemia	1382	5	4.3	0.01	0.9	5.85 (1.9 to 13.65)	44.5	69.9
M	Bones and Joints	Brain and Other Nervous System	1382	15	12.9	0.03	1.1	14.02 (7.85 to 23.12)	44.5	58.7
M	Bones and Joints	Colon and Rectum	1382	5	4.3	0.01	3.7	1.34 (0.44 to 3.14)	44.5	73.7
M	Bones and Joints	Lung and Bronchus	1382	26	22.3	0.06	12.2	2.14 (1.4 to 3.13)	44.5	66.4
M	Bones and Joints	Pancreas	1382	5	4.3	0.01	2.6	1.92 (0.62 to 4.49)	44.5	67.3
M	Bones and Joints	Soft Tissue including Heart	1382	14	12.0	0.03	0.3	49.61 (27.12 to 83.24)	44.5	56.4
M	Brain and Other Nervous System	Acute Non-lymphocytic Leukemia	4776	8	2.3	0.02	1.7	4.69 (2.03 to 9.25)	42.1	56.3
M	Brain and Other Nervous System	Colon and Rectum	4776	8	2.3	0.02	7.7	1.04 (0.45 to 2.05)	42.1	62.8
M	Brain and Other Nervous System	Esophagus	4776	6	1.8	0.01	3.5	1.7 (0.62 to 3.7)	42.1	58.5
M	Brain and Other Nervous System	Kidney and Renal Pelvis	4776	5	1.5	0.01	2.5	1.97 (0.64 to 4.6)	42.1	59.9
M	Brain and Other Nervous System	Lung and Bronchus	4776	16	4.7	0.04	24.7	0.65 (0.37 to 1.05)	42.1	68.3
M	Brain and Other Nervous System	Melanoma of the Skin	4776	7	2.1	0.02	1.8	3.96 (1.59 to 8.16)	42.1	60.6
M	Brain and Other Nervous System	Non-Hodgkin Lymphoma	4776	7	2.1	0.02	3.7	1.9 (0.77 to 3.92)	42.1	69.0
M	Brain and Other Nervous System	Pancreas	4776	7	2.1	0.02	5.5	1.27 (0.51 to 2.62)	42.1	60.8
M	Brain and Other Nervous System	Prostate	4776	5	1.5	0.01	5.8	0.86 (0.28 to 2)	42.1	77.4

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Brain and Other Nervous System	Soft Tissue including Heart	4776	10	2.9	0.02	0.6	15.43 (7.4 to 28.38)	42.1	54.5
M	Breast	Acute Non-lymphocytic Leukemia	1861	5	4.2	0.01	2.5	1.99 (0.65 to 4.64)	63.2	73.2
M	Breast	Brain and Other Nervous System	1861	6	5.0	0.01	2.2	2.73 (1 to 5.93)	63.2	75.9
M	Breast	Colon and Rectum	1861	13	10.8	0.03	10.6	1.23 (0.65 to 2.1)	63.2	79.4
M	Breast	Liver and Intrahepatic Bile Duct	1861	5	4.2	0.01	4.4	1.13 (0.37 to 2.64)	63.2	74.4
M	Breast	Lung and Bronchus	1861	34	28.3	0.08	34.4	0.99 (0.69 to 1.38)	63.2	75.3
M	Breast	Non-Hodgkin Lymphoma	1861	11	9.2	0.03	5.9	1.86 (0.93 to 3.32)	63.2	80.3
M	Breast	Pancreas	1861	19	15.8	0.04	7.1	2.69 (1.62 to 4.2)	63.2	76.5
M	Breast	Prostate	1861	15	12.5	0.03	14.9	1.01 (0.56 to 1.66)	63.2	75.4
M	Breast	Stomach	1861	5	4.2	0.01	2.7	1.89 (0.61 to 4.4)	63.2	83.5
M	Chronic Myeloid Leukemia	Acute Lymphocytic Leukemia	2726	5	2.9	0.01	0.1	38.7 (12.57 to 90.32)	51.7	48.2
M	Chronic Myeloid Leukemia	Colon and Rectum	2726	7	4.1	0.02	6.9	1.02 (0.41 to 2.1)	51.7	71.0
M	Chronic Myeloid Leukemia	Lung and Bronchus	2726	13	7.6	0.03	22.5	0.58 (0.31 to 0.99)	51.7	72.7
M	Chronic Myeloid Leukemia	Non-Hodgkin Lymphoma	2726	11	6.4	0.03	3.5	3.14 (1.57 to 5.62)	51.7	72.4
M	Chronic Myeloid Leukemia	Prostate	2726	6	3.5	0.01	7.4	0.81 (0.3 to 1.77)	51.7	79.1
M	Colon and Rectum	Acute Lymphocytic Leukemia	74184	14	0.3	0.03	6.4	2.17 (1.19 to 3.64)	63.4	68.1
M	Colon and Rectum	Acute Non-lymphocytic Leukemia	74184	156	3.1	0.35	108.8	1.43 (1.22 to 1.68)	63.4	76.7
M	Colon and Rectum	Brain and Other Nervous System	74184	101	2.0	0.23	91.9	1.1 (0.9 to 1.34)	63.4	72.8
M	Colon and Rectum	Breast	74184	6	0.1	0.01	6.9	0.87 (0.32 to 1.89)	63.4	76.5
M	Colon and Rectum	Chronic Myeloid Leukemia	74184	16	0.3	0.04	10.9	1.47 (0.84 to 2.38)	63.4	78.5
M	Colon and Rectum	Esophagus	74184	165	3.3	0.38	163.1	1.01 (0.86 to 1.18)	63.4	76.7
M	Colon and Rectum	Gallbladder and Other Biliary	74184	33	0.7	0.08	27.1	1.22 (0.84 to 1.71)	63.4	76.8
M	Colon and Rectum	Hodgkin Lymphoma	74184	7	0.1	0.02	8.0	0.88 (0.35 to 1.81)	63.4	72.7
M	Colon and Rectum	Kidney and Renal Pelvis	74184	130	2.6	0.30	131.2	0.99 (0.83 to 1.18)	63.4	77.3
M	Colon and Rectum	Larynx	74184	37	0.7	0.08	44.2	0.84 (0.59 to 1.15)	63.4	76.1
M	Colon and Rectum	Liver and Intrahepatic Bile Duct	74184	268	5.3	0.61	194.8	1.38 (1.22 to 1.55)	63.4	73.8
M	Colon and Rectum	Lung and Bronchus	74184	1597	31.5	3.63	1472.0	1.09 (1.03 to 1.14)	63.4	76.9
M	Colon and Rectum	Melanoma of the Skin	74184	66	1.3	0.15	81.5	0.81 (0.63 to 1.03)	63.4	77.4
M	Colon and Rectum	Myeloma	74184	132	2.6	0.30	111.8	1.18 (0.99 to 1.4)	63.4	77.9
M	Colon and Rectum	Non-Hodgkin Lymphoma	74184	245	4.8	0.56	257.7	0.95 (0.84 to 1.08)	63.4	79.3
M	Colon and Rectum	Oral Cavity and Pharynx	74184	85	1.7	0.19	80.4	1.06 (0.84 to 1.31)	63.4	75.4
M	Colon and Rectum	Pancreas	74184	412	8.1	0.94	301.6	1.37 (1.24 to 1.51)	63.4	75.9

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Colon and Rectum	Penis and Other Genital Organs	74184	7	0.1	0.02	5.2	1.36 (0.55 to 2.8)	63.4	78.2
M	Colon and Rectum	Prostate	74184	466	9.2	1.06	662.1	0.7 (0.64 to 0.77)	63.4	81.1
M	Colon and Rectum	Small Intestine	74184	41	0.8	0.09	11.0	3.73 (2.68 to 5.06)	63.4	70.8
M	Colon and Rectum	Soft Tissue including Heart	74184	51	1.0	0.12	29.0	1.76 (1.31 to 2.32)	63.4	78.0
M	Colon and Rectum	Stomach	74184	180	3.5	0.41	121.4	1.48 (1.27 to 1.72)	63.4	75.9
M	Colon and Rectum	Thyroid	74184	10	0.2	0.02	12.3	0.81 (0.39 to 1.5)	63.4	80.3
M	Colon and Rectum	Urinary Bladder	74184	210	4.1	0.48	213.1	0.99 (0.86 to 1.13)	63.4	79.7
M	Esophagus	Brain and Other Nervous System	2736	6	4.0	0.01	2.8	2.15 (0.79 to 4.69)	62.8	71.8
M	Esophagus	Colon and Rectum	2736	14	9.2	0.03	11.9	1.18 (0.64 to 1.97)	62.8	75.5
M	Esophagus	Lung and Bronchus	2736	82	54.1	0.19	40.6	2.02 (1.61 to 2.51)	62.8	71.2
M	Esophagus	Non-Hodgkin Lymphoma	2736	6	4.0	0.01	6.7	0.89 (0.33 to 1.94)	62.8	82.2
M	Esophagus	Oral Cavity and Pharynx	2736	18	11.9	0.04	2.3	7.79 (4.61 to 12.3)	62.8	68.9
M	Esophagus	Pancreas	2736	12	7.9	0.03	8.4	1.42 (0.74 to 2.48)	62.8	71.5
M	Esophagus	Prostate	2736	13	8.6	0.03	15.4	0.84 (0.45 to 1.44)	62.8	78.7
M	Esophagus	Stomach	2736	21	13.9	0.05	3.0	7.04 (4.36 to 10.76)	62.8	71.4
M	Esophagus	Urinary Bladder	2736	6	4.0	0.01	5.5	1.1 (0.4 to 2.39)	62.8	78.0
M	Eye and Orbit	Colon and Rectum	1609	9	7.7	0.02	7.7	1.18 (0.54 to 2.23)	58.1	77.7
M	Eye and Orbit	Liver and Intrahepatic Bile Duct	1609	14	12.0	0.03	3.3	4.24 (2.32 to 7.12)	58.1	66.8
M	Eye and Orbit	Lung and Bronchus	1609	40	34.3	0.09	25.5	1.57 (1.12 to 2.14)	58.1	73.8
M	Eye and Orbit	Melanoma of the Skin	1609	99	84.8	0.23	1.7	60 (48.77 to 73.05)	58.1	66.5
M	Eye and Orbit	Pancreas	1609	9	7.7	0.02	5.3	1.7 (0.78 to 3.22)	58.1	73.3
M	Eye and Orbit	Prostate	1609	9	7.7	0.02	9.6	0.94 (0.43 to 1.78)	58.1	81.8
M	Gallbladder and Other Biliary	Colon and Rectum	1005	9	15.6	0.02	4.7	1.94 (0.89 to 3.67)	62.6	74.0
M	Gallbladder and Other Biliary	Liver and Intrahepatic Bile Duct	1005	60	103.7	0.14	2.2	27.8 (21.21 to 35.78)	62.6	68.5
M	Gallbladder and Other Biliary	Lung and Bronchus	1005	18	31.1	0.04	15.0	1.2 (0.71 to 1.9)	62.6	72.4
M	Gallbladder and Other Biliary	Pancreas	1005	63	108.9	0.14	3.1	20.22 (15.54 to 25.87)	62.6	72.1
M	Hodgkin Lymphoma	Acute Non-lymphocytic Leukemia	7211	16	2.5	0.04	3.0	5.38 (3.08 to 8.74)	40.2	54.6
M	Hodgkin Lymphoma	Colon and Rectum	7211	21	3.3	0.05	13.6	1.55 (0.96 to 2.37)	40.2	65.5
M	Hodgkin Lymphoma	Esophagus	7211	8	1.2	0.02	6.0	1.34 (0.58 to 2.64)	40.2	66.4
M	Hodgkin Lymphoma	Liver and Intrahepatic Bile Duct	7211	5	0.8	0.01	7.5	0.67 (0.22 to 1.55)	40.2	59.9
M	Hodgkin Lymphoma	Lung and Bronchus	7211	90	13.9	0.20	42.5	2.12 (1.71 to 2.61)	40.2	65.3
M	Hodgkin Lymphoma	Melanoma of the Skin	7211	5	0.8	0.01	3.0	1.67 (0.54 to 3.89)	40.2	65.9

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Hodgkin Lymphoma	Non-Hodgkin Lymphoma	7211	128	19.8	0.29	6.4	19.89 (16.59 to 23.65)	40.2	62.2
M	Hodgkin Lymphoma	Oral Cavity and Pharynx	7211	10	1.5	0.02	3.3	3.02 (1.45 to 5.55)	40.2	58.7
M	Hodgkin Lymphoma	Pancreas	7211	15	2.3	0.03	9.5	1.58 (0.88 to 2.61)	40.2	68.4
M	Hodgkin Lymphoma	Prostate	7211	14	2.2	0.03	11.1	1.26 (0.69 to 2.12)	40.2	70.3
M	Hodgkin Lymphoma	Stomach	7211	8	1.2	0.02	3.4	2.38 (1.03 to 4.68)	40.2	67.5
M	Kaposi Sarcoma	Anus, Anal Canal and Anorectum	3836	14	4.1	0.03	0.1	107.5 (58.77 to 180.37)	43.5	55.7
M	Kaposi Sarcoma	Colon and Rectum	3836	11	3.2	0.03	9.3	1.19 (0.59 to 2.12)	43.5	52.6
M	Kaposi Sarcoma	Gallbladder and Other Biliary	3836	5	1.4	0.01	0.5	11 (3.57 to 25.68)	43.5	61.6
M	Kaposi Sarcoma	Liver and Intrahepatic Bile Duct	3836	16	4.6	0.04	5.3	3.04 (1.74 to 4.94)	43.5	54.2
M	Kaposi Sarcoma	Lung and Bronchus	3836	14	4.1	0.03	28.0	0.5 (0.27 to 0.84)	43.5	63.2
M	Kaposi Sarcoma	Melanoma of the Skin	3836	5	1.4	0.01	1.9	2.61 (0.85 to 6.08)	43.5	58.4
M	Kaposi Sarcoma	Non-Hodgkin Lymphoma	3836	9	2.6	0.02	4.4	2.05 (0.94 to 3.9)	43.5	58.7
M	Kaposi Sarcoma	Oral Cavity and Pharynx	3836	6	1.7	0.01	2.3	2.65 (0.97 to 5.76)	43.5	52.3
M	Kaposi Sarcoma	Pancreas	3836	10	2.9	0.02	6.3	1.58 (0.76 to 2.91)	43.5	56.4
M	Kaposi Sarcoma	Prostate	3836	10	2.9	0.02	8.2	1.22 (0.58 to 2.24)	43.5	70.5
M	Kidney and Renal Pelvis	Acute Lymphocytic Leukemia	25791	5	0.3	0.01	1.8	2.77 (0.9 to 6.46)	59.5	68.5
M	Kidney and Renal Pelvis	Acute Non-lymphocytic Leukemia	25791	36	2.2	0.08	27.9	1.29 (0.9 to 1.79)	59.5	73.4
M	Kidney and Renal Pelvis	Bones and Joints	25791	5	0.3	0.01	2.2	2.24 (0.73 to 5.23)	59.5	65.4
M	Kidney and Renal Pelvis	Brain and Other Nervous System	25791	49	2.9	0.11	27.3	1.79 (1.33 to 2.37)	59.5	72.8
M	Kidney and Renal Pelvis	Colon and Rectum	25791	97	5.8	0.22	116.2	0.83 (0.68 to 1.02)	59.5	73.4
M	Kidney and Renal Pelvis	Esophagus	25791	43	2.6	0.10	46.2	0.93 (0.67 to 1.25)	59.5	74.0
M	Kidney and Renal Pelvis	Gallbladder and Other Biliary	25791	12	0.7	0.03	6.7	1.8 (0.93 to 3.14)	59.5	72.2
M	Kidney and Renal Pelvis	Larynx	25791	7	0.4	0.02	12.3	0.57 (0.23 to 1.18)	59.5	74.5
M	Kidney and Renal Pelvis	Liver and Intrahepatic Bile Duct	25791	81	4.8	0.18	55.3	1.47 (1.16 to 1.82)	59.5	68.9
M	Kidney and Renal Pelvis	Lung and Bronchus	25791	416	24.9	0.95	389.0	1.07 (0.97 to 1.18)	59.5	74.8
M	Kidney and Renal Pelvis	Melanoma of the Skin	25791	13	0.8	0.03	22.1	0.59 (0.31 to 1.01)	59.5	73.7
M	Kidney and Renal Pelvis	Myeloma	25791	31	1.9	0.07	28.7	1.08 (0.73 to 1.53)	59.5	77.9
M	Kidney and Renal Pelvis	Non-Hodgkin Lymphoma	25791	64	3.8	0.15	63.4	1.01 (0.78 to 1.29)	59.5	76.6
M	Kidney and Renal Pelvis	Oral Cavity and Pharynx	25791	13	0.8	0.03	23.1	0.56 (0.3 to 0.96)	59.5	69.6
M	Kidney and Renal Pelvis	Pancreas	25791	104	6.2	0.24	81.8	1.27 (1.04 to 1.54)	59.5	75.0
M	Kidney and Renal Pelvis	Prostate	25791	103	6.2	0.23	147.9	0.7 (0.57 to 0.85)	59.5	78.8
M	Kidney and Renal Pelvis	Small Intestine	25791	5	0.3	0.01	2.9	1.7 (0.55 to 3.96)	59.5	76.2

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Kidney and Renal Pelvis	Soft Tissue including Heart	25791	8	0.5	0.02	7.8	1.02 (0.44 to 2.01)	59.5	74.8
M	Kidney and Renal Pelvis	Stomach	25791	34	2.0	0.08	29.5	1.15 (0.8 to 1.61)	59.5	77.6
M	Kidney and Renal Pelvis	Urinary Bladder	25791	87	5.2	0.20	50.9	1.71 (1.37 to 2.11)	59.5	77.3
M	Larynx	Acute Non-lymphocytic Leukemia	9081	22	3.6	0.05	12.0	1.83 (1.15 to 2.77)	62.5	76.4
M	Larynx	Brain and Other Nervous System	9081	7	1.2	0.02	10.9	0.64 (0.26 to 1.32)	62.5	74.8
M	Larynx	Colon and Rectum	9081	82	13.6	0.19	51.8	1.59 (1.26 to 1.97)	62.5	75.5
M	Larynx	Esophagus	9081	83	13.7	0.19	19.4	4.28 (3.41 to 5.31)	62.5	73.3
M	Larynx	Kidney and Renal Pelvis	9081	17	2.8	0.04	15.0	1.14 (0.66 to 1.82)	62.5	70.9
M	Larynx	Liver and Intrahepatic Bile Duct	9081	45	7.4	0.10	21.7	2.08 (1.51 to 2.78)	62.5	73.3
M	Larynx	Lung and Bronchus	9081	644	106.4	1.46	173.7	3.71 (3.43 to 4)	62.5	73.6
M	Larynx	Melanoma of the Skin	9081	10	1.7	0.02	9.1	1.1 (0.53 to 2.02)	62.5	77.0
M	Larynx	Myeloma	9081	9	1.5	0.02	12.8	0.71 (0.32 to 1.34)	62.5	77.0
M	Larynx	Non-Hodgkin Lymphoma	9081	28	4.6	0.06	27.8	1.01 (0.67 to 1.46)	62.5	77.4
M	Larynx	Oral Cavity and Pharynx	9081	143	23.6	0.33	9.5	15.07 (12.7 to 17.76)	62.5	70.6
M	Larynx	Pancreas	9081	54	8.9	0.12	34.4	1.57 (1.18 to 2.05)	62.5	75.2
M	Larynx	Prostate	9081	59	9.8	0.13	69.5	0.85 (0.65 to 1.1)	62.5	79.6
M	Larynx	Small Intestine	9081	5	0.8	0.01	1.2	4.01 (1.3 to 9.37)	62.5	78.2
M	Larynx	Soft Tissue including Heart	9081	6	1.0	0.01	3.2	1.86 (0.68 to 4.05)	62.5	76.3
M	Larynx	Stomach	9081	21	3.5	0.05	13.3	1.58 (0.98 to 2.41)	62.5	79.5
M	Larynx	Urinary Bladder	9081	31	5.1	0.07	22.0	1.41 (0.96 to 2)	62.5	78.3
M	Liver and Intrahepatic Bile Duct	Acute Non-lymphocytic Leukemia	3613	8	4.9	0.02	1.9	4.19 (1.81 to 8.26)	58.9	73.5
M	Liver and Intrahepatic Bile Duct	Colon and Rectum	3613	10	6.2	0.02	8.1	1.23 (0.59 to 2.27)	58.9	70.0
M	Liver and Intrahepatic Bile Duct	Lung and Bronchus	3613	36	22.2	0.08	26.8	1.34 (0.94 to 1.86)	58.9	69.9
M	Liver and Intrahepatic Bile Duct	Melanoma of the Skin	3613	5	3.1	0.01	1.3	3.99 (1.3 to 9.31)	58.9	69.9
M	Liver and Intrahepatic Bile Duct	Non-Hodgkin Lymphoma	3613	16	9.9	0.04	4.0	4.03 (2.31 to 6.55)	58.9	65.5
M	Liver and Intrahepatic Bile Duct	Pancreas	3613	10	6.2	0.02	6.1	1.63 (0.78 to 3)	58.9	66.0
M	Liver and Intrahepatic Bile Duct	Prostate	3613	7	4.3	0.02	7.9	0.89 (0.36 to 1.82)	58.9	70.3
M	Liver and Intrahepatic Bile Duct	Stomach	3613	5	3.1	0.01	2.8	1.79 (0.58 to 4.18)	58.9	71.8
M	Lung and Bronchus	Acute Non-lymphocytic Leukemia	20842	40	3.7	0.09	22.8	1.75 (1.25 to 2.39)	64.3	74.6
M	Lung and Bronchus	Brain and Other Nervous System	20842	27	2.5	0.06	20.0	1.35 (0.89 to 1.97)	64.3	75.0
M	Lung and Bronchus	Colon and Rectum	20842	142	13.0	0.32	96.5	1.47 (1.24 to 1.73)	64.3	75.9
M	Lung and Bronchus	Esophagus	20842	97	8.9	0.22	35.4	2.74 (2.22 to 3.34)	64.3	71.8

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Lung and Bronchus	Gallbladder and Other Biliary	20842	9	0.8	0.02	5.6	1.61 (0.74 to 3.06)	64.3	75.5
M	Lung and Bronchus	Kidney and Renal Pelvis	20842	32	2.9	0.07	27.8	1.15 (0.79 to 1.63)	64.3	77.2
M	Lung and Bronchus	Larynx	20842	26	2.4	0.06	9.8	2.66 (1.74 to 3.9)	64.3	73.0
M	Lung and Bronchus	Liver and Intrahepatic Bile Duct	20842	61	5.6	0.14	40.9	1.49 (1.14 to 1.92)	64.3	74.8
M	Lung and Bronchus	Melanoma of the Skin	20842	15	1.4	0.03	17.0	0.88 (0.5 to 1.46)	64.3	75.0
M	Lung and Bronchus	Myeloma	20842	20	1.8	0.05	23.7	0.84 (0.52 to 1.3)	64.3	75.7
M	Lung and Bronchus	Non-Hodgkin Lymphoma	20842	55	5.0	0.13	53.0	1.04 (0.78 to 1.35)	64.3	77.1
M	Lung and Bronchus	Oral Cavity and Pharynx	20842	36	3.3	0.08	17.3	2.08 (1.46 to 2.88)	64.3	74.7
M	Lung and Bronchus	Pancreas	20842	96	8.8	0.22	64.1	1.5 (1.21 to 1.83)	64.3	75.4
M	Lung and Bronchus	Prostate	20842	117	10.7	0.27	131.0	0.89 (0.74 to 1.07)	64.3	78.4
M	Lung and Bronchus	Small Intestine	20842	6	0.5	0.01	2.3	2.58 (0.95 to 5.62)	64.3	70.0
M	Lung and Bronchus	Soft Tissue including Heart	20842	14	1.3	0.03	6.1	2.31 (1.27 to 3.88)	64.3	71.1
M	Lung and Bronchus	Stomach	20842	48	4.4	0.11	25.4	1.89 (1.39 to 2.5)	64.3	74.3
M	Lung and Bronchus	Urinary Bladder	20842	75	6.9	0.17	42.2	1.78 (1.4 to 2.23)	64.3	77.6
M	Melanoma of the Skin	Acute Lymphocytic Leukemia	44828	6	0.2	0.01	3.7	1.62 (0.6 to 3.53)	56.5	69.0
M	Melanoma of the Skin	Acute Non-lymphocytic Leukemia	44828	52	1.5	0.12	54.5	0.95 (0.71 to 1.25)	56.5	73.0
M	Melanoma of the Skin	Bones and Joints	44828	6	0.2	0.01	4.4	1.37 (0.5 to 2.98)	56.5	70.7
M	Melanoma of the Skin	Brain and Other Nervous System	44828	95	2.6	0.22	57.0	1.67 (1.35 to 2.04)	56.5	70.7
M	Melanoma of the Skin	Breast	44828	9	0.3	0.02	3.3	2.7 (1.23 to 5.12)	56.5	66.7
M	Melanoma of the Skin	Colon and Rectum	44828	159	4.4	0.36	213.7	0.74 (0.63 to 0.87)	56.5	74.8
M	Melanoma of the Skin	Esophagus	44828	79	2.2	0.18	91.1	0.87 (0.69 to 1.08)	56.5	71.4
M	Melanoma of the Skin	Eye and Orbit	44828	5	0.1	0.01	1.2	4.03 (1.31 to 9.4)	56.5	74.1
M	Melanoma of the Skin	Gallbladder and Other Biliary	44828	5	0.1	0.01	12.0	0.42 (0.14 to 0.97)	56.5	78.5
M	Melanoma of the Skin	Kidney and Renal Pelvis	44828	60	1.7	0.14	69.0	0.87 (0.66 to 1.12)	56.5	72.9
M	Melanoma of the Skin	Larynx	44828	8	0.2	0.02	21.9	0.36 (0.16 to 0.72)	56.5	74.0
M	Melanoma of the Skin	Liver and Intrahepatic Bile Duct	44828	73	2.0	0.17	96.4	0.76 (0.59 to 0.95)	56.5	72.5
M	Melanoma of the Skin	Lung and Bronchus	44828	493	13.7	1.12	726.5	0.68 (0.62 to 0.74)	56.5	75.2
M	Melanoma of the Skin	Myeloma	44828	71	2.0	0.16	51.2	1.39 (1.08 to 1.75)	56.5	73.8
M	Melanoma of the Skin	Non-Hodgkin Lymphoma	44828	131	3.7	0.30	124.5	1.05 (0.88 to 1.25)	56.5	75.6
M	Melanoma of the Skin	Oral Cavity and Pharynx	44828	40	1.1	0.09	43.5	0.92 (0.66 to 1.25)	56.5	71.7
M	Melanoma of the Skin	Pancreas	44828	174	4.9	0.40	153.8	1.13 (0.97 to 1.31)	56.5	74.8
M	Melanoma of the Skin	Prostate	44828	188	5.2	0.43	257.7	0.73 (0.63 to 0.84)	56.5	78.4

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Melanoma of the Skin	Small Intestine	44828	8	0.2	0.02	5.4	1.48 (0.64 to 2.92)	56.5	70.7
M	Melanoma of the Skin	Soft Tissue including Heart	44828	31	0.9	0.07	15.4	2.01 (1.37 to 2.85)	56.5	73.3
M	Melanoma of the Skin	Stomach	44828	34	0.9	0.08	47.5	0.72 (0.5 to 1)	56.5	70.9
M	Melanoma of the Skin	Urinary Bladder	44828	64	1.8	0.15	101.3	0.63 (0.49 to 0.81)	56.5	78.8
M	Myeloma	Acute Non-lymphocytic Leukemia	6683	26	8.7	0.06	4.8	5.42 (3.54 to 7.93)	61.1	67.7
M	Myeloma	Brain and Other Nervous System	6683	6	2.0	0.01	4.7	1.27 (0.47 to 2.76)	61.1	76.9
M	Myeloma	Colon and Rectum	6683	23	7.7	0.05	21.1	1.09 (0.69 to 1.63)	61.1	75.8
M	Myeloma	Esophagus	6683	9	3.0	0.02	8.2	1.09 (0.5 to 2.08)	61.1	75.5
M	Myeloma	Liver and Intrahepatic Bile Duct	6683	17	5.7	0.04	10.1	1.69 (0.99 to 2.71)	61.1	68.7
M	Myeloma	Lung and Bronchus	6683	40	13.4	0.09	70.7	0.57 (0.4 to 0.77)	61.1	74.9
M	Myeloma	Melanoma of the Skin	6683	10	3.3	0.02	3.6	2.76 (1.33 to 5.08)	61.1	70.4
M	Myeloma	Non-Hodgkin Lymphoma	6683	30	10.0	0.07	10.8	2.77 (1.87 to 3.96)	61.1	73.0
M	Myeloma	Pancreas	6683	15	5.0	0.03	14.7	1.02 (0.57 to 1.69)	61.1	72.6
M	Myeloma	Prostate	6683	25	8.4	0.06	27.5	0.91 (0.59 to 1.34)	61.1	76.4
M	Myeloma	Urinary Bladder	6683	10	3.3	0.02	8.5	1.17 (0.56 to 2.15)	61.1	78.3
M	Non-Hodgkin Lymphoma	Acute Lymphocytic Leukemia	44041	28	1.0	0.06	3.1	9.06 (6.02 to 13.1)	59.2	68.0
M	Non-Hodgkin Lymphoma	Acute Non-lymphocytic Leukemia	44041	201	6.9	0.46	47.5	4.24 (3.67 to 4.86)	59.2	70.1
M	Non-Hodgkin Lymphoma	Anus, Anal Canal and Anorectum	44041	5	0.2	0.01	1.8	2.79 (0.9 to 6.5)	59.2	61.5
M	Non-Hodgkin Lymphoma	Brain and Other Nervous System	44041	61	2.1	0.14	46.0	1.33 (1.01 to 1.7)	59.2	71.6
M	Non-Hodgkin Lymphoma	Chronic Myeloid Leukemia	44041	23	0.8	0.05	4.6	5.03 (3.19 to 7.54)	59.2	72.8
M	Non-Hodgkin Lymphoma	Colon and Rectum	44041	193	6.7	0.44	193.3	1 (0.86 to 1.15)	59.2	75.4
M	Non-Hodgkin Lymphoma	Esophagus	44041	86	3.0	0.20	76.6	1.12 (0.9 to 1.39)	59.2	72.6
M	Non-Hodgkin Lymphoma	Gallbladder and Other Biliary	44041	12	0.4	0.03	11.1	1.08 (0.56 to 1.89)	59.2	74.1
M	Non-Hodgkin Lymphoma	Hodgkin Lymphoma	44041	74	2.6	0.17	3.7	20.12 (15.8 to 25.26)	59.2	70.6
M	Non-Hodgkin Lymphoma	Kidney and Renal Pelvis	44041	57	2.0	0.13	59.3	0.96 (0.73 to 1.25)	59.2	72.4
M	Non-Hodgkin Lymphoma	Larynx	44041	13	0.4	0.03	19.7	0.66 (0.35 to 1.13)	59.2	73.1
M	Non-Hodgkin Lymphoma	Liver and Intrahepatic Bile Duct	44041	125	4.3	0.28	88.6	1.41 (1.18 to 1.68)	59.2	71.0
M	Non-Hodgkin Lymphoma	Lung and Bronchus	44041	672	23.2	1.53	642.7	1.05 (0.97 to 1.13)	59.2	73.9
M	Non-Hodgkin Lymphoma	Melanoma of the Skin	44041	77	2.7	0.18	38.7	1.99 (1.57 to 2.49)	59.2	75.3
M	Non-Hodgkin Lymphoma	Myeloma	44041	69	2.4	0.16	46.9	1.47 (1.15 to 1.86)	59.2	74.5
M	Non-Hodgkin Lymphoma	Oral Cavity and Pharynx	44041	45	1.6	0.10	37.7	1.19 (0.87 to 1.6)	59.2	72.2
M	Non-Hodgkin Lymphoma	Pancreas	44041	167	5.8	0.38	134.8	1.24 (1.06 to 1.44)	59.2	75.0

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Non-Hodgkin Lymphoma	Prostate	44041	184	6.4	0.42	246.3	0.75 (0.64 to 0.86)	59.2	80.0
M	Non-Hodgkin Lymphoma	Small Intestine	44041	8	0.3	0.02	4.8	1.66 (0.72 to 3.26)	59.2	76.5
M	Non-Hodgkin Lymphoma	Soft Tissue including Heart	44041	31	1.1	0.07	13.2	2.34 (1.59 to 3.32)	59.2	71.4
M	Non-Hodgkin Lymphoma	Stomach	44041	76	2.6	0.17	47.5	1.6 (1.26 to 2)	59.2	75.1
M	Non-Hodgkin Lymphoma	Thyroid	44041	5	0.2	0.01	5.4	0.92 (0.3 to 2.15)	59.2	74.8
M	Non-Hodgkin Lymphoma	Urinary Bladder	44041	99	3.4	0.23	88.5	1.12 (0.91 to 1.36)	59.2	78.7
M	Oral Cavity and Pharynx	Acute Non-lymphocytic Leukemia	22743	29	1.9	0.07	22.2	1.31 (0.88 to 1.88)	57.5	70.1
M	Oral Cavity and Pharynx	Bones and Joints	22743	18	1.2	0.04	1.8	10.09 (5.98 to 15.95)	57.5	68.2
M	Oral Cavity and Pharynx	Brain and Other Nervous System	22743	36	2.3	0.08	23.3	1.54 (1.08 to 2.14)	57.5	70.1
M	Oral Cavity and Pharynx	Colon and Rectum	22743	141	9.2	0.32	93.0	1.52 (1.28 to 1.79)	57.5	74.1
M	Oral Cavity and Pharynx	Esophagus	22743	195	12.7	0.44	38.4	5.08 (4.39 to 5.85)	57.5	67.8
M	Oral Cavity and Pharynx	Gallbladder and Other Biliary	22743	10	0.6	0.02	5.3	1.88 (0.9 to 3.46)	57.5	72.9
M	Oral Cavity and Pharynx	Kidney and Renal Pelvis	22743	29	1.9	0.07	28.9	1 (0.67 to 1.44)	57.5	72.4
M	Oral Cavity and Pharynx	Larynx	22743	214	13.9	0.49	9.9	21.51 (18.73 to 24.6)	57.5	70.1
M	Oral Cavity and Pharynx	Liver and Intrahepatic Bile Duct	22743	71	4.6	0.16	46.4	1.53 (1.19 to 1.93)	57.5	69.1
M	Oral Cavity and Pharynx	Lung and Bronchus	22743	794	51.6	1.80	316.0	2.51 (2.34 to 2.69)	57.5	71.0
M	Oral Cavity and Pharynx	Melanoma of the Skin	22743	30	1.9	0.07	18.1	1.65 (1.12 to 2.36)	57.5	69.4
M	Oral Cavity and Pharynx	Myeloma	22743	16	1.0	0.04	22.0	0.73 (0.42 to 1.18)	57.5	69.0
M	Oral Cavity and Pharynx	Non-Hodgkin Lymphoma	22743	98	6.4	0.22	50.0	1.96 (1.59 to 2.39)	57.5	72.3
M	Oral Cavity and Pharynx	Pancreas	22743	79	5.1	0.18	65.7	1.2 (0.95 to 1.5)	57.5	73.1
M	Oral Cavity and Pharynx	Prostate	22743	110	7.1	0.25	106.7	1.03 (0.85 to 1.24)	57.5	76.0
M	Oral Cavity and Pharynx	Soft Tissue including Heart	22743	15	1.0	0.03	6.4	2.36 (1.32 to 3.89)	57.5	68.4
M	Oral Cavity and Pharynx	Stomach	22743	23	1.5	0.05	23.6	0.97 (0.62 to 1.46)	57.5	74.2
M	Oral Cavity and Pharynx	Urinary Bladder	22743	51	3.3	0.12	38.5	1.33 (0.99 to 1.74)	57.5	77.4
M	Pancreas	Colon and Rectum	1667	6	7.7	0.01	5.4	1.11 (0.41 to 2.42)	60.1	70.1
M	Pancreas	Liver and Intrahepatic Bile Duct	1667	7	9.0	0.02	2.6	2.69 (1.08 to 5.53)	60.1	71.4
M	Pancreas	Lung and Bronchus	1667	26	33.3	0.06	17.9	1.45 (0.95 to 2.13)	60.1	73.0
M	Pancreas	Non-Hodgkin Lymphoma	1667	6	7.7	0.01	3.0	2.03 (0.74 to 4.41)	60.1	78.7
M	Pancreas	Prostate	1667	7	9.0	0.02	6.9	1.02 (0.41 to 2.1)	60.1	77.3
M	Penis and Other Genital Organs	Acute Non-lymphocytic Leukemia	1566	5	4.7	0.01	2.1	2.41 (0.78 to 5.61)	61.7	80.5
M	Penis and Other Genital Organs	Colon and Rectum	1566	13	12.1	0.03	8.8	1.49 (0.79 to 2.54)	61.7	72.9
M	Penis and Other Genital Organs	Kidney and Renal Pelvis	1566	6	5.6	0.01	2.5	2.38 (0.87 to 5.17)	61.7	82.1

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Penis and Other Genital Organs	Liver and Intrahepatic Bile Duct	1566	5	4.7	0.01	3.8	1.31 (0.43 to 3.06)	61.7	72.5
M	Penis and Other Genital Organs	Lung and Bronchus	1566	44	41.0	0.10	28.2	1.56 (1.13 to 2.09)	61.7	73.3
M	Penis and Other Genital Organs	Non-Hodgkin Lymphoma	1566	10	9.3	0.02	4.9	2.05 (0.98 to 3.76)	61.7	76.8
M	Penis and Other Genital Organs	Prostate	1566	16	14.9	0.04	12.0	1.34 (0.76 to 2.17)	61.7	77.7
M	Penis and Other Genital Organs	Soft Tissue including Heart	1566	19	17.7	0.04	0.6	33.91 (20.42 to 52.96)	61.7	69.6
M	Prostate	Acute Lymphocytic Leukemia	384653	41	0.2	0.09	39.1	1.05 (0.75 to 1.42)	66.4	78.2
M	Prostate	Acute Non-lymphocytic Leukemia	384653	838	3.1	1.90	699.0	1.2 (1.12 to 1.28)	66.4	79.2
M	Prostate	Anus, Anal Canal and Anorectum	384653	32	0.1	0.07	22.2	1.44 (0.99 to 2.03)	66.4	78.1
M	Prostate	Bones and Joints	384653	55	0.2	0.13	52.5	1.05 (0.79 to 1.37)	66.4	78.8
M	Prostate	Brain and Other Nervous System	384653	654	2.4	1.49	558.8	1.17 (1.08 to 1.26)	66.4	76.8
M	Prostate	Breast	384653	33	0.1	0.08	45.4	0.73 (0.5 to 1.02)	66.4	78.8
M	Prostate	Chronic Myeloid Leukemia	384653	70	0.3	0.16	70.6	0.99 (0.77 to 1.25)	66.4	78.8
M	Prostate	Colon and Rectum	384653	2405	8.9	5.47	2959.8	0.81 (0.78 to 0.85)	66.4	79.5
M	Prostate	Esophagus	384653	897	3.3	2.04	1026.1	0.87 (0.82 to 0.93)	66.4	77.7
M	Prostate	Eye and Orbit	384653	21	0.1	0.05	13.0	1.62 (1 to 2.47)	66.4	75.9
M	Prostate	Gallbladder and Other Biliary	384653	173	0.6	0.39	170.4	1.02 (0.87 to 1.18)	66.4	79.0
M	Prostate	Hodgkin Lymphoma	384653	45	0.2	0.10	49.7	0.91 (0.66 to 1.21)	66.4	79.6
M	Prostate	Kidney and Renal Pelvis	384653	715	2.6	1.63	828.6	0.86 (0.8 to 0.93)	66.4	78.4
M	Prostate	Larynx	384653	156	0.6	0.35	287.3	0.54 (0.46 to 0.64)	66.4	78.2
M	Prostate	Liver and Intrahepatic Bile Duct	384653	959	3.6	2.18	1144.8	0.84 (0.79 to 0.89)	66.4	78.1
M	Prostate	Lung and Bronchus	384653	7208	26.7	16.38	9500.0	0.76 (0.74 to 0.78)	66.4	78.2
M	Prostate	Melanoma of the Skin	384653	483	1.8	1.10	511.4	0.94 (0.86 to 1.03)	66.4	79.0
M	Prostate	Myeloma	384653	814	3.0	1.85	751.4	1.08 (1.01 to 1.16)	66.4	79.1
M	Prostate	Non-Hodgkin Lymphoma	384653	1481	5.5	3.37	1652.3	0.9 (0.85 to 0.94)	66.4	80.1
M	Prostate	Oral Cavity and Pharynx	384653	356	1.3	0.81	493.9	0.72 (0.65 to 0.8)	66.4	77.5
M	Prostate	Pancreas	384653	2088	7.7	4.75	1925.7	1.08 (1.04 to 1.13)	66.4	78.2
M	Prostate	Penis and Other Genital Organs	384653	29	0.1	0.07	33.5	0.87 (0.58 to 1.24)	66.4	79.9
M	Prostate	Small Intestine	384653	83	0.3	0.19	71.4	1.16 (0.93 to 1.44)	66.4	78.2
M	Prostate	Soft Tissue including Heart	384653	234	0.9	0.53	181.1	1.29 (1.13 to 1.47)	66.4	77.7
M	Prostate	Stomach	384653	722	2.7	1.64	759.4	0.95 (0.88 to 1.02)	66.4	78.7
M	Prostate	Testis	384653	5	0.0	0.01	8.1	0.62 (0.2 to 1.45)	66.4	82.1
M	Prostate	Thyroid	384653	58	0.2	0.13	75.9	0.77 (0.58 to 0.99)	66.4	77.5

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Prostate	Urinary Bladder	384653	1354	5.0	3.08	1391.8	0.97 (0.92 to 1.03)	66.4	80.3
M	Small Intestine	Colon and Rectum	2755	71	41.9	0.16	11.3	6.29 (4.91 to 7.93)	59.1	70.5
M	Small Intestine	Liver and Intrahepatic Bile Duct	2755	25	14.7	0.06	5.5	4.57 (2.96 to 6.75)	59.1	71.9
M	Small Intestine	Lung and Bronchus	2755	33	19.5	0.08	37.5	0.88 (0.61 to 1.24)	59.1	75.2
M	Small Intestine	Non-Hodgkin Lymphoma	2755	10	5.9	0.02	6.0	1.68 (0.8 to 3.08)	59.1	75.5
M	Small Intestine	Oral Cavity and Pharynx	2755	6	3.5	0.01	2.3	2.62 (0.96 to 5.7)	59.1	68.9
M	Small Intestine	Pancreas	2755	18	10.6	0.04	7.9	2.27 (1.34 to 3.58)	59.1	67.2
M	Small Intestine	Prostate	2755	14	8.3	0.03	14.5	0.97 (0.53 to 1.62)	59.1	78.3
M	Small Intestine	Soft Tissue including Heart	2755	35	20.6	0.08	0.8	46.37 (32.3 to 64.49)	59.1	65.2
M	Small Intestine	Stomach	2755	19	11.2	0.04	2.9	6.57 (3.95 to 10.25)	59.1	67.8
M	Soft Tissue including Heart	Acute Non-lymphocytic Leukemia	5080	11	2.8	0.03	4.8	2.29 (1.14 to 4.1)	52.9	66.7
M	Soft Tissue including Heart	Bones and Joints	5080	32	8.2	0.07	0.4	78.36 (53.6 to 110.62)	52.9	55.8
M	Soft Tissue including Heart	Brain and Other Nervous System	5080	10	2.6	0.02	5.0	2.01 (0.97 to 3.7)	52.9	61.7
M	Soft Tissue including Heart	Colon and Rectum	5080	27	6.9	0.06	20.5	1.32 (0.87 to 1.92)	52.9	68.2
M	Soft Tissue including Heart	Esophagus	5080	5	1.3	0.01	8.0	0.62 (0.2 to 1.45)	52.9	72.9
M	Soft Tissue including Heart	Kidney and Renal Pelvis	5080	8	2.0	0.02	6.2	1.29 (0.56 to 2.55)	52.9	69.1
M	Soft Tissue including Heart	Liver and Intrahepatic Bile Duct	5080	8	2.0	0.02	9.8	0.82 (0.35 to 1.61)	52.9	66.4
M	Soft Tissue including Heart	Lung and Bronchus	5080	84	21.5	0.19	66.4	1.27 (1.01 to 1.57)	52.9	71.4
M	Soft Tissue including Heart	Melanoma of the Skin	5080	8	2.0	0.02	4.0	2.02 (0.87 to 3.99)	52.9	75.3
M	Soft Tissue including Heart	Myeloma	5080	13	3.3	0.03	4.9	2.68 (1.43 to 4.58)	52.9	77.8
M	Soft Tissue including Heart	Non-Hodgkin Lymphoma	5080	17	4.3	0.04	11.0	1.54 (0.9 to 2.46)	52.9	75.5
M	Soft Tissue including Heart	Oral Cavity and Pharynx	5080	6	1.5	0.01	4.1	1.46 (0.53 to 3.17)	52.9	67.5
M	Soft Tissue including Heart	Pancreas	5080	19	4.9	0.04	14.1	1.35 (0.81 to 2.11)	52.9	75.0
M	Soft Tissue including Heart	Prostate	5080	21	5.4	0.05	25.3	0.83 (0.51 to 1.27)	52.9	79.0
M	Soft Tissue including Heart	Stomach	5080	13	3.3	0.03	5.2	2.49 (1.33 to 4.26)	52.9	63.2
M	Soft Tissue including Heart	Urinary Bladder	5080	14	3.6	0.03	8.8	1.6 (0.87 to 2.68)	52.9	74.6
M	Stomach	Acute Non-lymphocytic Leukemia	6114	8	2.2	0.02	7.0	1.14 (0.49 to 2.25)	63.1	76.7
M	Stomach	Brain and Other Nervous System	6114	8	2.2	0.02	5.8	1.38 (0.6 to 2.72)	63.1	76.2
M	Stomach	Colon and Rectum	6114	26	7.0	0.06	30.7	0.85 (0.55 to 1.24)	63.1	74.7
M	Stomach	Esophagus	6114	190	51.1	0.43	10.3	18.37 (15.85 to 21.18)	63.1	69.5
M	Stomach	Kidney and Renal Pelvis	6114	6	1.6	0.01	8.5	0.71 (0.26 to 1.54)	63.1	73.8
M	Stomach	Liver and Intrahepatic Bile Duct	6114	30	8.1	0.07	15.5	1.94 (1.31 to 2.77)	63.1	74.7

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Stomach	Lung and Bronchus	6114	138	37.1	0.31	96.2	1.43 (1.21 to 1.7)	63.1	75.6
M	Stomach	Non-Hodgkin Lymphoma	6114	24	6.5	0.05	16.2	1.48 (0.95 to 2.2)	63.1	76.3
M	Stomach	Pancreas	6114	44	11.8	0.10	20.2	2.18 (1.58 to 2.92)	63.1	73.8
M	Stomach	Prostate	6114	31	8.3	0.07	42.7	0.73 (0.49 to 1.03)	63.1	80.3
M	Stomach	Soft Tissue including Heart	6114	29	7.8	0.07	1.9	15.19 (10.17 to 21.82)	63.1	72.3
M	Stomach	Urinary Bladder	6114	19	5.1	0.04	12.9	1.47 (0.88 to 2.29)	63.1	77.8
M	Testis	Acute Non-lymphocytic Leukemia	17695	13	0.7	0.03	4.9	2.66 (1.42 to 4.54)	35.8	63.5
M	Testis	Brain and Other Nervous System	17695	13	0.7	0.03	10.6	1.23 (0.65 to 2.1)	35.8	53.3
M	Testis	Colon and Rectum	17695	30	1.7	0.07	23.7	1.27 (0.85 to 1.81)	35.8	57.0
M	Testis	Esophagus	17695	10	0.6	0.02	11.5	0.87 (0.42 to 1.6)	35.8	55.3
M	Testis	Liver and Intrahepatic Bile Duct	17695	13	0.7	0.03	15.4	0.85 (0.45 to 1.45)	35.8	60.6
M	Testis	Lung and Bronchus	17695	60	3.4	0.14	67.8	0.88 (0.68 to 1.14)	35.8	64.5
M	Testis	Melanoma of the Skin	17695	8	0.5	0.02	6.3	1.27 (0.55 to 2.5)	35.8	56.8
M	Testis	Non-Hodgkin Lymphoma	17695	11	0.6	0.03	10.1	1.09 (0.55 to 1.96)	35.8	61.9
M	Testis	Oral Cavity and Pharynx	17695	5	0.3	0.01	6.8	0.74 (0.24 to 1.73)	35.8	63.7
M	Testis	Pancreas	17695	31	1.7	0.07	16.8	1.85 (1.26 to 2.63)	35.8	60.6
M	Testis	Prostate	17695	9	0.5	0.02	11.0	0.82 (0.38 to 1.56)	35.8	60.1
M	Testis	Soft Tissue including Heart	17695	12	0.7	0.03	2.4	4.99 (2.58 to 8.71)	35.8	53.1
M	Testis	Stomach	17695	14	0.8	0.03	5.8	2.4 (1.31 to 4.02)	35.8	61.7
M	Testis	Urinary Bladder	17695	12	0.7	0.03	5.9	2.04 (1.05 to 3.56)	35.8	61.0
M	Thyroid	Acute Non-lymphocytic Leukemia	12333	18	1.8	0.04	9.1	1.99 (1.18 to 3.14)	49.8	67.8
M	Thyroid	Bones and Joints	12333	5	0.5	0.01	0.8	6.13 (1.99 to 14.3)	49.8	55.1
M	Thyroid	Brain and Other Nervous System	12333	19	1.9	0.04	11.2	1.7 (1.03 to 2.66)	49.8	63.6
M	Thyroid	Colon and Rectum	12333	31	3.2	0.07	38.1	0.81 (0.55 to 1.15)	49.8	73.9
M	Thyroid	Esophagus	12333	15	1.5	0.03	16.8	0.89 (0.5 to 1.47)	49.8	68.2
M	Thyroid	Kidney and Renal Pelvis	12333	26	2.7	0.06	12.4	2.1 (1.37 to 3.07)	49.8	69.8
M	Thyroid	Liver and Intrahepatic Bile Duct	12333	22	2.2	0.05	21.5	1.02 (0.64 to 1.55)	49.8	70.7
M	Thyroid	Lung and Bronchus	12333	93	9.5	0.21	127.6	0.73 (0.59 to 0.89)	49.8	70.3
M	Thyroid	Melanoma of the Skin	12333	11	1.1	0.03	8.0	1.38 (0.69 to 2.47)	49.8	70.0
M	Thyroid	Myeloma	12333	17	1.7	0.04	8.8	1.94 (1.13 to 3.11)	49.8	71.8
M	Thyroid	Non-Hodgkin Lymphoma	12333	24	2.5	0.05	19.7	1.22 (0.78 to 1.81)	49.8	72.6
M	Thyroid	Pancreas	12333	34	3.5	0.08	28.0	1.21 (0.84 to 1.69)	49.8	70.2

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
M	Thyroid	Prostate	12333	34	3.5	0.08	38.1	0.89 (0.62 to 1.25)	49.8	78.4
M	Thyroid	Soft Tissue including Heart	12333	7	0.7	0.02	2.9	2.43 (0.98 to 5.01)	49.8	56.3
M	Thyroid	Stomach	12333	14	1.4	0.03	9.8	1.43 (0.78 to 2.4)	49.8	74.2
M	Thyroid	Urinary Bladder	12333	11	1.1	0.03	14.8	0.75 (0.37 to 1.33)	49.8	75.3
M	Urinary Bladder	Acute Lymphocytic Leukemia	51094	6	0.2	0.01	4.8	1.25 (0.46 to 2.72)	65.7	73.1
M	Urinary Bladder	Acute Non-lymphocytic Leukemia	51094	120	3.5	0.27	83.2	1.44 (1.2 to 1.73)	65.7	78.8
M	Urinary Bladder	Bones and Joints	51094	6	0.2	0.01	6.2	0.97 (0.35 to 2.1)	65.7	79.2
M	Urinary Bladder	Brain and Other Nervous System	51094	93	2.7	0.21	69.5	1.34 (1.08 to 1.64)	65.7	75.1
M	Urinary Bladder	Chronic Myeloid Leukemia	51094	9	0.3	0.02	8.4	1.07 (0.49 to 2.03)	65.7	76.8
M	Urinary Bladder	Colon and Rectum	51094	319	9.2	0.73	338.1	0.94 (0.84 to 1.05)	65.7	78.9
M	Urinary Bladder	Esophagus	51094	157	4.5	0.36	122.1	1.29 (1.09 to 1.5)	65.7	75.9
M	Urinary Bladder	Gallbladder and Other Biliary	51094	18	0.5	0.04	19.5	0.92 (0.55 to 1.46)	65.7	78.3
M	Urinary Bladder	Kidney and Renal Pelvis	51094	182	5.2	0.41	98.3	1.85 (1.59 to 2.14)	65.7	76.2
M	Urinary Bladder	Larynx	51094	32	0.9	0.07	31.5	1.02 (0.7 to 1.44)	65.7	75.8
M	Urinary Bladder	Liver and Intrahepatic Bile Duct	51094	178	5.1	0.40	130.6	1.36 (1.17 to 1.58)	65.7	76.4
M	Urinary Bladder	Lung and Bronchus	51094	1789	51.6	4.07	1088.6	1.64 (1.57 to 1.72)	65.7	77.2
M	Urinary Bladder	Melanoma of the Skin	51094	56	1.6	0.13	65.8	0.85 (0.64 to 1.11)	65.7	78.5
M	Urinary Bladder	Myeloma	51094	94	2.7	0.21	81.8	1.15 (0.93 to 1.41)	65.7	78.3
M	Urinary Bladder	Non-Hodgkin Lymphoma	51094	169	4.9	0.38	199.4	0.85 (0.73 to 0.99)	65.7	79.4
M	Urinary Bladder	Oral Cavity and Pharynx	51094	56	1.6	0.13	57.5	0.97 (0.74 to 1.26)	65.7	76.0
M	Urinary Bladder	Pancreas	51094	255	7.4	0.58	221.7	1.15 (1.01 to 1.3)	65.7	78.0
M	Urinary Bladder	Prostate	51094	352	10.2	0.80	489.6	0.72 (0.65 to 0.8)	65.7	80.9
M	Urinary Bladder	Small Intestine	51094	6	0.2	0.01	8.0	0.75 (0.28 to 1.63)	65.7	80.4
M	Urinary Bladder	Soft Tissue including Heart	51094	24	0.7	0.05	21.7	1.11 (0.71 to 1.65)	65.7	72.4
M	Urinary Bladder	Stomach	51094	93	2.7	0.21	80.7	1.15 (0.93 to 1.41)	65.7	78.0
M	Urinary Bladder	Thyroid	51094	11	0.3	0.03	9.0	1.22 (0.61 to 2.18)	65.7	76.6
W	Acute Lymphocytic Leukemia	Acute Non-lymphocytic Leukemia	483	5	14.0	0.02	0.1	45.42 (14.75 to 105.99)	41.2	53.9
W	Acute Non-Lymphocytic Leukemia	Breast	1850	6	4.1	0.02	5.9	1.02 (0.37 to 2.22)	46.9	65.7
W	Acute Non-Lymphocytic Leukemia	Liver and Intrahepatic Bile Duct	1850	5	3.4	0.02	1.1	4.57 (1.48 to 10.67)	46.9	76.6
W	Acute Non-Lymphocytic Leukemia	Lung and Bronchus	1850	15	10.3	0.05	10.5	1.43 (0.8 to 2.36)	46.9	70.6
W	Anus, Anal Canal and Anorectum	Acute Non-lymphocytic Leukemia	3027	7	3.4	0.03	2.0	3.55 (1.43 to 7.32)	59.8	70.3
W	Anus, Anal Canal and Anorectum	Breast	3027	10	4.9	0.04	15.2	0.66 (0.32 to 1.21)	59.8	78.3

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Anus, Anal Canal and Anorectum	Colon and Rectum	3027	115	55.8	0.41	10.6	10.87 (8.97 to 13.04)	59.8	71.8
W	Anus, Anal Canal and Anorectum	Corpus and Uterus, NOS	3027	23	11.2	0.08	3.5	6.5 (4.12 to 9.76)	59.8	75.1
W	Anus, Anal Canal and Anorectum	Liver and Intrahepatic Bile Duct	3027	6	2.9	0.02	2.9	2.07 (0.76 to 4.49)	59.8	77.2
W	Anus, Anal Canal and Anorectum	Lung and Bronchus	3027	60	29.1	0.22	29.7	2.02 (1.54 to 2.6)	59.8	72.3
W	Anus, Anal Canal and Anorectum	Non-Hodgkin Lymphoma	3027	11	5.3	0.04	4.9	2.24 (1.12 to 4.01)	59.8	72.8
W	Anus, Anal Canal and Anorectum	Ovary	3027	9	4.4	0.03	5.8	1.55 (0.71 to 2.94)	59.8	75.2
W	Anus, Anal Canal and Anorectum	Pancreas	3027	13	6.3	0.05	7.9	1.64 (0.87 to 2.8)	59.8	72.3
W	Anus, Anal Canal and Anorectum	Vulva and Other Genital Organs	3027	5	2.4	0.02	0.8	6.16 (2 to 14.38)	59.8	56.1
W	Bones and Joints	Brain and Other Nervous System	1237	15	13.9	0.05	0.7	20.78 (11.63 to 34.28)	45.5	61.6
W	Bones and Joints	Lung and Bronchus	1237	11	10.2	0.04	7.8	1.41 (0.7 to 2.53)	45.5	71.2
W	Bones and Joints	Soft Tissue including Heart	1237	10	9.2	0.04	0.2	45.94 (22.03 to 84.48)	45.5	52.6
W	Brain and Other Nervous System	Bones and Joints	4105	6	1.9	0.02	0.1	51.85 (19.03 to 112.85)	42.8	47.4
W	Brain and Other Nervous System	Breast	4105	10	3.2	0.04	10.2	0.98 (0.47 to 1.8)	42.8	57.6
W	Brain and Other Nervous System	Lung and Bronchus	4105	24	7.8	0.09	16.3	1.48 (0.95 to 2.2)	42.8	65.2
W	Brain and Other Nervous System	Non-Hodgkin Lymphoma	4105	6	1.9	0.02	2.1	2.8 (1.03 to 6.08)	42.8	67.9
W	Brain and Other Nervous System	Pancreas	4105	5	1.6	0.02	4.0	1.25 (0.41 to 2.92)	42.8	76.7
W	Brain and Other Nervous System	Soft Tissue including Heart	4105	10	3.2	0.04	0.5	19.69 (9.44 to 36.21)	42.8	67.8
W	Breast	Acute Lymphocytic Leukemia	332998	40	0.2	0.14	20.3	1.97 (1.41 to 2.69)	58.8	69.4
W	Breast	Acute Non-lymphocytic Leukemia	332998	433	1.6	1.56	250.0	1.73 (1.57 to 1.9)	58.8	73.7
W	Breast	Anus, Anal Canal and Anorectum	332998	18	0.1	0.06	22.7	0.79 (0.47 to 1.25)	58.8	72.9
W	Breast	Bones and Joints	332998	40	0.2	0.14	22.5	1.78 (1.27 to 2.42)	58.8	75.5
W	Breast	Brain and Other Nervous System	332998	301	1.1	1.09	286.4	1.05 (0.94 to 1.18)	58.8	72.5
W	Breast	Cervix Uteri	332998	70	0.3	0.25	138.4	0.51 (0.39 to 0.64)	58.8	70.5
W	Breast	Chronic Myeloid Leukemia	332998	15	0.1	0.05	25.3	0.59 (0.33 to 0.98)	58.8	74.8
W	Breast	Colon and Rectum	332998	1118	4.3	4.03	1321.0	0.85 (0.8 to 0.9)	58.8	77.1
W	Breast	Corpus and Uterus, NOS	332998	725	2.8	2.62	433.7	1.67 (1.55 to 1.8)	58.8	74.4
W	Breast	Esophagus	332998	187	0.7	0.67	155.8	1.2 (1.04 to 1.39)	58.8	75.3
W	Breast	Eye and Orbit	332998	8	0.0	0.03	6.5	1.23 (0.53 to 2.42)	58.8	68.9
W	Breast	Gallbladder and Other Biliary	332998	118	0.4	0.43	121.8	0.97 (0.8 to 1.16)	58.8	76.3
W	Breast	Hodgkin Lymphoma	332998	18	0.1	0.06	21.4	0.84 (0.5 to 1.33)	58.8	77.2
W	Breast	Kidney and Renal Pelvis	332998	199	0.8	0.72	251.8	0.79 (0.68 to 0.91)	58.8	75.9
W	Breast	Larynx	332998	28	0.1	0.10	38.4	0.73 (0.49 to 1.05)	58.8	73.7

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Breast	Liver and Intrahepatic Bile Duct	332998	427	1.6	1.54	375.6	1.14 (1.03 to 1.25)	58.8	75.6
W	Breast	Lung and Bronchus	332998	3815	14.5	13.76	3754.0	1.02 (0.98 to 1.05)	58.8	74.7
W	Breast	Melanoma of the Skin	332998	113	0.4	0.41	138.2	0.82 (0.67 to 0.98)	58.8	74.4
W	Breast	Myeloma	332998	241	0.9	0.87	286.3	0.84 (0.74 to 0.96)	58.8	76.4
W	Breast	Non-Hodgkin Lymphoma	332998	557	2.1	2.01	618.5	0.9 (0.83 to 0.98)	58.8	77.6
W	Breast	Oral Cavity and Pharynx	332998	138	0.5	0.50	134.4	1.03 (0.86 to 1.21)	58.8	76.0
W	Breast	Ovary	332998	984	3.7	3.55	730.6	1.35 (1.26 to 1.43)	58.8	71.7
W	Breast	Pancreas	332998	1277	4.9	4.61	994.8	1.28 (1.21 to 1.36)	58.8	75.9
W	Breast	Small Intestine	332998	39	0.1	0.14	29.8	1.31 (0.93 to 1.79)	58.8	73.6
W	Breast	Soft Tissue including Heart	332998	160	0.6	0.58	87.7	1.82 (1.55 to 2.13)	58.8	71.7
W	Breast	Stomach	332998	306	1.2	1.10	241.8	1.27 (1.13 to 1.42)	58.8	75.1
W	Breast	Thyroid	332998	47	0.2	0.17	52.0	0.9 (0.66 to 1.2)	58.8	77.7
W	Breast	Urinary Bladder	332998	194	0.7	0.70	238.2	0.81 (0.7 to 0.94)	58.8	78.7
W	Breast	Vulva and Other Genital Organs	332998	79	0.3	0.28	99.7	0.79 (0.63 to 0.99)	58.8	76.9
W	Cervix Uteri	Acute Non-lymphocytic Leukemia	19943	13	0.7	0.05	8.3	1.57 (0.84 to 2.69)	46.4	61.7
W	Cervix Uteri	Brain and Other Nervous System	19943	14	0.7	0.05	11.6	1.21 (0.66 to 2.03)	46.4	68.4
W	Cervix Uteri	Breast	19943	70	3.7	0.25	77.0	0.91 (0.71 to 1.15)	46.4	63.2
W	Cervix Uteri	Colon and Rectum	19943	87	4.6	0.31	43.6	2 (1.6 to 2.46)	46.4	68.8
W	Cervix Uteri	Corpus and Uterus, NOS	19943	89	4.7	0.32	16.4	5.44 (4.37 to 6.7)	46.4	67.6
W	Cervix Uteri	Esophagus	19943	6	0.3	0.02	5.2	1.14 (0.42 to 2.49)	46.4	71.3
W	Cervix Uteri	Gallbladder and Other Biliary	19943	9	0.5	0.03	4.1	2.18 (1 to 4.13)	46.4	70.4
W	Cervix Uteri	Kidney and Renal Pelvis	19943	10	0.5	0.04	8.2	1.22 (0.59 to 2.25)	46.4	68.7
W	Cervix Uteri	Liver and Intrahepatic Bile Duct	19943	17	0.9	0.06	14.3	1.19 (0.69 to 1.91)	46.4	66.5
W	Cervix Uteri	Lung and Bronchus	19943	316	16.8	1.14	126.5	2.5 (2.23 to 2.79)	46.4	67.3
W	Cervix Uteri	Melanoma of the Skin	19943	5	0.3	0.02	5.1	0.98 (0.32 to 2.29)	46.4	62.7
W	Cervix Uteri	Myeloma	19943	12	0.6	0.04	9.1	1.31 (0.68 to 2.29)	46.4	73.4
W	Cervix Uteri	Non-Hodgkin Lymphoma	19943	21	1.1	0.08	17.3	1.21 (0.75 to 1.85)	46.4	75.0
W	Cervix Uteri	Oral Cavity and Pharynx	19943	7	0.4	0.03	4.8	1.46 (0.59 to 3.01)	46.4	68.1
W	Cervix Uteri	Ovary	19943	50	2.7	0.18	26.9	1.86 (1.38 to 2.45)	46.4	63.4
W	Cervix Uteri	Pancreas	19943	37	2.0	0.13	32.7	1.13 (0.8 to 1.56)	46.4	70.8
W	Cervix Uteri	Soft Tissue including Heart	19943	18	1.0	0.06	3.7	4.82 (2.86 to 7.62)	46.4	62.0
W	Cervix Uteri	Stomach	19943	26	1.4	0.09	9.5	2.74 (1.79 to 4.01)	46.4	68.2

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Cervix Uteri	Urinary Bladder	19943	19	1.0	0.07	6.4	2.98 (1.8 to 4.66)	46.4	72.7
W	Cervix Uteri	Vulva and Other Genital Organs	19943	24	1.3	0.09	3.2	7.58 (4.86 to 11.28)	46.4	67.3
W	Chronic Myeloid Leukemia	Breast	1930	5	4.0	0.02	6.4	0.79 (0.26 to 1.83)	53.5	65.8
W	Chronic Myeloid Leukemia	Colon and Rectum	1930	9	7.3	0.03	4.0	2.27 (1.04 to 4.31)	53.5	79.8
W	Chronic Myeloid Leukemia	Lung and Bronchus	1930	14	11.3	0.05	11.9	1.18 (0.65 to 1.98)	53.5	74.1
W	Chronic Myeloid Leukemia	Non-Hodgkin Lymphoma	1930	18	14.5	0.06	1.8	10.15 (6.01 to 16.03)	53.5	72.7
W	Chronic Myeloid Leukemia	Ovary	1930	5	4.0	0.02	2.4	2.11 (0.68 to 4.91)	53.5	74.6
W	Colon and Rectum	Acute Lymphocytic Leukemia	68385	7	0.1	0.03	4.3	1.62 (0.65 to 3.34)	65.1	78.4
W	Colon and Rectum	Acute Non-lymphocytic Leukemia	68385	65	1.4	0.23	59.4	1.1 (0.85 to 1.4)	65.1	78.2
W	Colon and Rectum	Bones and Joints	68385	8	0.2	0.03	5.5	1.46 (0.63 to 2.88)	65.1	76.3
W	Colon and Rectum	Brain and Other Nervous System	68385	72	1.5	0.26	58.2	1.24 (0.97 to 1.56)	65.1	79.1
W	Colon and Rectum	Breast	68385	290	6.2	1.05	423.5	0.69 (0.61 to 0.77)	65.1	77.6
W	Colon and Rectum	Cervix Uteri	68385	23	0.5	0.08	27.7	0.83 (0.53 to 1.25)	65.1	72.4
W	Colon and Rectum	Chronic Myeloid Leukemia	68385	10	0.2	0.04	6.7	1.5 (0.72 to 2.75)	65.1	81.1
W	Colon and Rectum	Corpus and Uterus, NOS	68385	146	3.1	0.53	97.5	1.5 (1.27 to 1.76)	65.1	75.7
W	Colon and Rectum	Esophagus	68385	46	1.0	0.17	37.2	1.24 (0.91 to 1.65)	65.1	77.7
W	Colon and Rectum	Gallbladder and Other Biliary	68385	33	0.7	0.12	30.4	1.09 (0.75 to 1.53)	65.1	77.2
W	Colon and Rectum	Kidney and Renal Pelvis	68385	55	1.2	0.20	60.3	0.91 (0.69 to 1.19)	65.1	77.1
W	Colon and Rectum	Larynx	68385	6	0.1	0.02	8.3	0.73 (0.27 to 1.58)	65.1	73.6
W	Colon and Rectum	Liver and Intrahepatic Bile Duct	68385	111	2.4	0.40	90.1	1.23 (1.01 to 1.48)	65.1	76.6
W	Colon and Rectum	Lung and Bronchus	68385	997	21.3	3.60	837.3	1.19 (1.12 to 1.27)	65.1	78.4
W	Colon and Rectum	Melanoma of the Skin	68385	33	0.7	0.12	30.5	1.08 (0.74 to 1.52)	65.1	79.5
W	Colon and Rectum	Myeloma	68385	80	1.7	0.29	72.3	1.11 (0.88 to 1.38)	65.1	78.4
W	Colon and Rectum	Non-Hodgkin Lymphoma	68385	152	3.3	0.55	161.2	0.94 (0.8 to 1.11)	65.1	81.2
W	Colon and Rectum	Oral Cavity and Pharynx	68385	26	0.6	0.09	32.1	0.81 (0.53 to 1.19)	65.1	76.2
W	Colon and Rectum	Ovary	68385	156	3.3	0.56	161.1	0.97 (0.82 to 1.13)	65.1	76.4
W	Colon and Rectum	Pancreas	68385	292	6.2	1.05	241.9	1.21 (1.07 to 1.35)	65.1	79.3
W	Colon and Rectum	Small Intestine	68385	23	0.5	0.08	7.2	3.2 (2.03 to 4.81)	65.1	76.3
W	Colon and Rectum	Soft Tissue including Heart	68385	38	0.8	0.14	19.2	1.98 (1.4 to 2.72)	65.1	73.6
W	Colon and Rectum	Stomach	68385	104	2.2	0.38	64.7	1.61 (1.31 to 1.95)	65.1	76.7
W	Colon and Rectum	Thyroid	68385	15	0.3	0.05	13.1	1.15 (0.64 to 1.89)	65.1	78.7
W	Colon and Rectum	Urinary Bladder	68385	67	1.4	0.24	64.6	1.04 (0.8 to 1.32)	65.1	79.5

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Colon and Rectum	Vulva and Other Genital Organs	68385	24	0.5	0.09	24.1	1 (0.64 to 1.49)	65.1	79.8
W	Corpus and Uterus, NOS	Acute Lymphocytic Leukemia	62541	6	0.1	0.02	4.1	1.47 (0.54 to 3.19)	60.3	71.2
W	Corpus and Uterus, NOS	Acute Non-lymphocytic Leukemia	62541	87	1.8	0.31	52.4	1.66 (1.33 to 2.05)	60.3	74.0
W	Corpus and Uterus, NOS	Bones and Joints	62541	12	0.2	0.04	4.6	2.61 (1.35 to 4.55)	60.3	73.5
W	Corpus and Uterus, NOS	Brain and Other Nervous System	62541	70	1.4	0.25	58.9	1.19 (0.93 to 1.5)	60.3	71.3
W	Corpus and Uterus, NOS	Breast	62541	301	6.1	1.09	380.1	0.79 (0.71 to 0.89)	60.3	75.7
W	Corpus and Uterus, NOS	Chronic Myeloid Leukemia	62541	6	0.1	0.02	5.3	1.14 (0.42 to 2.48)	60.3	75.7
W	Corpus and Uterus, NOS	Colon and Rectum	62541	355	7.2	1.28	271.0	1.31 (1.18 to 1.45)	60.3	75.3
W	Corpus and Uterus, NOS	Esophagus	62541	33	0.7	0.12	32.1	1.03 (0.71 to 1.44)	60.3	73.6
W	Corpus and Uterus, NOS	Gallbladder and Other Biliary	62541	26	0.5	0.09	25.1	1.04 (0.68 to 1.52)	60.3	72.6
W	Corpus and Uterus, NOS	Hodgkin Lymphoma	62541	6	0.1	0.02	4.5	1.35 (0.49 to 2.93)	60.3	72.3
W	Corpus and Uterus, NOS	Kidney and Renal Pelvis	62541	52	1.1	0.19	52.4	0.99 (0.74 to 1.3)	60.3	72.5
W	Corpus and Uterus, NOS	Liver and Intrahepatic Bile Duct	62541	91	1.8	0.33	75.9	1.2 (0.97 to 1.47)	60.3	75.4
W	Corpus and Uterus, NOS	Lung and Bronchus	62541	621	12.6	2.24	786.5	0.79 (0.73 to 0.85)	60.3	76.0
W	Corpus and Uterus, NOS	Melanoma of the Skin	62541	32	0.6	0.12	28.7	1.11 (0.76 to 1.57)	60.3	74.7
W	Corpus and Uterus, NOS	Myeloma	62541	61	1.2	0.22	58.9	1.04 (0.79 to 1.33)	60.3	75.5
W	Corpus and Uterus, NOS	Non-Hodgkin Lymphoma	62541	129	2.6	0.47	131.0	0.99 (0.82 to 1.17)	60.3	77.0
W	Corpus and Uterus, NOS	Oral Cavity and Pharynx	62541	24	0.5	0.09	27.6	0.87 (0.56 to 1.3)	60.3	77.3
W	Corpus and Uterus, NOS	Pancreas	62541	231	4.7	0.83	205.5	1.12 (0.98 to 1.28)	60.3	74.8
W	Corpus and Uterus, NOS	Small Intestine	62541	14	0.3	0.05	6.1	2.31 (1.26 to 3.88)	60.3	71.1
W	Corpus and Uterus, NOS	Soft Tissue including Heart	62541	111	2.3	0.40	17.6	6.31 (5.19 to 7.59)	60.3	65.6
W	Corpus and Uterus, NOS	Stomach	62541	65	1.3	0.23	48.0	1.35 (1.05 to 1.73)	60.3	77.2
W	Corpus and Uterus, NOS	Thyroid	62541	9	0.2	0.03	10.6	0.85 (0.39 to 1.61)	60.3	81.7
W	Corpus and Uterus, NOS	Urinary Bladder	62541	72	1.5	0.26	49.9	1.44 (1.13 to 1.82)	60.3	77.8
W	Esophagus	Colon and Rectum	845	6	13.0	0.02	3.0	1.98 (0.73 to 4.32)	65.0	74.9
W	Esophagus	Lung and Bronchus	845	36	78.0	0.13	8.3	4.33 (3.04 to 6)	65.0	73.6
W	Esophagus	Oral Cavity and Pharynx	845	5	10.8	0.02	0.3	16.94 (5.5 to 39.52)	65.0	72.5
W	Esophagus	Stomach	845	6	13.0	0.02	0.6	10.65 (3.91 to 23.19)	65.0	74.3
W	Eye and Orbit	Breast	1349	11	11.0	0.04	6.8	1.61 (0.8 to 2.88)	58.0	78.6
W	Eye and Orbit	Colon and Rectum	1349	9	9.0	0.03	4.7	1.91 (0.87 to 3.62)	58.0	79.9
W	Eye and Orbit	Liver and Intrahepatic Bile Duct	1349	12	12.0	0.04	1.2	9.68 (5 to 16.91)	58.0	74.8
W	Eye and Orbit	Lung and Bronchus	1349	14	14.0	0.05	13.8	1.01 (0.55 to 1.7)	58.0	76.0

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Eye and Orbit	Melanoma of the Skin	1349	118	118.4	0.43	0.6	212.86 (176.19 to 254.91)	58.0	69.7
W	Eye and Orbit	Ovary	1349	5	5.0	0.02	2.7	1.85 (0.6 to 4.33)	58.0	72.7
W	Gallbladder and Other Biliary	Breast	1308	8	9.8	0.03	6.8	1.17 (0.51 to 2.31)	64.5	71.4
W	Gallbladder and Other Biliary	Colon and Rectum	1308	9	11.1	0.03	5.5	1.65 (0.75 to 3.12)	64.5	81.8
W	Gallbladder and Other Biliary	Liver and Intrahepatic Bile Duct	1308	53	65.2	0.19	1.6	32.89 (24.64 to 43.02)	64.5	73.4
W	Gallbladder and Other Biliary	Lung and Bronchus	1308	27	33.2	0.10	14.0	1.92 (1.27 to 2.8)	64.5	75.5
W	Gallbladder and Other Biliary	Ovary	1308	10	12.3	0.04	2.7	3.74 (1.79 to 6.88)	64.5	78.0
W	Gallbladder and Other Biliary	Pancreas	1308	55	67.7	0.20	4.0	13.79 (10.39 to 17.95)	64.5	72.5
W	Gallbladder and Other Biliary	Stomach	1308	5	6.2	0.02	1.1	4.53 (1.47 to 10.57)	64.5	78.9
W	Gallbladder and Other Biliary	Urinary Bladder	1308	8	9.8	0.03	1.0	7.88 (3.4 to 15.53)	64.5	77.2
W	Hodgkin Lymphoma	Acute Non-lymphocytic Leukemia	6223	14	2.4	0.05	1.7	8.36 (4.57 to 14.02)	38.6	52.2
W	Hodgkin Lymphoma	Breast	6223	22	3.8	0.08	16.0	1.38 (0.86 to 2.09)	38.6	54.9
W	Hodgkin Lymphoma	Colon and Rectum	6223	11	1.9	0.04	8.2	1.34 (0.67 to 2.4)	38.6	69.6
W	Hodgkin Lymphoma	Corpus and Uterus, NOS	6223	6	1.0	0.02	3.0	1.98 (0.73 to 4.3)	38.6	60.5
W	Hodgkin Lymphoma	Lung and Bronchus	6223	54	9.2	0.19	23.7	2.28 (1.72 to 2.98)	38.6	68.0
W	Hodgkin Lymphoma	Non-Hodgkin Lymphoma	6223	80	13.7	0.29	3.3	24.25 (19.23 to 30.19)	38.6	66.7
W	Hodgkin Lymphoma	Ovary	6223	5	0.9	0.02	5.2	0.96 (0.31 to 2.23)	38.6	56.8
W	Kidney and Renal Pelvis	Acute Non-lymphocytic Leukemia	15880	16	1.5	0.06	10.6	1.52 (0.87 to 2.46)	60.5	76.6
W	Kidney and Renal Pelvis	Brain and Other Nervous System	15880	18	1.7	0.06	11.8	1.53 (0.91 to 2.42)	60.5	70.9
W	Kidney and Renal Pelvis	Breast	15880	69	6.6	0.25	78.9	0.87 (0.68 to 1.11)	60.5	73.2
W	Kidney and Renal Pelvis	Chronic Myeloid Leukemia	15880	5	0.5	0.02	1.1	4.63 (1.5 to 10.8)	60.5	80.1
W	Kidney and Renal Pelvis	Colon and Rectum	15880	49	4.7	0.18	56.3	0.87 (0.64 to 1.15)	60.5	75.5
W	Kidney and Renal Pelvis	Corpus and Uterus, NOS	15880	18	1.7	0.06	18.7	0.96 (0.57 to 1.52)	60.5	73.9
W	Kidney and Renal Pelvis	Gallbladder and Other Biliary	15880	7	0.7	0.03	5.2	1.36 (0.55 to 2.79)	60.5	75.6
W	Kidney and Renal Pelvis	Liver and Intrahepatic Bile Duct	15880	18	1.7	0.06	15.9	1.13 (0.67 to 1.79)	60.5	74.9
W	Kidney and Renal Pelvis	Lung and Bronchus	15880	190	18.0	0.69	157.4	1.21 (1.04 to 1.39)	60.5	75.3
W	Kidney and Renal Pelvis	Melanoma of the Skin	15880	5	0.5	0.02	5.7	0.88 (0.29 to 2.06)	60.5	69.2
W	Kidney and Renal Pelvis	Myeloma	15880	15	1.4	0.05	12.6	1.19 (0.67 to 1.96)	60.5	76.0
W	Kidney and Renal Pelvis	Non-Hodgkin Lymphoma	15880	18	1.7	0.06	26.2	0.69 (0.41 to 1.09)	60.5	75.2
W	Kidney and Renal Pelvis	Oral Cavity and Pharynx	15880	7	0.7	0.03	5.6	1.24 (0.5 to 2.56)	60.5	80.8
W	Kidney and Renal Pelvis	Ovary	15880	15	1.4	0.05	30.2	0.5 (0.28 to 0.82)	60.5	76.6
W	Kidney and Renal Pelvis	Pancreas	15880	56	5.3	0.20	42.7	1.31 (0.99 to 1.7)	60.5	74.6

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Kidney and Renal Pelvis	Soft Tissue including Heart	15880	5	0.5	0.02	3.7	1.37 (0.44 to 3.18)	60.5	68.5
W	Kidney and Renal Pelvis	Stomach	15880	12	1.1	0.04	10.3	1.16 (0.6 to 2.03)	60.5	76.6
W	Kidney and Renal Pelvis	Thyroid	15880	6	0.6	0.02	2.2	2.71 (1 to 5.9)	60.5	76.5
W	Kidney and Renal Pelvis	Urinary Bladder	15880	33	3.1	0.12	10.4	3.18 (2.19 to 4.46)	60.5	76.8
W	Kidney and Renal Pelvis	Vulva and Other Genital Organs	15880	6	0.6	0.02	4.3	1.41 (0.52 to 3.06)	60.5	83.3
W	Larynx	Breast	2087	8	5.8	0.03	10.7	0.75 (0.32 to 1.47)	61.0	74.4
W	Larynx	Colon and Rectum	2087	16	11.7	0.06	7.6	2.1 (1.2 to 3.41)	61.0	77.7
W	Larynx	Esophagus	2087	16	11.7	0.06	0.9	17.44 (9.97 to 28.33)	61.0	69.9
W	Larynx	Lung and Bronchus	2087	186	135.9	0.67	22.1	8.41 (7.25 to 9.71)	61.0	73.5
W	Larynx	Oral Cavity and Pharynx	2087	29	21.2	0.10	0.7	38.79 (25.98 to 55.71)	61.0	70.7
W	Larynx	Ovary	2087	7	5.1	0.03	4.2	1.68 (0.67 to 3.45)	61.0	72.3
W	Larynx	Pancreas	2087	8	5.8	0.03	5.7	1.41 (0.61 to 2.78)	61.0	75.4
W	Liver and Intrahepatic Bile Duct	Colon and Rectum	1454	6	8.8	0.02	2.8	2.11 (0.77 to 4.59)	60.4	68.6
W	Liver and Intrahepatic Bile Duct	Gallbladder and Other Biliary	1454	6	8.8	0.02	0.3	18.97 (6.96 to 41.29)	60.4	66.3
W	Liver and Intrahepatic Bile Duct	Lung and Bronchus	1454	15	22.0	0.05	8.0	1.88 (1.05 to 3.1)	60.4	73.5
W	Liver and Intrahepatic Bile Duct	Non-Hodgkin Lymphoma	1454	6	8.8	0.02	1.3	4.8 (1.76 to 10.44)	60.4	75.0
W	Liver and Intrahepatic Bile Duct	Pancreas	1454	7	10.3	0.03	2.3	2.99 (1.2 to 6.15)	60.4	64.8
W	Lung and Bronchus	Acute Non-lymphocytic Leukemia	24018	27	2.1	0.10	15.9	1.69 (1.12 to 2.46)	64.8	75.7
W	Lung and Bronchus	Brain and Other Nervous System	24018	22	1.7	0.08	16.8	1.31 (0.82 to 1.98)	64.8	72.5
W	Lung and Bronchus	Breast	24018	120	9.1	0.43	113.1	1.06 (0.88 to 1.27)	64.8	73.8
W	Lung and Bronchus	Cervix Uteri	24018	10	0.8	0.04	7.4	1.34 (0.64 to 2.47)	64.8	67.5
W	Lung and Bronchus	Colon and Rectum	24018	101	7.7	0.36	84.9	1.19 (0.97 to 1.45)	64.8	77.3
W	Lung and Bronchus	Corpus and Uterus, NOS	24018	18	1.4	0.06	26.4	0.68 (0.4 to 1.08)	64.8	79.7
W	Lung and Bronchus	Esophagus	24018	44	3.3	0.16	9.9	4.44 (3.23 to 5.97)	64.8	75.3
W	Lung and Bronchus	Kidney and Renal Pelvis	24018	22	1.7	0.08	16.0	1.38 (0.86 to 2.08)	64.8	76.8
W	Lung and Bronchus	Larynx	24018	7	0.5	0.03	2.4	2.97 (1.19 to 6.11)	64.8	72.5
W	Lung and Bronchus	Liver and Intrahepatic Bile Duct	24018	42	3.2	0.15	23.3	1.81 (1.3 to 2.44)	64.8	73.7
W	Lung and Bronchus	Melanoma of the Skin	24018	10	0.8	0.04	8.4	1.2 (0.57 to 2.2)	64.8	77.3
W	Lung and Bronchus	Myeloma	24018	24	1.8	0.09	18.9	1.27 (0.82 to 1.89)	64.8	76.5
W	Lung and Bronchus	Non-Hodgkin Lymphoma	24018	56	4.3	0.20	40.9	1.37 (1.03 to 1.78)	64.8	78.6
W	Lung and Bronchus	Oral Cavity and Pharynx	24018	15	1.1	0.05	8.3	1.8 (1.01 to 2.97)	64.8	73.8
W	Lung and Bronchus	Ovary	24018	57	4.3	0.21	44.6	1.28 (0.97 to 1.66)	64.8	75.3

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Lung and Bronchus	Pancreas	24018	94	7.1	0.34	63.5	1.48 (1.2 to 1.81)	64.8	77.0
W	Lung and Bronchus	Soft Tissue including Heart	24018	13	1.0	0.05	5.2	2.5 (1.33 to 4.28)	64.8	70.1
W	Lung and Bronchus	Stomach	24018	15	1.1	0.05	15.4	0.97 (0.54 to 1.6)	64.8	79.9
W	Lung and Bronchus	Thyroid	24018	6	0.5	0.02	3.3	1.81 (0.67 to 3.95)	64.8	68.4
W	Lung and Bronchus	Urinary Bladder	24018	28	2.1	0.10	15.8	1.77 (1.17 to 2.55)	64.8	81.0
W	Melanoma of the Skin	Acute Non-lymphocytic Leukemia	39213	29	0.9	0.10	22.4	1.29 (0.87 to 1.86)	51.4	74.9
W	Melanoma of the Skin	Brain and Other Nervous System	39213	58	1.7	0.21	29.5	1.96 (1.49 to 2.54)	51.4	69.1
W	Melanoma of the Skin	Breast	39213	134	4.0	0.48	176.9	0.76 (0.64 to 0.9)	51.4	68.5
W	Melanoma of the Skin	Colon and Rectum	39213	94	2.8	0.34	110.7	0.85 (0.69 to 1.04)	51.4	74.2
W	Melanoma of the Skin	Corpus and Uterus, NOS	39213	33	1.0	0.12	37.3	0.88 (0.61 to 1.24)	51.4	73.6
W	Melanoma of the Skin	Esophagus	39213	5	0.1	0.02	13.5	0.37 (0.12 to 0.87)	51.4	71.4
W	Melanoma of the Skin	Gallbladder and Other Biliary	39213	11	0.3	0.04	10.0	1.1 (0.55 to 1.98)	51.4	78.8
W	Melanoma of the Skin	Kidney and Renal Pelvis	39213	21	0.6	0.08	22.3	0.94 (0.58 to 1.44)	51.4	73.5
W	Melanoma of the Skin	Liver and Intrahepatic Bile Duct	39213	32	1.0	0.12	30.6	1.05 (0.72 to 1.48)	51.4	71.4
W	Melanoma of the Skin	Lung and Bronchus	39213	309	9.2	1.11	336.1	0.92 (0.82 to 1.03)	51.4	73.2
W	Melanoma of the Skin	Myeloma	39213	36	1.1	0.13	22.6	1.59 (1.12 to 2.21)	51.4	72.3
W	Melanoma of the Skin	Non-Hodgkin Lymphoma	39213	66	2.0	0.24	52.5	1.26 (0.97 to 1.6)	51.4	76.1
W	Melanoma of the Skin	Oral Cavity and Pharynx	39213	10	0.3	0.04	12.0	0.84 (0.4 to 1.54)	51.4	77.9
W	Melanoma of the Skin	Ovary	39213	61	1.8	0.22	67.8	0.9 (0.69 to 1.16)	51.4	69.4
W	Melanoma of the Skin	Pancreas	39213	82	2.5	0.30	84.3	0.97 (0.77 to 1.21)	51.4	73.4
W	Melanoma of the Skin	Soft Tissue including Heart	39213	21	0.6	0.08	8.4	2.51 (1.55 to 3.83)	51.4	67.9
W	Melanoma of the Skin	Stomach	39213	20	0.6	0.07	18.0	1.11 (0.68 to 1.71)	51.4	79.3
W	Melanoma of the Skin	Urinary Bladder	39213	13	0.4	0.05	19.9	0.65 (0.35 to 1.12)	51.4	74.4
W	Melanoma of the Skin	Vulva and Other Genital Organs	39213	10	0.3	0.04	9.2	1.09 (0.52 to 2)	51.4	72.1
W	Myeloma	Acute Non-lymphocytic Leukemia	5549	22	9.1	0.08	2.4	9.33 (5.85 to 14.13)	63.0	70.9
W	Myeloma	Breast	5549	11	4.6	0.04	18.7	0.59 (0.29 to 1.05)	63.0	71.2
W	Myeloma	Colon and Rectum	5549	13	5.4	0.05	13.4	0.97 (0.52 to 1.66)	63.0	75.7
W	Myeloma	Corpus and Uterus, NOS	5549	6	2.5	0.02	4.8	1.26 (0.46 to 2.74)	63.0	80.5
W	Myeloma	Liver and Intrahepatic Bile Duct	5549	7	2.9	0.03	3.8	1.84 (0.74 to 3.79)	63.0	78.9
W	Myeloma	Lung and Bronchus	5549	25	10.4	0.09	36.0	0.7 (0.45 to 1.03)	63.0	75.3
W	Myeloma	Non-Hodgkin Lymphoma	5549	9	3.7	0.03	5.8	1.56 (0.72 to 2.97)	63.0	78.6
W	Myeloma	Ovary	5549	7	2.9	0.03	6.9	1.02 (0.41 to 2.1)	63.0	73.0

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Myeloma	Stomach	5549	5	2.1	0.02	2.6	1.9 (0.62 to 4.44)	63.0	80.6
W	Non-Hodgkin Lymphoma	Acute Lymphocytic Leukemia	36978	22	0.9	0.08	2.0	10.84 (6.79 to 16.41)	61.6	69.2
W	Non-Hodgkin Lymphoma	Acute Non-lymphocytic Leukemia	36978	130	5.2	0.47	26.1	4.97 (4.16 to 5.91)	61.6	72.9
W	Non-Hodgkin Lymphoma	Bones and Joints	36978	12	0.5	0.04	2.4	5.07 (2.62 to 8.86)	61.6	73.6
W	Non-Hodgkin Lymphoma	Brain and Other Nervous System	36978	53	2.1	0.19	28.4	1.87 (1.4 to 2.44)	61.6	73.2
W	Non-Hodgkin Lymphoma	Breast	36978	141	5.7	0.51	189.3	0.75 (0.63 to 0.88)	61.6	74.3
W	Non-Hodgkin Lymphoma	Cervix Uteri	36978	8	0.3	0.03	12.9	0.62 (0.27 to 1.22)	61.6	63.8
W	Non-Hodgkin Lymphoma	Chronic Myeloid Leukemia	36978	14	0.6	0.05	2.7	5.1 (2.79 to 8.55)	61.6	80.3
W	Non-Hodgkin Lymphoma	Colon and Rectum	36978	165	6.7	0.60	139.0	1.19 (1.01 to 1.38)	61.6	78.6
W	Non-Hodgkin Lymphoma	Corpus and Uterus, NOS	36978	53	2.1	0.19	43.0	1.23 (0.92 to 1.61)	61.6	74.9
W	Non-Hodgkin Lymphoma	Esophagus	36978	29	1.2	0.10	16.0	1.81 (1.21 to 2.6)	61.6	73.4
W	Non-Hodgkin Lymphoma	Gallbladder and Other Biliary	36978	9	0.4	0.03	12.6	0.72 (0.33 to 1.36)	61.6	80.6
W	Non-Hodgkin Lymphoma	Hodgkin Lymphoma	36978	56	2.3	0.20	2.2	24.9 (18.81 to 32.34)	61.6	73.6
W	Non-Hodgkin Lymphoma	Kidney and Renal Pelvis	36978	28	1.1	0.10	26.2	1.07 (0.71 to 1.55)	61.6	79.3
W	Non-Hodgkin Lymphoma	Larynx	36978	5	0.2	0.02	3.8	1.33 (0.43 to 3.09)	61.6	69.5
W	Non-Hodgkin Lymphoma	Liver and Intrahepatic Bile Duct	36978	60	2.4	0.22	37.9	1.59 (1.21 to 2.04)	61.6	75.0
W	Non-Hodgkin Lymphoma	Lung and Bronchus	36978	517	20.9	1.87	380.4	1.36 (1.24 to 1.48)	61.6	75.7
W	Non-Hodgkin Lymphoma	Melanoma of the Skin	36978	35	1.4	0.13	14.4	2.44 (1.7 to 3.39)	61.6	75.1
W	Non-Hodgkin Lymphoma	Myeloma	36978	41	1.7	0.15	29.7	1.38 (0.99 to 1.87)	61.6	77.5
W	Non-Hodgkin Lymphoma	Oral Cavity and Pharynx	36978	18	0.7	0.06	13.9	1.3 (0.77 to 2.05)	61.6	76.6
W	Non-Hodgkin Lymphoma	Ovary	36978	93	3.8	0.34	73.3	1.27 (1.02 to 1.55)	61.6	75.0
W	Non-Hodgkin Lymphoma	Pancreas	36978	130	5.2	0.47	103.0	1.26 (1.05 to 1.5)	61.6	78.5
W	Non-Hodgkin Lymphoma	Small Intestine	36978	9	0.4	0.03	3.1	2.94 (1.35 to 5.59)	61.6	73.5
W	Non-Hodgkin Lymphoma	Soft Tissue including Heart	36978	11	0.4	0.04	8.7	1.26 (0.63 to 2.25)	61.6	75.8
W	Non-Hodgkin Lymphoma	Stomach	36978	44	1.8	0.16	24.6	1.79 (1.3 to 2.4)	61.6	76.6
W	Non-Hodgkin Lymphoma	Thyroid	36978	9	0.4	0.03	5.4	1.67 (0.77 to 3.18)	61.6	79.3
W	Non-Hodgkin Lymphoma	Urinary Bladder	36978	25	1.0	0.09	26.2	0.96 (0.62 to 1.41)	61.6	77.7
W	Non-Hodgkin Lymphoma	Vulva and Other Genital Organs	36978	10	0.4	0.04	10.6	0.95 (0.45 to 1.74)	61.6	78.5
W	Oral Cavity and Pharynx	Acute Non-lymphocytic Leukemia	10680	8	1.1	0.03	6.6	1.21 (0.52 to 2.38)	58.1	73.5
W	Oral Cavity and Pharynx	Bones and Joints	10680	14	1.8	0.05	0.6	23.18 (12.67 to 38.9)	58.1	71.9
W	Oral Cavity and Pharynx	Brain and Other Nervous System	10680	9	1.2	0.03	7.5	1.19 (0.55 to 2.27)	58.1	71.0
W	Oral Cavity and Pharynx	Breast	10680	55	7.2	0.20	50.4	1.09 (0.82 to 1.42)	58.1	74.3

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Oral Cavity and Pharynx	Colon and Rectum	10680	52	6.8	0.19	35.6	1.46 (1.09 to 1.92)	58.1	75.3
W	Oral Cavity and Pharynx	Corpus and Uterus, NOS	10680	11	1.4	0.04	11.4	0.97 (0.48 to 1.73)	58.1	68.3
W	Oral Cavity and Pharynx	Esophagus	10680	62	8.2	0.22	4.1	15.01 (11.51 to 19.24)	58.1	68.3
W	Oral Cavity and Pharynx	Kidney and Renal Pelvis	10680	8	1.1	0.03	6.6	1.2 (0.52 to 2.37)	58.1	71.1
W	Oral Cavity and Pharynx	Larynx	10680	59	7.8	0.21	1.0	58.35 (44.42 to 75.27)	58.1	72.1
W	Oral Cavity and Pharynx	Liver and Intrahepatic Bile Duct	10680	17	2.2	0.06	10.1	1.68 (0.98 to 2.69)	58.1	73.4
W	Oral Cavity and Pharynx	Lung and Bronchus	10680	295	38.8	1.06	98.7	2.99 (2.66 to 3.35)	58.1	73.3
W	Oral Cavity and Pharynx	Melanoma of the Skin	10680	7	0.9	0.03	3.6	1.93 (0.78 to 3.98)	58.1	68.3
W	Oral Cavity and Pharynx	Myeloma	10680	11	1.4	0.04	7.6	1.46 (0.73 to 2.61)	58.1	85.4
W	Oral Cavity and Pharynx	Non-Hodgkin Lymphoma	10680	22	2.9	0.08	16.5	1.33 (0.84 to 2.02)	58.1	78.1
W	Oral Cavity and Pharynx	Ovary	10680	18	2.4	0.06	19.4	0.93 (0.55 to 1.47)	58.1	74.6
W	Oral Cavity and Pharynx	Pancreas	10680	34	4.5	0.12	26.3	1.3 (0.9 to 1.81)	58.1	75.9
W	Oral Cavity and Pharynx	Soft Tissue including Heart	10680	6	0.8	0.02	2.3	2.56 (0.94 to 5.56)	58.1	62.6
W	Oral Cavity and Pharynx	Stomach	10680	9	1.2	0.03	6.7	1.34 (0.61 to 2.54)	58.1	75.4
W	Oral Cavity and Pharynx	Urinary Bladder	10680	9	1.2	0.03	6.3	1.43 (0.66 to 2.72)	58.1	74.7
W	Ovary	Acute Non-lymphocytic Leukemia	18095	26	2.0	0.09	9.8	2.67 (1.74 to 3.91)	55.1	65.7
W	Ovary	Brain and Other Nervous System	18095	15	1.1	0.05	12.1	1.24 (0.7 to 2.05)	55.1	70.0
W	Ovary	Breast	18095	84	6.4	0.30	76.9	1.09 (0.87 to 1.35)	55.1	68.3
W	Ovary	Colon and Rectum	18095	68	5.2	0.25	50.1	1.36 (1.06 to 1.72)	55.1	73.0
W	Ovary	Esophagus	18095	6	0.5	0.02	6.0	1 (0.37 to 2.17)	55.1	64.9
W	Ovary	Gallbladder and Other Biliary	18095	6	0.5	0.02	4.7	1.27 (0.47 to 2.77)	55.1	78.3
W	Ovary	Kidney and Renal Pelvis	18095	7	0.5	0.03	9.8	0.72 (0.29 to 1.48)	55.1	69.9
W	Ovary	Liver and Intrahepatic Bile Duct	18095	11	0.8	0.04	15.0	0.74 (0.37 to 1.32)	55.1	70.0
W	Ovary	Lung and Bronchus	18095	155	11.9	0.56	149.0	1.04 (0.88 to 1.22)	55.1	71.8
W	Ovary	Myeloma	18095	9	0.7	0.03	10.7	0.84 (0.39 to 1.6)	55.1	77.5
W	Ovary	Non-Hodgkin Lymphoma	18095	23	1.8	0.08	23.0	1 (0.63 to 1.5)	55.1	74.1
W	Ovary	Oral Cavity and Pharynx	18095	6	0.5	0.02	5.3	1.13 (0.42 to 2.46)	55.1	71.2
W	Ovary	Pancreas	18095	60	4.6	0.22	38.2	1.57 (1.2 to 2.02)	55.1	73.7
W	Ovary	Soft Tissue including Heart	18095	9	0.7	0.03	3.6	2.48 (1.14 to 4.71)	55.1	65.3
W	Ovary	Stomach	18095	14	1.1	0.05	9.5	1.48 (0.81 to 2.49)	55.1	75.3
W	Ovary	Urinary Bladder	18095	5	0.4	0.02	8.6	0.58 (0.19 to 1.36)	55.1	72.6
W	Pancreas	Breast	1665	6	6.9	0.02	6.1	0.98 (0.36 to 2.13)	59.8	78.5

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Pancreas	Colon and Rectum	1665	9	10.3	0.03	4.5	2.01 (0.92 to 3.82)	59.8	72.4
W	Pancreas	Lung and Bronchus	1665	23	26.4	0.08	11.8	1.95 (1.24 to 2.92)	59.8	74.3
W	Pancreas	Ovary	1665	5	5.7	0.02	2.3	2.19 (0.71 to 5.1)	59.8	68.0
W	Pancreas	Stomach	1665	8	9.2	0.03	0.9	9.04 (3.9 to 17.81)	59.8	64.1
W	Small Intestine	Breast	2493	10	6.6	0.04	11.5	0.87 (0.42 to 1.6)	60.4	71.0
W	Small Intestine	Colon and Rectum	2493	61	40.3	0.22	8.1	7.53 (5.76 to 9.67)	60.4	71.7
W	Small Intestine	Liver and Intrahepatic Bile Duct	2493	18	11.9	0.06	2.2	8.08 (4.79 to 12.77)	60.4	75.0
W	Small Intestine	Lung and Bronchus	2493	26	17.2	0.09	22.3	1.16 (0.76 to 1.71)	60.4	78.1
W	Small Intestine	Non-Hodgkin Lymphoma	2493	5	3.3	0.02	3.7	1.34 (0.44 to 3.13)	60.4	76.6
W	Small Intestine	Ovary	2493	7	4.6	0.03	4.3	1.64 (0.66 to 3.37)	60.4	72.8
W	Small Intestine	Pancreas	2493	13	8.6	0.05	6.1	2.12 (1.13 to 3.63)	60.4	69.0
W	Small Intestine	Soft Tissue including Heart	2493	31	20.5	0.11	0.5	58.45 (39.71 to 82.97)	60.4	70.9
W	Small Intestine	Stomach	2493	15	9.9	0.05	1.5	10.34 (5.79 to 17.05)	60.4	63.2
W	Soft Tissue including Heart	Acute Non-lymphocytic Leukemia	4197	6	1.8	0.02	2.3	2.55 (0.94 to 5.56)	52.9	64.0
W	Soft Tissue including Heart	Bones and Joints	4197	22	6.6	0.08	0.2	98.15 (61.51 to 148.6)	52.9	59.5
W	Soft Tissue including Heart	Breast	4197	16	4.8	0.06	18.8	0.85 (0.49 to 1.38)	52.9	68.7
W	Soft Tissue including Heart	Colon and Rectum	4197	17	5.1	0.06	12.6	1.35 (0.79 to 2.16)	52.9	78.5
W	Soft Tissue including Heart	Corpus and Uterus, NOS	4197	7	2.1	0.03	4.3	1.64 (0.66 to 3.38)	52.9	60.9
W	Soft Tissue including Heart	Lung and Bronchus	4197	55	16.4	0.20	34.8	1.58 (1.19 to 2.06)	52.9	72.3
W	Soft Tissue including Heart	Melanoma of the Skin	4197	7	2.1	0.03	1.3	5.28 (2.12 to 10.88)	52.9	68.2
W	Soft Tissue including Heart	Non-Hodgkin Lymphoma	4197	9	2.7	0.03	5.7	1.59 (0.73 to 3.02)	52.9	76.5
W	Soft Tissue including Heart	Ovary	4197	11	3.3	0.04	6.9	1.59 (0.79 to 2.84)	52.9	73.1
W	Soft Tissue including Heart	Pancreas	4197	11	3.3	0.04	9.4	1.17 (0.59 to 2.1)	52.9	71.1
W	Soft Tissue including Heart	Stomach	4197	6	1.8	0.02	2.4	2.51 (0.92 to 5.45)	52.9	74.5
W	Stomach	Breast	4496	10	3.6	0.04	21.3	0.47 (0.23 to 0.87)	63.8	71.6
W	Stomach	Colon and Rectum	4496	30	10.9	0.11	17.8	1.69 (1.14 to 2.41)	63.8	77.8
W	Stomach	Corpus and Uterus, NOS	4496	6	2.2	0.02	5.1	1.18 (0.43 to 2.57)	63.8	71.9
W	Stomach	Esophagus	4496	42	15.2	0.15	1.9	22.34 (16.1 to 30.2)	63.8	75.2
W	Stomach	Liver and Intrahepatic Bile Duct	4496	13	4.7	0.05	5.8	2.26 (1.2 to 3.86)	63.8	68.4
W	Stomach	Lung and Bronchus	4496	40	14.5	0.14	41.7	0.96 (0.69 to 1.31)	63.8	77.1
W	Stomach	Non-Hodgkin Lymphoma	4496	8	2.9	0.03	7.8	1.02 (0.44 to 2.01)	63.8	80.3
W	Stomach	Ovary	4496	9	3.3	0.03	8.0	1.13 (0.52 to 2.14)	63.8	72.6

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Stomach	Pancreas	4496	20	7.2	0.07	12.8	1.56 (0.95 to 2.41)	63.8	77.4
W	Stomach	Soft Tissue including Heart	4496	23	8.3	0.08	1.0	22.86 (14.49 to 34.29)	63.8	66.5
W	Thyroid	Acute Non-lymphocytic Leukemia	43042	32	0.9	0.12	15.3	2.09 (1.43 to 2.96)	46.4	68.7
W	Thyroid	Brain and Other Nervous System	43042	33	0.9	0.12	22.1	1.49 (1.03 to 2.1)	46.4	66.3
W	Thyroid	Breast	43042	105	3.0	0.38	135.1	0.78 (0.64 to 0.94)	46.4	64.2
W	Thyroid	Cervix Uteri	43042	8	0.2	0.03	14.4	0.55 (0.24 to 1.09)	46.4	56.5
W	Thyroid	Colon and Rectum	43042	60	1.7	0.22	75.7	0.79 (0.61 to 1.02)	46.4	67.3
W	Thyroid	Corpus and Uterus, NOS	43042	30	0.9	0.11	29.5	1.02 (0.69 to 1.45)	46.4	66.4
W	Thyroid	Esophagus	43042	9	0.3	0.03	9.3	0.97 (0.44 to 1.84)	46.4	70.2
W	Thyroid	Gallbladder and Other Biliary	43042	10	0.3	0.04	7.3	1.37 (0.66 to 2.52)	46.4	67.8
W	Thyroid	Kidney and Renal Pelvis	43042	18	0.5	0.06	14.9	1.21 (0.72 to 1.91)	46.4	69.4
W	Thyroid	Liver and Intrahepatic Bile Duct	43042	40	1.1	0.14	25.5	1.57 (1.12 to 2.13)	46.4	66.2
W	Thyroid	Lung and Bronchus	43042	180	5.2	0.65	230.2	0.78 (0.67 to 0.91)	46.4	72.0
W	Thyroid	Melanoma of the Skin	43042	11	0.3	0.04	9.7	1.13 (0.56 to 2.02)	46.4	71.3
W	Thyroid	Myeloma	43042	20	0.6	0.07	15.6	1.28 (0.78 to 1.98)	46.4	77.0
W	Thyroid	Non-Hodgkin Lymphoma	43042	32	0.9	0.12	31.4	1.02 (0.7 to 1.44)	46.4	70.4
W	Thyroid	Oral Cavity and Pharynx	43042	9	0.3	0.03	8.7	1.04 (0.47 to 1.97)	46.4	67.6
W	Thyroid	Ovary	43042	60	1.7	0.22	48.9	1.23 (0.94 to 1.58)	46.4	69.2
W	Thyroid	Pancreas	43042	69	2.0	0.25	59.3	1.16 (0.91 to 1.47)	46.4	72.0
W	Thyroid	Soft Tissue including Heart	43042	22	0.6	0.08	6.7	3.27 (2.05 to 4.95)	46.4	64.1
W	Thyroid	Stomach	43042	22	0.6	0.08	15.6	1.41 (0.89 to 2.14)	46.4	63.7
W	Thyroid	Urinary Bladder	43042	9	0.3	0.03	11.7	0.77 (0.35 to 1.46)	46.4	74.4
W	Thyroid	Vulva and Other Genital Organs	43042	5	0.1	0.02	6.1	0.82 (0.27 to 1.91)	46.4	66.0
W	Urinary Bladder	Acute Non-lymphocytic Leukemia	15578	16	1.5	0.06	14.8	1.08 (0.62 to 1.76)	66.4	79.7
W	Urinary Bladder	Brain and Other Nervous System	15578	18	1.6	0.06	14.9	1.21 (0.72 to 1.91)	66.4	77.4
W	Urinary Bladder	Breast	15578	72	6.6	0.26	102.3	0.7 (0.55 to 0.89)	66.4	77.0
W	Urinary Bladder	Cervix Uteri	15578	7	0.6	0.03	6.1	1.15 (0.46 to 2.37)	66.4	73.1
W	Urinary Bladder	Colon and Rectum	15578	71	6.5	0.26	81.2	0.87 (0.68 to 1.1)	66.4	81.7
W	Urinary Bladder	Corpus and Uterus, NOS	15578	18	1.6	0.06	22.7	0.79 (0.47 to 1.25)	66.4	74.3
W	Urinary Bladder	Esophagus	15578	11	1.0	0.04	9.0	1.22 (0.61 to 2.18)	66.4	78.8
W	Urinary Bladder	Gallbladder and Other Biliary	15578	13	1.2	0.05	7.1	1.82 (0.97 to 3.11)	66.4	82.5
W	Urinary Bladder	Kidney and Renal Pelvis	15578	36	3.3	0.13	14.9	2.42 (1.7 to 3.35)	66.4	79.4

Sex	First Primary Cancer (FPC)	Subsequent Primary Cancer (SPC)	Survivors, No.	Observed Number of SPC Deaths	Mortality per 10,000 person-years	% Contribution to the Total Mortality	Expected Number of SPC Deaths	SMR (95% CI)	Mean Age at FPC	Mean Age at SPC Death
W	Urinary Bladder	Liver and Intrahepatic Bile Duct	15578	22	2.0	0.08	20.5	1.07 (0.67 to 1.63)	66.4	79.6
W	Urinary Bladder	Lung and Bronchus	15578	511	46.8	1.84	210.1	2.43 (2.23 to 2.65)	66.4	77.3
W	Urinary Bladder	Melanoma of the Skin	15578	5	0.5	0.02	8.0	0.63 (0.2 to 1.46)	66.4	78.3
W	Urinary Bladder	Myeloma	15578	20	1.8	0.07	16.9	1.18 (0.72 to 1.83)	66.4	82.5
W	Urinary Bladder	Non-Hodgkin Lymphoma	15578	39	3.6	0.14	40.0	0.97 (0.69 to 1.33)	66.4	80.1
W	Urinary Bladder	Oral Cavity and Pharynx	15578	8	0.7	0.03	7.8	1.03 (0.45 to 2.03)	66.4	75.0
W	Urinary Bladder	Ovary	15578	45	4.1	0.16	40.1	1.12 (0.82 to 1.5)	66.4	76.7
W	Urinary Bladder	Pancreas	15578	71	6.5	0.26	57.9	1.23 (0.96 to 1.55)	66.4	78.2
W	Urinary Bladder	Soft Tissue including Heart	15578	6	0.5	0.02	4.6	1.3 (0.48 to 2.83)	66.4	73.7
W	Urinary Bladder	Stomach	15578	19	1.7	0.07	14.0	1.36 (0.82 to 2.12)	66.4	78.1
W	Urinary Bladder	Vulva and Other Genital Organs	15578	9	0.8	0.03	6.0	1.5 (0.69 to 2.85)	66.4	78.1
W	Vulva and Other Genital Organs	Acute Non-lymphocytic Leukemia	6035	6	1.4	0.02	4.0	1.49 (0.55 to 3.23)	58.9	69.4
W	Vulva and Other Genital Organs	Anus, Anal Canal and Anorectum	6035	5	1.2	0.02	0.4	13.73 (4.46 to 32.04)	58.9	75.7
W	Vulva and Other Genital Organs	Brain and Other Nervous System	6035	8	1.8	0.03	4.5	1.77 (0.77 to 3.49)	58.9	71.9
W	Vulva and Other Genital Organs	Breast	6035	31	7.1	0.11	30.7	1.01 (0.69 to 1.43)	58.9	68.2
W	Vulva and Other Genital Organs	Cervix Uteri	6035	17	3.9	0.06	2.2	7.57 (4.41 to 12.13)	58.9	69.2
W	Vulva and Other Genital Organs	Colon and Rectum	6035	25	5.8	0.09	22.1	1.13 (0.73 to 1.67)	58.9	73.2
W	Vulva and Other Genital Organs	Corpus and Uterus, NOS	6035	27	6.2	0.10	6.9	3.94 (2.6 to 5.73)	58.9	70.4
W	Vulva and Other Genital Organs	Liver and Intrahepatic Bile Duct	6035	7	1.6	0.03	5.9	1.19 (0.48 to 2.45)	58.9	75.3
W	Vulva and Other Genital Organs	Lung and Bronchus	6035	119	27.4	0.43	59.0	2.02 (1.67 to 2.41)	58.9	71.8
W	Vulva and Other Genital Organs	Melanoma of the Skin	6035	23	5.3	0.08	2.3	10.14 (6.43 to 15.22)	58.9	69.1
W	Vulva and Other Genital Organs	Non-Hodgkin Lymphoma	6035	8	1.8	0.03	10.3	0.77 (0.33 to 1.52)	58.9	72.0
W	Vulva and Other Genital Organs	Oral Cavity and Pharynx	6035	10	2.3	0.04	2.2	4.57 (2.19 to 8.4)	58.9	65.6
W	Vulva and Other Genital Organs	Ovary	6035	87	20.0	0.31	11.6	7.49 (6 to 9.24)	58.9	71.2
W	Vulva and Other Genital Organs	Pancreas	6035	14	3.2	0.05	16.0	0.88 (0.48 to 1.47)	58.9	77.2
W	Vulva and Other Genital Organs	Soft Tissue including Heart	6035	16	3.7	0.06	1.4	11.32 (6.47 to 18.38)	58.9	67.1
W	Vulva and Other Genital Organs	Urinary Bladder	6035	8	1.8	0.03	4.0	1.98 (0.86 to 3.91)	58.9	81.9

eTable 8. Percentage contribution of each subsequent primary cancer types to the total incidence of subsequent primary cancer and to the total subsequent primary cancer mortality among all 5-year cancer survivors by sex in 12 SEER registries

Incidence							
<i>Men</i>				<i>Women</i>			
Subsequent Primary Cancer	Observed number of Subsequent Primary Cancers	Incidence per 10,000 person-years	Incidence, %	Subsequent Primary Cancer	Observed number of Subsequent Primary Cancers	Incidence per 10,000 person-years	Incidence, %
Total person-years	5648059			Total person-years ^a	5427488		
Total subsequent primary cancers ^a	88703	157.1	100	Total subsequent primary cancers ^a	59041	108.8	100
Lung and Bronchus	16913	29.9	19.1	Lung and Bronchus	11375	21.0	19.3
Prostate	12115	21.4	13.7	Breast	10240	18.9	17.3
Urinary Bladder	9809	17.4	11.1	Colon and Rectum	6514	12.0	11.0
Colon and Rectum	8987	15.9	10.1	Corpus and Uterus, NOS	4351	8.0	7.4
Non-Hodgkin Lymphoma	6694	11.9	7.5	Non-Hodgkin Lymphoma	3673	6.8	6.2
Melanoma of the Skin	5559	9.8	6.3	Pancreas	2489	4.6	4.2
Kidney and Renal Pelvis	4363	7.7	4.9	Melanoma of the Skin	2270	4.2	3.8
Pancreas	3419	6.1	3.9	Urinary Bladder	2128	3.9	3.6
Oral Cavity and Pharynx	2955	5.2	3.3	Kidney and Renal Pelvis	1820	3.4	3.1
Stomach	2331	4.1	2.6	Thyroid	1731	3.2	2.9
Myeloma	2018	3.6	2.3	Ovary	1704	3.1	2.9
Liver and Intrahepatic Bile Duct	1919	3.4	2.2	Oral Cavity and Pharynx	1438	2.6	2.3
Esophagus	1860	3.3	2.1	Stomach	1092	2.0	1.8
Acute Non-Lymphocytic Leukemia	1630	2.9	1.8	Acute Non-Lymphocytic Leukemia	998	1.8	1.7
Larynx	1161	2.1	1.3	Myeloma	970	1.8	1.6
Brain and Other Nervous System	1094	1.9	1.2	Vulva and Other Genital Organs	967	1.8	1.6
Thyroid	982	1.7	1.1	Liver and Intrahepatic Bile Duct	829	1.5	1.4
Soft Tissue including Heart	871	1.5	1.0	Soft Tissue including Heart	611	1.1	1.0
Gallbladder and Other Biliary	780	1.4	0.9	Brain and Other Nervous System	594	1.1	1.0
Small Intestine	750	1.3	0.8	Gallbladder and Other Biliary	557	1.0	0.9
Chronic Myeloid Leukemia	505	0.9	0.6	Esophagus	476	0.9	0.8
Anus, Anal Canal and Anorectum	417	0.7	0.5	Small Intestine	446	0.8	0.8
Hodgkin Lymphoma	330	0.6	0.4	Anus, Anal Canal and Anorectum	356	0.7	0.6
Breast	310	0.5	0.3	Cervix Uteri	345	0.6	0.6
Penis and Other Genital Organs	280	0.5	0.3	Chronic Myeloid Leukemia	285	0.5	0.5
Eye and Orbit	191	0.3	0.2	Larynx	226	0.4	0.4
Acute Lymphocytic Leukemia	149	0.3	0.2	Hodgkin Lymphoma	188	0.3	0.3
Bones and Joints	143	0.3	0.2	Acute Lymphocytic Leukemia	130	0.2	0.2
Testis	86	0.2	0.1	Eye and Orbit	115	0.2	0.2
Kaposi Sarcoma	82	0.1	0.1	Bones and Joints	109	0.2	0.2
				Kaposi Sarcoma	14	0.0	0.0

Mortality

<i>Men</i>				<i>Women</i>			
Subsequent Primary Cancer	Observed number of Subsequent Primary Cancer Deaths	Mortality per 10,000 person-years	Mortality, %	Subsequent Primary Cancer	Observed number of Subsequent Primary Cancer Deaths	Mortality per 10,000 person-years	Mortality, %
Total person-years ^a	5364982			Total person-years ^a	5608782		
Total subsequent primary cancers deaths ^a	43993	82.0	100	Total subsequent primary cancers deaths ^a	27707	49.4	100
Lung and Bronchus	14555	27.1	33.1	Lung and Bronchus	8656	15.4	31.2
Colon and Rectum	3878	7.2	8.8	Pancreas	2600	4.6	9.4
Pancreas	3761	7.0	8.5	Colon and Rectum	2450	4.4	8.8
Non-Hodgkin Lymphoma	2621	4.9	6.0	Breast	1614	2.9	5.8
Liver and Intrahepatic Bile Duct	2105	3.9	4.8	Ovary	1579	2.8	5.7
Urinary Bladder	2090	3.9	4.8	Non-Hodgkin Lymphoma	1294	2.3	4.7
Esophagus	2075	3.9	4.7	Corpus and Uterus, NOS	1116	2.0	4.0
Prostate	1832	3.4	4.2	Liver and Intrahepatic Bile Duct	1033	1.8	3.7
Acute Non-lymphocytic Leukemia	1628	3.0	3.7	Acute Non-lymphocytic Leukemia	959	1.7	3.5
Stomach	1352	2.5	3.1	Brain and Other Nervous System	739	1.3	2.7
Myeloma	1321	2.5	3.0	Stomach	717	1.3	2.6
Kidney and Renal Pelvis	1305	2.4	3.0	Myeloma	594	1.1	2.1
Brain and Other Nervous System	1227	2.3	2.8	Soft Tissue including Heart	528	0.9	1.9
Melanoma of the Skin	927	1.7	2.1	Esophagus	515	0.9	1.9
Oral Cavity and Pharynx	860	1.6	2.0	Urinary Bladder	511	0.9	1.8
Soft Tissue including Heart	559	1.0	1.3	Kidney and Renal Pelvis	476	0.8	1.7
Larynx	518	1.0	1.2	Melanoma of the Skin	415	0.7	1.5
Gallbladder and Other Biliary	296	0.6	0.7	Oral Cavity and Pharynx	334	0.6	1.2
Small Intestine	178	0.3	0.4	Gallbladder and Other Biliary	272	0.5	1.0
Bones and Joints	155	0.3	0.4	Vulva and Other Genital Organs	257	0.5	0.9
Hodgkin Lymphoma	143	0.3	0.3	Cervix Uteri	233	0.4	0.8
Chronic Myeloid Leukemia	140	0.3	0.3	Bones and Joints	140	0.2	0.5
Acute Lymphocytic Leukemia	125	0.2	0.3	Larynx	119	0.2	0.4
Thyroid	103	0.2	0.2	Small Intestine	115	0.2	0.4
Anus, Anal Canal and Anorectum	68	0.1	0.2	Thyroid	115	0.2	0.4
Breast	67	0.1	0.2	Acute Lymphocytic Leukemia	106	0.2	0.4
Penis and Other Genital Organs	47	0.1	0.1	Hodgkin Lymphoma	90	0.2	0.3
Eye and Orbit	41	0.1	0.1	Chronic Myeloid Leukemia	69	0.1	0.2
Testis	16	0.0	0.0	Anus, Anal Canal and Anorectum	61	0.1	0.2

^aExcluding other and unspecified primary cancer sites

eTable 9. Risk of developing smoking- or obesity-related subsequent primary cancers among smoking or obesity-related cancer survivors

SEX	First primary cancer	Survivors, No.	Observed number of subsequent primary cancers	Incidence per 10,000 person-years	Expected number of subsequent primary cancers	Standardized Incidence Ratio (95% CI)
<i>Risk of developing any type of smoking-related cancers</i>						
Men	Larynx	9,107	1651	272	671	2.46 (2.34 to 2.58)
Men	Oral Cavity and Pharynx	22,937	2101	135	1265	1.66 (1.59 to 1.73)
Men	Esophagus	2,746	263	173	160	1.64 (1.45 to 1.86)
Men	Lung and Bronchus	20,874	1398	128	914	1.53 (1.45 to 1.61)
Men	Acute Non-Lymphocytic Leukemia	1,907	90	64	64	1.4 (1.13 to 1.72)
Men	Pancreas	1,674	97	124	70	1.38 (1.12 to 1.68)
Men	Urinary Bladder	51,513	4846	139	3538	1.37 (1.33 to 1.41)
Men	Kidney and Renal Pelvis	25,977	1980	118	1501	1.32 (1.26 to 1.38)
Men	Stomach	6,149	476	127	380	1.25 (1.14 to 1.37)
Men	Colon and Rectum	74,722	5186	102	4804	1.08 (1.05 to 1.11)
Men	Liver and Intrahepatic Bile Duct	3,629	119	73	120	0.99 (0.82 to 1.18)
Women	Larynx	2,096	379	275	82	4.62 (4.17 to 5.11)
Women	Esophagus	846	91	197	30	2.99 (2.4 to 3.67)
Women	Oral Cavity and Pharynx	10,788	679	88	367	1.85 (1.71 to 1.99)
Women	Pancreas	1,675	76	86	42	1.79 (1.41 to 2.25)
Women	Urinary Bladder	15,717	1172	107	716	1.64 (1.54 to 1.73)
Women	Kidney and Renal Pelvis	15,980	890	84	561	1.59 (1.48 to 1.69)
Women	Lung and Bronchus	24,065	857	65	571	1.5 (1.4 to 1.6)
Women	Liver and Intrahepatic Bile Duct	1,458	48	70	32	1.5 (1.1 to 1.98)
Women	Cervix Uteri	20,153	761	40	527	1.44 (1.34 to 1.55)
Women	Stomach	4,518	179	65	160	1.12 (0.96 to 1.29)
Women	Acute Non-Lymphocytic Leukemia	1,861	44	30	40	1.11 (0.81 to 1.49)
Women	Colon and Rectum	68,770	2560	54	2365	1.08 (1.04 to 1.13)
<i>Risk of developing any type of obesity-related cancers</i>						
Men	Gallbladder and Other Biliary	1,010	53	91	26	2.04 (1.53 to 2.67)
Men	Pancreas	1,674	47	60	29	1.64 (1.2 to 2.18)
Men	Thyroid	12,442	307	31	259	1.19 (1.06 to 1.33)
Men	Stomach Cardia	1,651	48	51	42	1.14 (0.84 to 1.51)
Men	Esophageal Adenocarcinoma	1,892	52	49	47	1.11 (0.83 to 1.45)
Men	Colon and Rectum	74,722	1581	31	1479	1.07 (1.02 to 1.12)
Men	Kidney and Renal Pelvis	25,977	626	37	598	1.05 (0.97 to 1.13)
Men	Multiple Myeloma	5,908	93	38	101	0.92 (0.74 to 1.12)
Men	Liver and Intrahepatic Bile Duct	3,629	43	26	52	0.83 (0.6 to 1.12)
Women	Stomach Cardia	463	29	117	20	1.44 (0.96 to 2.06)
Women	Pancreas	1,675	74	84	61	1.22 (0.96 to 1.54)
Women	Gallbladder and Other Biliary	1,314	78	96	67	1.17 (0.93 to 1.46)
Women	Thyroid	43,436	1829	52	1644	1.11 (1.06 to 1.17)
Women	Kidney and Renal Pelvis	15,980	875	83	791	1.11 (1.03 to 1.18)
Women	Corpus and Uterus, NOS	62,859	3840	78	3600	1.07 (1.03 to 1.1)
Women	Breast	334,273	11158	42	10569	1.06 (1.04 to 1.08)
Women	Ovary	18,169	864	66	834	1.04 (0.97 to 1.11)
Women	Colon and Rectum	68,770	3310	70	3233	1.02 (0.99 to 1.06)
Women	Multiple Myeloma	5,163	148	68	171	0.87 (0.73 to 1.02)
Women	Esophageal Adenocarcinoma	294	11	71	13	0.82 (0.41 to 1.46)
Women	Liver and Intrahepatic Bile Duct	1,458	35	51	47	0.75 (0.52 to 1.04)

eTable 10. Standardized incidence ratio (SIR) and ratios of standardized ratios (RR) by diagnosis year (1975-1989, 1990-1999, 2000-2011) for the risk of select 6 subsequent primary cancers among 5-year survivors of 16 first primary cancer types in 9 SEER registries

Sex	First primary cancer	Subsequent primary cancer	1975-1999, SIR				2000-2011, SIR				1975-1989, RR (ref)			P _{trend} ^a
			Obs.	1975-1999, SIR (95% CI)	Obs.	1990-1999, SIR (95% CI)	Obs.	2000-2011, SIR (95% CI)	Obs.	1990-1999, RR (95% CI)	2000-2011, RR (95% CI)			
W	Cervix Uteri	ANLL	12	0.74 (0.38-1.28)	4	0.6 (0.17-1.52)	4	1.58 (0.43-4.03)	1 (ref)	1.46 (0.48-2.43)	2.11 (0.69-3.53)	0.28		
W	Cervix Uteri	Colon and Rectum	306	1.34 (1.19-1.49)	106	1.32 (1.08-1.6)	36	1.35 (0.95-1.87)	1 (ref)	1.08 (0.91-1.24)	1.15 (0.97-1.33)	0.39		
W	Cervix Uteri	Corpus and Uterus, NOS	53	0.39 (0.29-0.5)	30	0.48 (0.33-0.69)	13	0.54 (0.29-0.91)	1 (ref)	1.03 (0.73-1.33)	1.06 (0.75-1.37)	0.85		
W	Cervix Uteri	Lung and Bronchus	478	1.67 (1.52-1.83)	204	1.86 (1.62-2.14)	84	2.26 (1.81-2.8)	1 (ref)	0.99 (0.88-1.1)	0.98 (0.87-1.09)	0.82		
W	Cervix Uteri	Oral Cavity and Pharynx	46	1.35 (0.99-1.8)	25	1.82 (1.18-2.68)	5	0.97 (0.32-2.26)	1 (ref)	1.03 (0.66-1.4)	1.06 (0.68-1.43)	0.89		
W	Cervix Uteri	Urinary Bladder	107	2.11 (1.73-2.55)	39	2.11 (1.5-2.88)	10	1.62 (0.78-2.98)	1 (ref)	0.98 (0.71-1.25)	0.95 (0.69-1.21)	0.85		
M	Colon and Rectum	ANLL	76	0.88 (0.7-1.11)	66	1.07 (0.83-1.35)	58	1.41 (1.07-1.83)	1 (ref)	1.16 (0.96-1.37)	1.35 (1.11-1.59)	0.11		
T	Colon and Rectum	ANLL	126	0.9 (0.75-1.07)	108	1.11 (0.91-1.34)	71	1.11 (0.87-1.4)	1 (ref)	1.08 (0.92-1.23)	1.15 (0.98-1.32)	0.36		
W	Colon and Rectum	ANLL	50	0.91 (0.68-1.2)	42	1.19 (0.86-1.6)	13	0.57 (0.3-0.96)	1 (ref)	0.91 (0.67-1.16)	0.83 (0.61-1.05)	0.48		
W	Colon and Rectum	Corpus and Uterus, NOS	386	1.24 (1.12-1.37)	232	1.22 (1.07-1.39)	210	1.51 (1.31-1.73)	1 (ref)	1.1 (1-1.19)	1.2 (1.09-1.3)	0.06		
M	Colon and Rectum	Lung and Bronchus	1332	0.91 (0.86-0.96)	951	1.02 (0.95-1.08)	590	1.11 (1.02-1.2)	1 (ref)	1.08 (1.03-1.13)	1.16 (1.1-1.21)	4.8E-03		
T	Colon and Rectum	Lung and Bronchus	2162	0.95 (0.91-0.99)	1582	1.05 (0.99-1.1)	1050	1.17 (1.1-1.24)	1 (ref)	1.08 (1.03-1.12)	1.15 (1.11-1.19)	4.6E-04		
W	Colon and Rectum	Lung and Bronchus	830	1.02 (0.95-1.09)	631	1.09 (1.01-1.18)	460	1.25 (1.14-1.37)	1 (ref)	1.07 (1.01-1.14)	1.15 (1.08-1.22)	0.03		
M	Colon and Rectum	Oral Cavity and Pharynx	199	0.95 (0.82-1.09)	139	0.99 (0.83-1.17)	125	1.21 (1-1.44)	1 (ref)	1.09 (0.96-1.21)	1.18 (1.04-1.31)	0.18		
T	Colon and Rectum	Oral Cavity and Pharynx	279	0.91 (0.81-1.03)	181	0.92 (0.79-1.06)	172	1.22 (1.04-1.41)	1 (ref)	1.11 (1-1.22)	1.22 (1.1-1.35)	0.05		
W	Colon and Rectum	Oral Cavity and Pharynx	80	0.84 (0.67-1.04)	42	0.74 (0.53-1)	47	1.25 (0.92-1.66)	1 (ref)	1.18 (0.95-1.41)	1.39 (1.12-1.66)	0.11		
M	Colon and Rectum	Urinary Bladder	682	0.97 (0.9-1.04)	528	1.03 (0.94-1.12)	337	1.09 (0.98-1.21)	1 (ref)	1.08 (1.01-1.15)	1.16 (1.08-1.24)	0.03		
T	Colon and Rectum	Urinary Bladder	883	0.99 (0.92-1.06)	664	1.05 (0.98-1.14)	423	1.12 (1.01-1.23)	1 (ref)	1.08 (1.02-1.14)	1.16 (1.09-1.23)	0.02		
W	Colon and Rectum	Urinary Bladder	201	1.07 (0.93-1.23)	136	1.16 (0.97-1.37)	86	1.23 (0.98-1.52)	1 (ref)	1.08 (0.94-1.22)	1.15 (1-1.3)	0.29		
W	Corpus and Uterus, NOS	ANLL	79	1.13 (0.9-1.41)	48	1.41 (1.04-1.87)	35	1.71 (1.2-2.38)	1 (ref)	1.2 (0.95-1.45)	1.44 (1.14-1.74)	0.09		
W	Corpus and Uterus, NOS	Colon and Rectum	1290	1.15 (1.09-1.21)	555	1.31 (1.2-1.42)	284	1.44 (1.27-1.61)	1 (ref)	1.14 (1.07-1.21)	1.29 (1.2-1.37)	1.2E-04		
W	Corpus and Uterus, NOS	Lung and Bronchus	842	0.74 (0.7-0.8)	398	0.68 (0.61-0.75)	242	0.72 (0.63-0.81)	1 (ref)	0.93 (0.86-0.99)	0.85 (0.79-0.91)	0.03		
W	Corpus and Uterus, NOS	Oral Cavity and Pharynx	114	0.88 (0.73-1.06)	53	0.91 (0.69-1.19)	29	0.8 (0.54-1.15)	1 (ref)	0.97 (0.78-1.16)	0.93 (0.75-1.12)	0.71		
W	Corpus and Uterus, NOS	Urinary Bladder	375	1.55 (1.4-1.72)	153	1.36 (1.15-1.59)	73	1.2 (0.94-1.51)	1 (ref)	0.94 (0.83-1.06)	0.88 (0.77-0.99)	0.29		
W	Female Breast	ANLL	253	1.38 (1.22-1.57)	211	1.35 (1.17-1.54)	169	1.71 (1.46-1.98)	1 (ref)	1.07 (0.95-1.18)	1.13 (1.01-1.25)	0.28		
W	Female Breast	Colon and Rectum	2612	0.94 (0.9-0.97)	1853	0.95 (0.91-1)	983	0.99 (0.93-1.06)	1 (ref)	1 (0.97-1.04)	1 (0.97-1.04)	0.95		
W	Female Breast	Corpus and Uterus, NOS	1481	1.21 (1.15-1.28)	1557	1.46 (1.39-1.53)	859	1.15 (1.07-1.23)	1 (ref)	0.95 (0.91-0.99)	0.9 (0.86-0.94)	0.01		
W	Female Breast	Lung and Bronchus	3053	0.99 (0.96-1.03)	2958	1.1 (1.06-1.14)	1843	1.14 (1.09-1.19)	1 (ref)	1.1 (1.07-1.14)	1.21 (1.17-1.25)	8.7E-09		
W	Female Breast	Oral Cavity and Pharynx	348	1.01 (0.91-1.13)	325	1.18 (1.06-1.32)	255	1.44 (1.27-1.62)	1 (ref)	1.2 (1.09-1.3)	1.42 (1.3-1.55)	8.3E-05		
W	Female Breast	Urinary Bladder	725	1.17 (1.09-1.26)	538	1.06 (0.97-1.16)	325	1.12 (1-1.24)	1 (ref)	0.98 (0.92-1.05)	0.96 (0.9-1.03)	0.56		
M	Hodgkin Lymphoma	ANLL	36	9.84 (6.89-13.6)	12	5.37 (2.78-9.37)	9	6.77 (3.1-12.85)	1 (ref)	0.53 (0.34-0.72)	0.28 (0.18-0.38)	6.3E-04		
T	Hodgkin Lymphoma	ANLL	56	9.66 (7.3-12.54)	17	4.68 (2.73-7.49)	14	6.52 (3.57-10.94)	1 (ref)	0.53 (0.37-0.69)	0.28 (0.2-0.37)	4.1E-05		
W	Hodgkin Lymphoma	ANLL	20	9.36 (5.72-14.5)	5	3.58 (1.16-8.34)	5	6.12 (1.99-14.26)	1 (ref)	0.55 (0.25-0.84)	0.3 (0.14-0.46)	0.03		
M	Hodgkin Lymphoma	Colon and Rectum	63	1.48 (1.14-1.89)	33	1.41 (0.97-1.98)	10	0.85 (0.41-1.55)	1 (ref)	0.88 (0.62-1.14)	0.77 (0.54-1)	0.39		
T	Hodgkin Lymphoma	Colon and Rectum	117	1.72 (1.43-2.07)	64	1.65 (1.27-2.11)	16	0.82 (0.47-1.33)	1 (ref)	0.86 (0.67-1.06)	0.74 (0.58-0.91)	0.19		
W	Hodgkin Lymphoma	Colon and Rectum	54	2.15 (1.61-2.8)	31	2.02 (1.38-2.87)	6	0.77 (0.29-1.68)	1 (ref)	0.85 (0.56-1.13)	0.71 (0.47-0.95)	0.32		
W	Hodgkin Lymphoma	Corpus and Uterus, NOS	33	1.59 (1.1-2.23)	18	1.4 (0.83-2.22)	5	0.75 (0.25-1.75)	1 (ref)	0.67 (0.39-0.96)	0.45 (0.26-0.64)	0.06		
M	Hodgkin Lymphoma	Lung and Bronchus	218	3.66 (3.19-4.18)	71	2.35 (1.84-2.97)	31	2.08 (1.41-2.94)	1 (ref)	0.85 (0.7-1.01)	0.73 (0.59-0.86)	0.09		
T	Hodgkin Lymphoma	Lung and Bronchus	335	3.68 (3.3-4.1)	144	2.9 (2.45-3.41)	43	1.7 (1.23-2.29)	1 (ref)	0.81 (0.69-0.93)	0.65 (0.56-0.75)	3.4E-03		

Sex	First primary cancer	Subsequent primary cancer	1975-1999, SIR		1990-1999, SIR		2000-2011, SIR		1975-1989, RR (ref)	1990-1999, RR (95% CI)	2000-2011, RR (95% CI)	P _{trend} ^a
			Obs.	(95% CI)	Obs.	(95% CI)	Obs.	(95% CI)				
W	Hodgkin Lymphoma	Lung and Bronchus	117	3.72 (3.08-4.46)	73	3.74 (2.94-4.71)	12	1.16 (0.6-2.03)	1 (ref)	0.73 (0.57-0.9)	0.54 (0.41-0.66)	7.1E-03
M	Hodgkin Lymphoma	Oral Cavity and Pharynx	28	1.69 (1.13-2.45)	23	2.47 (1.57-3.71)	9	1.71 (0.78-3.24)	1 (ref)	1.02 (0.65-1.39)	1.04 (0.66-1.41)	0.93
T	Hodgkin Lymphoma	Oral Cavity and Pharynx	51	2.41 (1.8-3.17)	34	2.79 (1.94-3.9)	17	2.5 (1.46-4)	1 (ref)	1 (0.72-1.29)	1 (0.72-1.29)	1.00
W	Hodgkin Lymphoma	Oral Cavity and Pharynx	23	4.97 (3.15-7.46)	11	3.83 (1.91-6.85)	8	5.19 (2.25-10.23)	1 (ref)	0.97 (0.54-1.41)	0.94 (0.52-1.37)	0.89
M	Hodgkin Lymphoma	Urinary Bladder	31	1.16 (0.79-1.65)	24	1.54 (0.99-2.28)	10	1.2 (0.58-2.2)	1 (ref)	1.07 (0.67-1.46)	1.13 (0.72-1.55)	0.75
T	Hodgkin Lymphoma	Urinary Bladder	39	1.21 (0.86-1.65)	31	1.63 (1.11-2.31)	15	1.47 (0.82-2.42)	1 (ref)	1.16 (0.79-1.53)	1.33 (0.91-1.76)	0.39
W	Hodgkin Lymphoma	Urinary Bladder	8	1.41 (0.61-2.78)	7	2.04 (0.83-4.21)	5	2.7 (0.88-6.3)	1 (ref)	1.49 (0.5-2.48)	2.21 (0.74-3.68)	0.25
M	Kidney and Renal Pelvis	ANLL	14	0.98 (0.54-1.64)	14	1.07 (0.59-1.79)	12	0.89 (0.46-1.55)	1 (ref)	1.06 (0.61-1.52)	1.12 (0.64-1.6)	0.80
T	Kidney and Renal Pelvis	ANLL	18	0.91 (0.54-1.44)	19	1.03 (0.62-1.61)	22	1.16 (0.73-1.76)	1 (ref)	1.22 (0.79-1.65)	1.47 (0.95-2)	0.29
W	Kidney and Renal Pelvis	ANLL	4	0.73 (0.2-1.86)	5	0.94 (0.31-2.18)	10	1.84 (0.88-3.38)	1 (ref)	1.62 (0.56-2.69)	2.63 (0.9-4.36)	0.15
M	Kidney and Renal Pelvis	Colon and Rectum	179	0.99 (0.85-1.14)	107	0.81 (0.66-0.98)	93	0.89 (0.72-1.09)	1 (ref)	0.87 (0.75-0.98)	0.75 (0.65-0.85)	0.03
T	Kidney and Renal Pelvis	Colon and Rectum	272	1.01 (0.9-1.14)	190	0.95 (0.82-1.09)	151	0.95 (0.81-1.11)	1 (ref)	0.92 (0.83-1.02)	0.85 (0.76-0.94)	0.11
W	Kidney and Renal Pelvis	Colon and Rectum	93	1.07 (0.86-1.31)	83	1.21 (0.96-1.5)	58	1.07 (0.82-1.39)	1 (ref)	1.03 (0.85-1.21)	1.06 (0.88-1.24)	0.76
W	Kidney and Renal Pelvis	Corpus and Uterus, NOS	36	1 (0.7-1.38)	27	0.77 (0.51-1.12)	43	1.13 (0.82-1.51)	1 (ref)	1.06 (0.8-1.33)	1.12 (0.84-1.41)	0.66
M	Kidney and Renal Pelvis	Lung and Bronchus	300	1.17 (1.04-1.31)	223	1.09 (0.95-1.24)	195	1.11 (0.96-1.27)	1 (ref)	0.96 (0.86-1.05)	0.91 (0.82-1)	0.31
T	Kidney and Renal Pelvis	Lung and Bronchus	406	1.17 (1.06-1.29)	332	1.12 (1-1.24)	336	1.27 (1.14-1.41)	1 (ref)	1.01 (0.93-1.09)	1.02 (0.94-1.11)	0.81
W	Kidney and Renal Pelvis	Lung and Bronchus	106	1.17 (0.96-1.41)	109	1.18 (0.97-1.42)	141	1.59 (1.34-1.88)	1 (ref)	1.15 (0.98-1.31)	1.31 (1.12-1.5)	0.07
M	Kidney and Renal Pelvis	Oral Cavity and Pharynx	31	0.78 (0.53-1.1)	26	0.74 (0.48-1.08)	39	1 (0.71-1.37)	1 (ref)	1.18 (0.87-1.49)	1.38 (1.02-1.75)	0.23
T	Kidney and Renal Pelvis	Oral Cavity and Pharynx	40	0.8 (0.57-1.08)	43	0.97 (0.7-1.3)	51	1.06 (0.79-1.39)	1 (ref)	1.2 (0.93-1.46)	1.42 (1.1-1.74)	0.13
W	Kidney and Renal Pelvis	Oral Cavity and Pharynx	9	0.88 (0.4-1.66)	17	1.84 (1.07-2.94)	12	1.28 (0.67-2.24)	1 (ref)	1.22 (0.7-1.75)	1.49 (0.84-2.13)	0.37
M	Kidney and Renal Pelvis	Urinary Bladder	128	1.08 (0.9-1.28)	129	1.19 (0.99-1.41)	141	1.41 (1.19-1.66)	1 (ref)	1.06 (0.92-1.19)	1.11 (0.97-1.25)	0.46
T	Kidney and Renal Pelvis	Urinary Bladder	152	1.11 (0.94-1.29)	154	1.22 (1.04-1.43)	164	1.41 (1.21-1.65)	1 (ref)	1.02 (0.9-1.15)	1.04 (0.92-1.17)	0.76
W	Kidney and Renal Pelvis	Urinary Bladder	24	1.28 (0.82-1.91)	25	1.43 (0.93-2.11)	23	1.43 (0.91-2.14)	1 (ref)	0.87 (0.61-1.12)	0.75 (0.53-0.97)	0.33
M	Larynx	ANLL	16	1.06 (0.61-1.71)	12	1.59 (0.82-2.77)	6	1.4 (0.52-3.05)	1 (ref)	1.19 (0.65-1.74)	1.41 (0.77-2.06)	0.46
T	Larynx	ANLL	19	1.12 (0.68-1.75)	13	1.51 (0.81-2.58)	9	1.87 (0.86-3.55)	1 (ref)	1.29 (0.76-1.81)	1.65 (0.98-2.33)	0.23
W	Larynx	ANLL	3	1.68 (0.35-4.89)	1	0.97 (0.03-5.39)	3	5.61 (1.16-16.39)	1 (ref)	1.77 (0.08-3.45)	3.12 (0.15-6.08)	0.24
M	Larynx	Colon and Rectum	214	1.06 (0.93-1.21)	111	1.4 (1.15-1.68)	39	1.18 (0.84-1.61)	1 (ref)	1.09 (0.93-1.25)	1.18 (1.01-1.36)	0.28
T	Larynx	Colon and Rectum	245	1.06 (0.93-1.2)	133	1.43 (1.2-1.69)	53	1.38 (1.03-1.8)	1 (ref)	1.16 (1.01-1.32)	1.35 (1.17-1.53)	0.03
W	Larynx	Colon and Rectum	31	1.05 (0.72-1.49)	22	1.61 (1.01-2.43)	14	2.61 (1.43-4.38)	1 (ref)	1.63 (1.1-2.17)	2.66 (1.78-3.54)	3.8E-03
W	Larynx	Corpus and Uterus, NOS	14	1.07 (0.59-1.79)	5	0.72 (0.24-1.67)	2	0.5 (0.07-1.8)	1 (ref)	0.63 (0.22-1.05)	0.4 (0.14-0.66)	0.17
M	Larynx	Lung and Bronchus	797	2.78 (2.59-2.98)	444	3.58 (3.26-3.93)	243	4.21 (3.69-4.77)	1 (ref)	1.22 (1.14-1.3)	1.48 (1.38-1.58)	4.5E-08
T	Larynx	Lung and Bronchus	990	3.1 (2.91-3.3)	570	3.98 (3.66-4.33)	343	5.12 (4.6-5.7)	1 (ref)	1.24 (1.16-1.31)	1.52 (1.43-1.62)	2.6E-11
W	Larynx	Lung and Bronchus	193	5.96 (5.15-6.86)	126	6.63 (5.52-7.89)	100	10.93 (8.89-13.3)	1 (ref)	1.3 (1.13-1.47)	1.69 (1.47-1.91)	9.1E-05
M	Larynx	Oral Cavity and Pharynx	230	5.37 (4.7-6.11)	136	7 (5.88-8.28)	102	8.75 (7.14-10.6)	1 (ref)	1.32 (1.16-1.47)	1.73 (1.53-1.94)	5.5E-06
T	Larynx	Oral Cavity and Pharynx	274	5.9 (5.22-6.64)	160	7.53 (6.41-8.79)	132	10.49 (8.77-12.4)	1 (ref)	1.36 (1.22-1.51)	1.85 (1.65-2.05)	1.9E-08
W	Larynx	Oral Cavity and Pharynx	44	12.1 (8.76-16.2)	24	13.2 (8.45-19.6)	30	32.2 (21.73-46.0)	1 (ref)	1.61 (1.2-2.02)	2.57 (1.91-3.23)	3.2E-04
M	Larynx	Urinary Bladder	170	1.35 (1.15-1.56)	90	1.42 (1.14-1.75)	61	1.89 (1.45-2.43)	1 (ref)	1.15 (0.97-1.32)	1.31 (1.11-1.51)	0.08
T	Larynx	Urinary Bladder	177	1.34 (1.15-1.55)	92	1.38 (1.11-1.69)	65	1.92 (1.48-2.44)	1 (ref)	1.15 (0.98-1.33)	1.33 (1.13-1.52)	0.07
W	Larynx	Urinary Bladder	7	1.13 (0.46-2.32)	2	0.59 (0.08-2.1)	4	2.49 (0.68-6.37)	1 (ref)	1.31 (0.33-2.29)	1.72 (0.44-3)	0.48
M	Lung and Bronchus	ANLL	26	1.47 (0.96-2.15)	16	1.33 (0.76-2.16)	22	2.2 (1.38-3.32)	1 (ref)	1.21 (0.83-1.6)	1.47 (1-1.93)	0.24
T	Lung and Bronchus	ANLL	40	1.53 (1.09-2.08)	26	1.28 (0.84-1.87)	44	2.51 (1.83-3.37)	1 (ref)	1.24 (0.93-1.54)	1.52 (1.15-1.89)	0.10
W	Lung and Bronchus	ANLL	14	1.64 (0.9-2.75)	10	1.21 (0.58-2.22)	22	2.93 (1.84-4.43)	1 (ref)	1.26 (0.77-1.76)	1.59 (0.96-2.21)	0.26

Sex	First primary cancer	Subsequent primary cancer	1975-1999, SIR (95% CI)		1990-1999, SIR (95% CI)		2000-2011, SIR (95% CI)		1975-1989, RR (ref)	1990-1999, RR (95% CI)	2000-2011, RR (95% CI)	P _{trend} ^a
			1975-1999, Obs.	1975-1999, SIR (95% CI)	1990-1999, Obs.	1990-1999, SIR (95% CI)	2000-2011, Obs.	2000-2011, SIR (95% CI)				
M	Lung and Bronchus	Colon and Rectum	277	1.14 (1.01-1.28)	181	1.41 (1.21-1.63)	103	1.36 (1.11-1.65)	1 (ref)	1.13 (1.01-1.26)	1.28 (1.14-1.42)	0.03
T	Lung and Bronchus	Colon and Rectum	447	1.17 (1.06-1.28)	335	1.4 (1.26-1.56)	189	1.26 (1.09-1.45)	1 (ref)	1.09 (1-1.18)	1.19 (1.09-1.29)	0.05
W	Lung and Bronchus	Colon and Rectum	170	1.21 (1.04-1.41)	154	1.4 (1.19-1.64)	86	1.16 (0.93-1.43)	1 (ref)	1.04 (0.91-1.18)	1.08 (0.94-1.22)	0.59
W	Lung and Bronchus	Corpus and Uterus, NOS	40	0.67 (0.48-0.91)	28	0.55 (0.37-0.79)	29	0.61 (0.41-0.88)	1 (ref)	0.96 (0.71-1.21)	0.93 (0.69-1.17)	0.76
M	Lung and Bronchus	Oral Cavity and Pharynx	94	1.82 (1.47-2.23)	66	2.19 (1.69-2.78)	51	2.06 (1.53-2.7)	1 (ref)	1 (0.83-1.17)	1 (0.83-1.16)	0.95
T	Lung and Bronchus	Oral Cavity and Pharynx	128	1.87 (1.56-2.22)	100	2.26 (1.84-2.74)	75	2.02 (1.59-2.53)	1 (ref)	0.99 (0.85-1.13)	0.98 (0.84-1.12)	0.86
W	Lung and Bronchus	Oral Cavity and Pharynx	34	2.03 (1.4-2.83)	34	2.4 (1.66-3.35)	24	1.93 (1.24-2.87)	1 (ref)	0.99 (0.73-1.25)	0.98 (0.72-1.24)	0.92
M	Lung and Bronchus	Urinary Bladder	202	1.39 (1.21-1.6)	161	1.6 (1.36-1.87)	127	1.68 (1.4-2)	1 (ref)	1.14 (1.01-1.27)	1.29 (1.14-1.44)	0.04
T	Lung and Bronchus	Urinary Bladder	265	1.52 (1.34-1.71)	216	1.68 (1.46-1.92)	178	1.8 (1.55-2.09)	1 (ref)	1.09 (0.98-1.2)	1.19 (1.07-1.31)	0.10
W	Lung and Bronchus	Urinary Bladder	63	2.13 (1.64-2.73)	55	1.97 (1.49-2.57)	51	2.22 (1.66-2.92)	1 (ref)	0.96 (0.77-1.15)	0.92 (0.74-1.1)	0.66
M	Melanoma of the Skin	ANLL	25	0.78 (0.5-1.14)	31	1.04 (0.71-1.47)	17	0.69 (0.41-1.11)	1 (ref)	1.07 (0.71-1.44)	1.15 (0.76-1.53)	0.70
T	Melanoma of the Skin	ANLL	43	0.8 (0.58-1.08)	37	0.83 (0.58-1.14)	29	0.82 (0.55-1.17)	1 (ref)	1 (0.73-1.27)	1 (0.73-1.27)	0.98
W	Melanoma of the Skin	ANLL	18	0.84 (0.5-1.32)	6	0.41 (0.15-0.88)	12	1.1 (0.57-1.92)	1 (ref)	0.91 (0.5-1.31)	0.82 (0.45-1.19)	0.66
M	Melanoma of the Skin	Colon and Rectum	273	0.75 (0.67-0.84)	230	0.82 (0.72-0.93)	138	0.76 (0.64-0.9)	1 (ref)	0.93 (0.83-1.02)	0.85 (0.76-0.94)	0.13
T	Melanoma of the Skin	Colon and Rectum	500	0.77 (0.71-0.84)	366	0.81 (0.73-0.9)	228	0.8 (0.7-0.91)	1 (ref)	0.96 (0.88-1.04)	0.92 (0.84-0.99)	0.29
W	Melanoma of the Skin	Colon and Rectum	227	0.8 (0.7-0.91)	136	0.8 (0.67-0.95)	90	0.87 (0.7-1.06)	1 (ref)	1.02 (0.88-1.15)	1.03 (0.9-1.17)	0.85
W	Melanoma of the Skin	Corpus and Uterus, NOS	123	0.73 (0.61-0.87)	99	0.83 (0.68-1.01)	68	0.77 (0.6-0.98)	1 (ref)	1.02 (0.85-1.19)	1.03 (0.86-1.2)	0.88
M	Melanoma of the Skin	Lung and Bronchus	357	0.67 (0.61-0.75)	264	0.61 (0.54-0.69)	196	0.65 (0.57-0.75)	1 (ref)	0.93 (0.84-1.02)	0.86 (0.77-0.94)	0.10
T	Melanoma of the Skin	Lung and Bronchus	653	0.73 (0.67-0.79)	480	0.71 (0.65-0.77)	321	0.69 (0.61-0.77)	1 (ref)	0.93 (0.86-1)	0.86 (0.8-0.93)	0.04
W	Melanoma of the Skin	Lung and Bronchus	296	0.81 (0.72-0.9)	216	0.87 (0.76-1)	125	0.75 (0.62-0.89)	1 (ref)	0.94 (0.83-1.05)	0.88 (0.78-0.98)	0.26
M	Melanoma of the Skin	Oral Cavity and Pharynx	74	0.77 (0.61-0.97)	64	0.73 (0.57-0.93)	61	0.84 (0.64-1.08)	1 (ref)	1.03 (0.83-1.23)	1.06 (0.86-1.27)	0.78
T	Melanoma of the Skin	Oral Cavity and Pharynx	121	0.87 (0.73-1.04)	94	0.81 (0.66-1)	85	0.91 (0.73-1.13)	1 (ref)	1.06 (0.89-1.23)	1.11 (0.93-1.29)	0.53
W	Melanoma of the Skin	Oral Cavity and Pharynx	47	1.11 (0.82-1.48)	30	1.07 (0.72-1.52)	24	1.17 (0.75-1.74)	1 (ref)	1.11 (0.79-1.42)	1.22 (0.88-1.57)	0.50
M	Melanoma of the Skin	Urinary Bladder	226	0.83 (0.73-0.95)	201	0.81 (0.7-0.93)	154	0.82 (0.69-0.96)	1 (ref)	0.93 (0.82-1.04)	0.86 (0.76-0.96)	0.20
T	Melanoma of the Skin	Urinary Bladder	277	0.81 (0.72-0.91)	254	0.86 (0.76-0.97)	184	0.84 (0.72-0.97)	1 (ref)	0.97 (0.87-1.07)	0.93 (0.83-1.03)	0.48
W	Melanoma of the Skin	Urinary Bladder	51	0.73 (0.54-0.96)	53	1.15 (0.86-1.5)	30	0.97 (0.65-1.38)	1 (ref)	1.15 (0.87-1.43)	1.31 (0.99-1.63)	0.29
M	Non-Hodgkin Lymphoma	ANLL	40	1.91 (1.37-2.6)	84	3.9 (3.11-4.82)	112	4.76 (3.92-5.73)	1 (ref)	1.57 (1.28-1.85)	2.45 (2-2.9)	1.6E-06
T	Non-Hodgkin Lymphoma	ANLL	69	2.02 (1.57-2.56)	136	3.91 (3.28-4.63)	161	4.44 (3.78-5.18)	1 (ref)	1.41 (1.21-1.61)	1.99 (1.71-2.27)	2.2E-06
W	Non-Hodgkin Lymphoma	ANLL	29	2.19 (1.47-3.14)	52	3.94 (2.94-5.16)	49	3.84 (2.84-5.07)	1 (ref)	1.18 (0.92-1.45)	1.4 (1.08-1.71)	0.15
M	Non-Hodgkin Lymphoma	Colon and Rectum	262	0.98 (0.87-1.11)	206	0.95 (0.83-1.09)	163	0.92 (0.79-1.08)	1 (ref)	0.99 (0.89-1.1)	0.98 (0.88-1.08)	0.84
T	Non-Hodgkin Lymphoma	Colon and Rectum	537	1.12 (1.03-1.22)	399	1.04 (0.94-1.14)	303	1 (0.89-1.12)	1 (ref)	0.95 (0.88-1.02)	0.9 (0.83-0.96)	0.14
W	Non-Hodgkin Lymphoma	Colon and Rectum	275	1.29 (1.14-1.45)	193	1.14 (0.99-1.32)	140	1.11 (0.93-1.31)	1 (ref)	0.91 (0.81-1)	0.82 (0.73-0.9)	0.06
W	Non-Hodgkin Lymphoma	Corpus and Uterus, NOS	91	1.03 (0.83-1.26)	72	0.86 (0.68-1.08)	85	1.02 (0.82-1.27)	1 (ref)	1.01 (0.84-1.17)	1.01 (0.85-1.17)	0.98
M	Non-Hodgkin Lymphoma	Lung and Bronchus	490	1.32 (1.21-1.44)	375	1.14 (1.03-1.27)	382	1.29 (1.16-1.42)	1 (ref)	0.97 (0.9-1.04)	0.94 (0.87-1)	0.34
T	Non-Hodgkin Lymphoma	Lung and Bronchus	812	1.39 (1.29-1.49)	711	1.29 (1.2-1.39)	702	1.4 (1.3-1.51)	1 (ref)	1 (0.94-1.05)	0.99 (0.93-1.04)	0.73
W	Non-Hodgkin Lymphoma	Lung and Bronchus	322	1.5 (1.35-1.68)	336	1.5 (1.34-1.67)	320	1.57 (1.4-1.75)	1 (ref)	1.03 (0.95-1.12)	1.06 (0.97-1.15)	0.53
M	Non-Hodgkin Lymphoma	Oral Cavity and Pharynx	114	1.86 (1.54-2.24)	91	1.53 (1.24-1.88)	81	1.26 (1-1.57)	1 (ref)	0.9 (0.76-1.04)	0.8 (0.68-0.93)	0.15
T	Non-Hodgkin Lymphoma	Oral Cavity and Pharynx	154	1.79 (1.52-2.09)	135	1.65 (1.38-1.95)	115	1.34 (1.11-1.61)	1 (ref)	0.95 (0.82-1.07)	0.89 (0.78-1.01)	0.36
W	Non-Hodgkin Lymphoma	Oral Cavity and Pharynx	40	1.6 (1.15-2.18)	44	1.94 (1.41-2.6)	34	1.58 (1.1-2.21)	1 (ref)	1.08 (0.82-1.34)	1.16 (0.88-1.44)	0.56
M	Non-Hodgkin Lymphoma	Urinary Bladder	236	1.36 (1.19-1.54)	216	1.21 (1.05-1.38)	198	1.12 (0.97-1.28)	1 (ref)	0.99 (0.88-1.09)	0.97 (0.87-1.07)	0.75
T	Non-Hodgkin Lymphoma	Urinary Bladder	328	1.5 (1.34-1.67)	259	1.17 (1.03-1.32)	247	1.14 (1.01-1.29)	1 (ref)	0.94 (0.85-1.03)	0.88 (0.8-0.96)	0.15
W	Non-Hodgkin Lymphoma	Urinary Bladder	92	2.04 (1.65-2.5)	43	0.99 (0.72-1.34)	49	1.27 (0.94-1.68)	1 (ref)	0.79 (0.63-0.94)	0.62 (0.5-0.74)	0.02

Sex	First primary cancer	Subsequent primary cancer	1975-1999, SIR		1990-1999, SIR		2000-2011, SIR		1975-1989, RR (ref)	1990-1999, RR (95% CI)	2000-2011, RR (95% CI)	P _{trend} ^a
			Obs.	(95% CI)	Obs.	(95% CI)	Obs.	(95% CI)				
M	Oral Cavity and Pharynx	ANLL	18	0.85 (0.51-1.35)	10	0.8 (0.39-1.46)	11	1.13 (0.57-2.02)	1 (ref)	1.06 (0.63-1.48)	1.11 (0.67-1.56)	0.81
T	Oral Cavity and Pharynx	ANLL	24	0.86 (0.55-1.27)	13	0.78 (0.42-1.32)	17	1.36 (0.79-2.17)	1 (ref)	1.13 (0.75-1.52)	1.28 (0.84-1.71)	0.49
W	Oral Cavity and Pharynx	ANLL	6	0.86 (0.32-1.86)	3	0.71 (0.15-2.07)	6	2.16 (0.79-4.69)	1 (ref)	1.35 (0.49-2.21)	1.81 (0.65-2.97)	0.37
M	Oral Cavity and Pharynx	Colon and Rectum	284	1.03 (0.92-1.16)	151	1.17 (0.99-1.37)	79	1.01 (0.8-1.25)	1 (ref)	0.98 (0.86-1.09)	0.95 (0.84-1.06)	0.64
T	Oral Cavity and Pharynx	Colon and Rectum	412	1.07 (0.97-1.17)	209	1.14 (0.99-1.31)	108	1.02 (0.83-1.23)	1 (ref)	0.97 (0.87-1.07)	0.94 (0.84-1.03)	0.48
W	Oral Cavity and Pharynx	Colon and Rectum	128	1.15 (0.96-1.36)	58	1.07 (0.81-1.38)	29	1.04 (0.7-1.49)	1 (ref)	0.95 (0.77-1.14)	0.9 (0.73-1.08)	0.59
W	Oral Cavity and Pharynx	Corpus and Uterus, NOS	24	0.49 (0.32-0.73)	28	0.97 (0.64-1.39)	15	0.72 (0.41-1.19)	1 (ref)	1.18 (0.82-1.55)	1.4 (0.97-1.82)	0.29
M	Oral Cavity and Pharynx	Lung and Bronchus	906	2.36 (2.21-2.52)	448	2.28 (2.07-2.5)	332	2.59 (2.32-2.89)	1 (ref)	0.98 (0.92-1.04)	0.95 (0.89-1.01)	0.40
T	Oral Cavity and Pharynx	Lung and Bronchus	1250	2.49 (2.36-2.64)	665	2.46 (2.28-2.66)	463	2.68 (2.45-2.94)	1 (ref)	0.96 (0.91-1.01)	0.91 (0.86-0.96)	0.07
W	Oral Cavity and Pharynx	Lung and Bronchus	344	2.93 (2.63-3.25)	217	2.98 (2.59-3.4)	131	2.95 (2.46-3.49)	1 (ref)	0.9 (0.81-0.99)	0.8 (0.72-0.88)	0.03
M	Oral Cavity and Pharynx	Urinary Bladder	173	0.98 (0.84-1.14)	108	1.04 (0.86-1.26)	86	1.19 (0.95-1.47)	1 (ref)	1.06 (0.92-1.2)	1.12 (0.97-1.27)	0.44
T	Oral Cavity and Pharynx	Urinary Bladder	194	0.97 (0.84-1.12)	124	1.06 (0.88-1.26)	95	1.18 (0.96-1.45)	1 (ref)	1.06 (0.92-1.19)	1.11 (0.97-1.25)	0.44
W	Oral Cavity and Pharynx	Urinary Bladder	21	0.89 (0.55-1.36)	16	1.18 (0.68-1.92)	9	1.12 (0.51-2.11)	1 (ref)	1.02 (0.63-1.41)	1.04 (0.64-1.43)	0.94
W	Ovary	ANLL	43	3.51 (2.54-4.73)	15	2.28 (1.28-3.75)	19	4.86 (2.93-7.58)	1 (ref)	0.82 (0.58-1.06)	0.67 (0.47-0.87)	0.18
W	Ovary	Colon and Rectum	270	1.51 (1.34-1.7)	104	1.3 (1.07-1.58)	44	1.14 (0.83-1.52)	1 (ref)	0.89 (0.76-1.02)	0.79 (0.67-0.91)	0.12
W	Ovary	Lung and Bronchus	237	1.12 (0.99-1.28)	111	0.98 (0.8-1.18)	55	0.88 (0.66-1.14)	1 (ref)	0.87 (0.74-1)	0.76 (0.65-0.87)	0.06
W	Ovary	Oral Cavity and Pharynx	21	0.88 (0.54-1.34)	11	0.91 (0.45-1.62)	12	1.64 (0.85-2.85)	1 (ref)	1.15 (0.7-1.6)	1.32 (0.81-1.83)	0.50
W	Ovary	Urinary Bladder	66	1.63 (1.26-2.07)	26	1.26 (0.82-1.84)	15	1.35 (0.76-2.22)	1 (ref)	1.02 (0.71-1.32)	1.03 (0.72-1.33)	0.94
M	Prostate	ANLL	131	0.95 (0.79-1.13)	361	1.04 (0.94-1.15)	262	0.94 (0.83-1.06)	1 (ref)	0.98 (0.88-1.08)	0.95 (0.85-1.05)	0.59
M	Prostate	Colon and Rectum	1640	0.89 (0.84-0.93)	3108	0.9 (0.87-0.94)	1827	0.89 (0.85-0.93)	1 (ref)	1.01 (0.98-1.04)	1.02 (0.98-1.05)	0.74
M	Prostate	Lung and Bronchus	1884	0.82 (0.78-0.86)	4247	0.81 (0.79-0.84)	3198	0.87 (0.84-0.9)	1 (ref)	1.05 (1.02-1.08)	1.09 (1.06-1.12)	0.01
M	Prostate	Oral Cavity and Pharynx	243	0.79 (0.69-0.89)	545	0.77 (0.71-0.84)	518	0.8 (0.73-0.87)	1 (ref)	1.01 (0.93-1.08)	1.01 (0.93-1.09)	0.96
M	Prostate	Urinary Bladder	1144	1.01 (0.96-1.07)	3077	1.06 (1.02-1.09)	2326	1.1 (1.06-1.15)	1 (ref)	1.06 (1.02-1.1)	1.12 (1.08-1.16)	3.9E-03
M	Testis	ANLL	24	2.42 (1.55-3.59)	9	1.89 (0.87-3.58)	6	2.9 (1.07-6.3)	1 (ref)	0.85 (0.43-1.26)	0.71 (0.36-1.06)	0.49
M	Testis	Colon and Rectum	108	1.03 (0.84-1.24)	55	1.09 (0.83-1.42)	35	1.66 (1.16-2.31)	1 (ref)	1.4 (1.09-1.71)	1.95 (1.52-2.38)	3.3E-03
M	Testis	Lung and Bronchus	156	1.06 (0.9-1.24)	54	0.96 (0.72-1.25)	34	1.79 (1.24-2.49)	1 (ref)	1.23 (0.98-1.48)	1.51 (1.19-1.82)	0.06
M	Testis	Oral Cavity and Pharynx	44	0.97 (0.71-1.3)	10	0.41 (0.2-0.75)	8	0.76 (0.33-1.5)	1 (ref)	0.67 (0.39-0.96)	0.45 (0.26-0.64)	0.07
M	Testis	Urinary Bladder	129	1.76 (1.47-2.09)	40	1.32 (0.94-1.79)	20	1.85 (1.13-2.85)	1 (ref)	1 (0.75-1.25)	1 (0.75-1.25)	0.98
M	Thyroid	ANLL	5	0.67 (0.22-1.55)	4	0.83 (0.23-2.11)	8	1.8 (0.78-3.54)	1 (ref)	1.47 (0.41-2.52)	2.15 (0.6-3.69)	0.30
T	Thyroid	ANLL	11	0.49 (0.25-0.88)	14	1 (0.55-1.67)	34	2.63 (1.82-3.67)	1 (ref)	2.82 (1.56-4.07)	7.92 (4.38-11.5)	5.6E-06
W	Thyroid	ANLL	6	0.4 (0.15-0.88)	10	1.09 (0.53-2)	26	3.06 (2-4.48)	1 (ref)	3.83 (1.69-5.97)	14.6 (6.44-22.8)	2.7E-06
M	Thyroid	Colon and Rectum	76	0.89 (0.7-1.11)	50	1.04 (0.77-1.36)	37	1 (0.7-1.37)	1 (ref)	1.02 (0.8-1.23)	1.03 (0.8-1.25)	0.93
T	Thyroid	Colon and Rectum	238	0.86 (0.75-0.98)	143	0.94 (0.79-1.11)	109	0.9 (0.74-1.09)	1 (ref)	0.94 (0.83-1.06)	0.89 (0.78-1)	0.33
W	Thyroid	Colon and Rectum	162	0.85 (0.72-0.99)	93	0.9 (0.73-1.1)	72	0.86 (0.67-1.08)	1 (ref)	0.91 (0.77-1.04)	0.82 (0.69-0.94)	0.18
W	Thyroid	Corpus and Uterus, NOS	109	0.87 (0.71-1.04)	85	1.02 (0.81-1.26)	78	0.97 (0.77-1.21)	1 (ref)	1 (0.83-1.17)	0.99 (0.82-1.16)	0.94
M	Thyroid	Lung and Bronchus	91	0.73 (0.59-0.89)	68	0.95 (0.74-1.21)	44	0.79 (0.58-1.06)	1 (ref)	1.02 (0.82-1.22)	1.04 (0.84-1.24)	0.86
T	Thyroid	Lung and Bronchus	292	0.77 (0.69-0.87)	200	0.92 (0.8-1.06)	159	0.88 (0.75-1.03)	1 (ref)	1.06 (0.94-1.18)	1.12 (0.99-1.25)	0.35
W	Thyroid	Lung and Bronchus	201	0.8 (0.69-0.91)	132	0.9 (0.76-1.07)	115	0.93 (0.76-1.11)	1 (ref)	1.09 (0.94-1.24)	1.18 (1.01-1.34)	0.27
M	Thyroid	Oral Cavity and Pharynx	24	0.94 (0.6-1.4)	13	0.77 (0.41-1.31)	9	0.57 (0.26-1.07)	1 (ref)	0.81 (0.47-1.16)	0.66 (0.38-0.94)	0.33
T	Thyroid	Oral Cavity and Pharynx	44	0.79 (0.57-1.06)	33	0.93 (0.64-1.31)	31	0.93 (0.64-1.32)	1 (ref)	1.04 (0.76-1.31)	1.07 (0.79-1.35)	0.81
W	Thyroid	Oral Cavity and Pharynx	20	0.66 (0.4-1.02)	20	1.08 (0.66-1.67)	22	1.27 (0.8-1.93)	1 (ref)	1.22 (0.8-1.64)	1.48 (0.96-1.99)	0.28
M	Thyroid	Urinary Bladder	47	0.79 (0.58-1.05)	24	0.64 (0.41-0.95)	44	1.4 (1.02-1.88)	1 (ref)	1.17 (0.86-1.48)	1.36 (1-1.72)	0.26

Sex	First primary cancer	Subsequent primary cancer	1975-1999, Obs.	1975-1999, SIR (95% CI)	1990-1999, Obs.	1990-1999, SIR (95% CI)	2000-2011, Obs.	2000-2011, SIR (95% CI)	1975-1989, RR (ref)	1990-1999, RR (95% CI)	2000-2011, RR (95% CI)	P_{trend}^a
T	Thyroid	Urinary Bladder	68	0.65 (0.51-0.83)	46	0.73 (0.54-0.98)	65	1.23 (0.95-1.57)	1 (ref)	1.25 (0.98-1.52)	1.55 (1.22-1.88)	0.04
W	Thyroid	Urinary Bladder	21	0.47 (0.29-0.71)	22	0.87 (0.55-1.31)	21	0.98 (0.61-1.5)	1 (ref)	1.42 (0.91-1.94)	2.02 (1.29-2.75)	0.06
M	Urinary Bladder	ANLL	76	1.26 (0.99-1.57)	52	1.15 (0.86-1.51)	30	0.92 (0.62-1.32)	1 (ref)	0.83 (0.66-1.01)	0.69 (0.55-0.83)	0.08
T	Urinary Bladder	ANLL	89	1.22 (0.98-1.5)	60	1.12 (0.85-1.44)	37	0.96 (0.68-1.32)	1 (ref)	0.84 (0.68-1)	0.71 (0.57-0.84)	0.07
W	Urinary Bladder	ANLL	13	1.04 (0.56-1.78)	8	0.92 (0.4-1.81)	7	1.16 (0.47-2.38)	1 (ref)	0.91 (0.47-1.35)	0.83 (0.43-1.23)	0.69
M	Urinary Bladder	Colon and Rectum	781	1.01 (0.94-1.09)	406	0.92 (0.83-1.01)	217	0.94 (0.82-1.07)	1 (ref)	0.95 (0.88-1.02)	0.89 (0.83-0.96)	0.11
T	Urinary Bladder	Colon and Rectum	971	1 (0.93-1.06)	491	0.88 (0.81-0.97)	282	0.97 (0.86-1.09)	1 (ref)	0.96 (0.9-1.02)	0.92 (0.86-0.98)	0.18
W	Urinary Bladder	Colon and Rectum	190	0.93 (0.8-1.07)	85	0.75 (0.6-0.93)	65	1.08 (0.84-1.38)	1 (ref)	1.02 (0.87-1.17)	1.04 (0.89-1.19)	0.82
W	Urinary Bladder	Corpus and Uterus, NOS	62	0.82 (0.63-1.05)	36	0.74 (0.52-1.02)	29	0.84 (0.56-1.2)	1 (ref)	1.02 (0.78-1.26)	1.03 (0.8-1.27)	0.90
M	Urinary Bladder	Lung and Bronchus	1616	1.56 (1.49-1.64)	1169	1.74 (1.65-1.85)	738	1.83 (1.7-1.97)	1 (ref)	1.08 (1.03-1.13)	1.16 (1.11-1.21)	1.3E-03
T	Urinary Bladder	Lung and Bronchus	2036	1.66 (1.59-1.73)	1527	1.87 (1.78-1.96)	945	1.89 (1.77-2.01)	1 (ref)	1.07 (1.02-1.11)	1.13 (1.08-1.17)	3.7E-03
W	Urinary Bladder	Lung and Bronchus	420	2.17 (1.97-2.39)	358	2.44 (2.2-2.71)	207	2.13 (1.85-2.44)	1 (ref)	1.01 (0.93-1.1)	1.02 (0.93-1.11)	0.85
M	Urinary Bladder	Oral Cavity and Pharynx	145	0.94 (0.79-1.1)	89	0.87 (0.7-1.07)	76	1.01 (0.79-1.26)	1 (ref)	1.02 (0.87-1.17)	1.04 (0.89-1.19)	0.83
T	Urinary Bladder	Oral Cavity and Pharynx	169	0.95 (0.82-1.11)	103	0.88 (0.72-1.07)	89	1.04 (0.84-1.28)	1 (ref)	1.03 (0.89-1.17)	1.05 (0.91-1.19)	0.74
W	Urinary Bladder	Oral Cavity and Pharynx	24	1.07 (0.69-1.59)	14	0.98 (0.54-1.64)	13	1.33 (0.71-2.28)	1 (ref)	1.08 (0.68-1.47)	1.15 (0.73-1.57)	0.71

Abbreviations: ANLL, acute non-lymphocytic leukemia; M, Men; Obs. Observed number of subsequent primary cancers; RR, ratio of SIR, SIR, standardized incidence ratio; Women, W; T, Total

^a P_{trend} in the SIRs were tested using the likelihood ratio test for the linear diagnosis year term in a multivariate Poisson regression model. The model included the observed number of cases as an outcome, calendar year of (1975-1989 [reference], 1990-1999, 2000-2011), age at (20-39, 40-64, 66-84 years), and time since first cancer diagnosis (60-119, 120-179, 180+ months) and sex as covariables, and the log of the expected number of cases as an offset to indirectly adjust for attained age and attained year of SPCs.

eTable 11. Results based on a single outcome analysis for the risk of developing subsequent primary cancer overall among 5-year cancer survivors in 12 SEER registries

	Survivors		Observed number of SPCs		Incidence per 10,000 person-years	Expected number of SPCs	SIR	(95% CI)	Mean age at FPCs	Mean age at SPCs	Mean person-years
	N	%	N	%							
Men	732888 ^a	100	76880	100							
Larynx	8194	1.1	1715	2.2	335	2770	1.62	(1.54 to 1.7)	62.2	72.2	6.2
Hodgkin Lymphoma	7043	1.0	548	0.7	89	817	1.49	(1.37 to 1.63)	39.7	60.0	8.8
Kaposi Sarcoma	3823	0.5	355	0.5	106	509	1.44	(1.29 to 1.6)	43.1	57.0	8.8
Esophagus	2501	0.3	332	0.4	255	431	1.30	(1.17 to 1.45)	62.5	71.8	5.2
Pancreas	1554	0.2	148	0.2	213	186	1.26	(1.07 to 1.48)	59.7	70.9	4.5
Oral Cavity and Pharynx	20841	2.8	2566	3.3	192	3184	1.24	(1.2 to 1.29)	57.0	69.6	6.4
Gallbladder and Other Biliary	934	0.1	113	0.1	223	133	1.18	(0.98 to 1.42)	62.3	71.6	5.4
Lung and Bronchus	18189	2.5	1839	2.4	206	2093	1.14	(1.09 to 1.2)	63.9	73.2	4.9
Breast	1704	0.2	239	0.3	233	272	1.14	(1 to 1.3)	62.8	74.1	6.0
Penis and Other Genital Organs	1453	0.2	199	0.3	212	225	1.13	(0.99 to 1.31)	60.9	72.7	6.5
Non Hodgkin-Lymphoma	41119	5.6	4488	5.8	173	4977	1.11	(1.08 to 1.15)	58.6	71.3	6.3
Thyroid	11790	1.6	1049	1.4	117	1151	1.10	(1.04 to 1.17)	49.2	66.4	7.6
Acute Non-Lymphocytic Leukemia	1838	0.3	134	0.2	101	146	1.09	(0.92 to 1.3)	47.1	65.4	7.2
Stomach	5650	0.8	632	0.8	193	660	1.04	(0.97 to 1.13)	62.8	73.4	5.8
Eye and Orbit	1538	0.2	182	0.2	169	189	1.04	(0.9 to 1.21)	57.5	73.2	7.0
Soft Tissue including Heart	4815	0.7	468	0.6	131	483	1.03	(0.95 to 1.14)	52.2	69.8	7.4
Urinary Bladder	44604	6.1	5992	7.8	208	6190	1.03	(1.01 to 1.06)	65.2	75.3	6.5
Kidney and Renal Pelvis	22881	3.1	2427	3.2	173	2490	1.03	(0.99 to 1.07)	58.9	71.4	6.1
Bones and Joints	1338	0.2	96	0.1	87	97	1.02	(0.83 to 1.24)	43.9	63.6	8.3
Small Intestine	2522	0.3	250	0.3	169	251	1.00	(0.89 to 1.14)	58.5	70.5	5.9
Testis	17490	2.4	726	0.9	42	721	0.99	(0.93 to 1.07)	35.7	56.8	9.8
Anus, Anal Canal and Anorectum	1818	0.2	185	0.2	153	184	0.99	(0.86 to 1.15)	55.4	67.9	6.7
Brain and Other Nervous System	4690	0.6	210	0.3	64	204	0.97	(0.85 to 1.12)	41.8	60.2	7.0
Myeloma	6293	0.9	461	0.6	171	438	0.95	(0.87 to 1.05)	60.9	70.0	4.3
Colon and Rectum	67061	9.2	7619	9.9	175	7109	0.93	(0.92 to 0.96)	62.9	74.5	6.5
Liver and Intrahepatic Bile Duct	3394	0.5	186	0.2	125	167	0.90	(0.78 to 1.04)	58.7	67.8	4.4
Melanoma of the Skin	41813	5.7	3959	5.1	125	3468	0.88	(0.85 to 0.91)	55.6	70.7	7.6
Prostate	373395	50.9	38403	50.0	151	32527	0.85	(0.84 to 0.86)	66.3	77.2	6.8

	Survivors		Observed number of SPCs		Incidence per 10,000 person-years	Expected number of SPCs	SIR	(95% CI)	Mean age at FPCs	Mean age at SPCs	Mean person-years
	N	%	N	%							
Women	704809 ^a	100	51325	100							
Larynx	1896	0.3	376	0.7	316	888	2.36	(2.13 to 2.62)	60.8	70.8	6.3
Esophagus	783	0.1	105	0.2	256	186	1.77	(1.45 to 2.15)	65.0	72.7	5.2
Hodgkin Lymphoma	6113	0.9	499	1.0	89	860	1.72	(1.58 to 1.89)	38.2	56.7	9.1
Anus, Anal Canal and Anorectum	2879	0.4	323	0.6	172	438	1.36	(1.22 to 1.52)	59.6	69.7	6.5
Pancreas	1593	0.2	124	0.2	153	167	1.35	(1.13 to 1.61)	59.5	69.7	5.1
Oral Cavity and Pharynx	9959	1.4	954	1.9	140	1198	1.26	(1.18 to 1.34)	57.5	70.4	6.8
Gallbladder and Other Biliary	1248	0.2	122	0.2	163	143	1.17	(0.98 to 1.41)	64.4	74.2	6.0
Small Intestine	2354	0.3	200	0.4	145	229	1.15	(1 to 1.32)	60.2	72.1	5.9
Urinary Bladder	14505	2.1	1626	3.2	167	1863	1.15	(1.1 to 1.21)	66.1	75.1	6.7
Liver and Intrahepatic Bile Duct	1387	0.2	79	0.2	124	90	1.14	(0.9 to 1.42)	60.1	68.8	4.6
Vagina and Other Genital Organs	5616	0.8	512	1.0	131	577	1.13	(1.04 to 1.23)	58.5	70.7	7.0
Acute Non-Lymphocytic Leukemia	1813	0.3	121	0.2	87	136	1.13	(0.94 to 1.35)	46.7	64.6	7.7
Non Hodgkin-Lymphoma	35268	5.0	3102	6.0	136	3484	1.12	(1.09 to 1.17)	61.2	72.4	6.5
Eye and Orbit	1305	0.2	119	0.2	129	130	1.09	(0.91 to 1.31)	57.6	69.9	7.1
Lung and Bronchus	21591	3.1	1478	2.9	132	1596	1.08	(1.03 to 1.14)	64.6	73.6	5.2
Ovary	16851	2.4	1169	2.3	100	1240	1.06	(1.01 to 1.13)	55.0	68.4	7.0
Kidney and Renal Pelvis	14692	2.1	1236	2.4	132	1310	1.06	(1.01 to 1.13)	60.2	71.7	6.4
Cervix Uteri	19486	2.8	1420	2.8	79	1487	1.05	(1 to 1.11)	46.1	63.3	9.2
Thyroid	42107	6.0	2483	4.8	75	2580	1.04	(1 to 1.08)	46.1	62.9	7.9
Soft Tissue including Heart	4036	0.6	313	0.6	100	325	1.04	(0.93 to 1.16)	52.4	67.9	7.8
Kaposi Sarcoma	162	0.0	12	0.0	124	12	1.00	(0.52 to 1.76)	63.6	71.1	6.0
Breast	314057	44.6	20506	40.0	87	20178	0.98	(0.98 to 1)	58.6	71.9	7.5
Colon and Rectum	63393	9.0	5144	10.0	123	4979	0.97	(0.95 to 1)	64.8	74.8	6.6
Corpus and Uterus, NOS	59246	8.4	5152	10.0	115	4936	0.96	(0.94 to 0.99)	60.2	72.3	7.6
Myeloma	5311	0.8	276	0.5	123	264	0.96	(0.85 to 1.08)	62.9	71.1	4.2
Brain and Other Nervous System	4023	0.6	178	0.3	60	169	0.95	(0.82 to 1.1)	42.6	59.3	7.3
Stomach	4227	0.6	287	0.6	114	259	0.90	(0.81 to 1.02)	63.7	75.1	6.0
Melanoma of the Skin	38110	5.4	2559	5.0	82	2298	0.90	(0.87 to 0.94)	50.8	67.1	8.2
Bones and Joints	1207	0.2	66	0.1	63	54	0.82	(0.64 to 1.05)	45.4	66.4	8.6

eTable 12. Results based on the earlier start of follow-up (since 1 year from first primary cancer diagnosis) for the risk of developing subsequent primary cancer overall among 1-year cancer survivors in 12 SEER registries

	Survivors		Observed number of SPCs		Incidence per 10,000 person-years	Expected number of SPCs	SIR	(95% CI)	Mean age at FPCs	Mean age at SPCs	Follow-up years since 1 year from first primary cancer	
	N	%	N	%							Total	Mean
Men	1066026	100.0	153260	100.0								
Kaposi Sarcoma	7348	0.7	785	0.5	142	375	2.10	(1.96 to 2.25)	41.8	53.0	55183	7.5
Larynx	14000	1.3	3884	2.5	371	2139	1.82	(1.76 to 1.88)	63.3	71.1	104747	7.5
Hodgkin Lymphoma	8398	0.8	931	0.6	97	580	1.61	(1.51 to 1.72)	41.2	60.7	96134	11.4
Oral Cavity and Pharynx	34788	3.3	5989	3.9	227	4047	1.48	(1.45 to 1.52)	58.9	68.6	263573	7.6
Miscellaneous	7654	0.7	1106	0.7	234	830	1.33	(1.26 to 1.42)	62.2	70.5	47351	6.2
Gallbladder and Other Biliary	3034	0.3	306	0.2	252	230	1.33	(1.19 to 1.49)	64.8	71.5	12143	4.0
Esophagus	8335	0.8	792	0.5	247	622	1.27	(1.19 to 1.37)	63.8	70.9	32021	3.8
Other Leukemia	8327	0.8	943	0.6	149	775	1.22	(1.14 to 1.3)	54.2	68.3	63436	7.6
Anus, Anal Canal and Anorectum	2990	0.3	402	0.3	177	335	1.20	(1.09 to 1.33)	56.6	67.3	22667	7.6
Other Male Genital Organs	2175	0.2	414	0.3	227	347	1.19	(1.09 to 1.32)	62.8	72.4	18251	8.4
Non-Hodgkin Lymphoma	60281	5.7	9448	6.2	190	7980	1.18	(1.16 to 1.21)	60.7	71.2	497059	8.2
Thyroid	13494	1.3	1886	1.2	125	1593	1.18	(1.14 to 1.24)	50.7	66.6	150447	11.1
Eye and Orbit	2209	0.2	383	0.2	195	323	1.18	(1.07 to 1.31)	59.6	71.6	19603	8.9
Other Digestive Organs	1243	0.1	127	0.1	165	107	1.18	(0.99 to 1.41)	58.0	66.9	7678	6.2
Kidney and Renal Pelvis	34479	3.2	5679	3.7	199	4809	1.18	(1.15 to 1.22)	60.7	70.7	285978	8.3
Lung and Bronchus	67627	6.3	5170	3.4	213	4411	1.17	(1.14 to 1.21)	65.9	72.3	242626	3.6
Urinary Bladder	67822	6.4	13907	9.1	238	11907	1.17	(1.15 to 1.19)	67.1	74.5	583599	8.6
Acute Non-Lymphocytic Leukemia	4294	0.4	274	0.2	114	236	1.16	(1.03 to 1.31)	53.7	65.9	24140	5.6
Small Intestine	3938	0.4	582	0.4	195	503	1.16	(1.07 to 1.26)	60.3	70.1	29869	7.6
Breast	2463	0.2	488	0.3	234	428	1.14	(1.05 to 1.25)	64.1	73.1	20821	8.5
Pancreas	7827	0.7	379	0.2	190	337	1.12	(1.02 to 1.25)	63.0	70.6	19941	2.5
Soft Tissue including Heart	7272	0.7	929	0.6	146	832	1.12	(1.05 to 1.2)	53.7	69.6	63468	8.7
Stomach	14193	1.3	1425	0.9	200	1319	1.08	(1.03 to 1.14)	64.1	72.4	71076	5.0
Testis	18904	1.8	1019	0.7	40	951	1.07	(1.01 to 1.14)	35.8	56.3	252557	13.4
Brain and Other Nervous System	10697	1.0	412	0.3	69	389	1.06	(0.96 to 1.17)	48.0	60.6	59739	5.6
Bones and Joints	1965	0.2	166	0.1	91	158	1.05	(0.9 to 1.23)	45.5	63.3	18263	9.3
Liver and Intrahepatic Bile Duct	10566	1.0	546	0.4	139	545	1.00	(0.92 to 1.09)	60.9	66.6	39365	3.7
Colon and Rectum	111330	10.4	15937	10.4	183	16098	0.99	(0.98 to 1.01)	64.3	73.7	868841	7.8
Melanoma of the Skin	54264	5.1	7959	5.2	140	8265	0.96	(0.95 to 0.99)	57.5	71.0	567561	10.5
Myeloma	13653	1.3	1195	0.8	174	1262	0.95	(0.9 to 1.01)	64.0	70.7	68525	5.0
Prostate	453527	42.5	68935	45.0	156	74929	0.92	(0.92 to 0.93)	67.2	76.0	4416994	9.7

	Survivors		Observed number of SPCs		Incidence per 10,000 person-years	Expected number of SPCs	SIR	(95% CI)	Mean age at FPCs	Mean age at SPCs	Follow-up years since 1 year from first primary cancer	
	N	%	N	%							Total	Mean
Women	990909	100.0	96125	100.0								
Larynx	3220	0.3	796	0.8	334	309	2.58	(2.41 to 2.77)	62.3	69.5	23846	7.4
Esophagus	2388	0.2	241	0.3	250	136	1.77	(1.56 to 2.01)	66.8	70.8	9627	4.0
Hodgkin Lymphoma	7008	0.7	748	0.8	88	427	1.75	(1.63 to 1.89)	39.9	57.4	85213	12.2
Oral Cavity and Pharynx	15186	1.5	2095	2.2	166	1409	1.49	(1.43 to 1.56)	60.0	69.5	126304	8.3
Anus, Anal Canal and Anorectum	4127	0.4	578	0.6	167	421	1.37	(1.27 to 1.49)	60.8	68.9	34602	8.4
Urinary Bladder	20211	2.0	3277	3.4	182	2605	1.26	(1.22 to 1.31)	67.6	74.5	180130	8.9
Gallbladder and Other Biliary	3702	0.4	268	0.3	167	217	1.24	(1.1 to 1.4)	66.2	72.7	16075	4.3
Kaposi Sarcoma	260	0.0	29	0.0	158	24	1.23	(0.83 to 1.77)	62.9	71.5	1837	7.1
Kidney and Renal Pelvis	20355	2.1	2626	2.7	149	2152	1.22	(1.18 to 1.27)	61.9	71.1	176810	8.7
Vagina and Other Genital Organs	8419	0.8	1017	1.1	141	835	1.22	(1.15 to 1.3)	60.9	69.8	71887	8.5
Non-Hodgkin Lymphoma	48121	4.9	6019	6.3	144	5049	1.19	(1.17 to 1.23)	63.0	72.0	418358	8.7
Cervix Uteri	26962	2.7	2374	2.5	85	1993	1.19	(1.15 to 1.24)	48.1	62.5	280045	10.4
Other Leukemia	5150	0.5	417	0.4	110	354	1.18	(1.07 to 1.3)	55.4	66.3	37959	7.4
Liver and Intrahepatic Bile Duct	4280	0.4	203	0.2	126	175	1.16	(1.01 to 1.34)	63.7	68.5	16095	3.8
Pancreas	7682	0.8	279	0.3	135	241	1.16	(1.03 to 1.31)	64.9	70.1	20727	2.7
Acute Non-Lymphocytic Leukemia	3669	0.4	209	0.2	87	181	1.16	(1.01 to 1.33)	52.4	64.4	23927	6.5
Eye and Orbit	1772	0.2	222	0.2	135	193	1.15	(1.01 to 1.32)	59.7	69.7	16500	9.3
Lung and Bronchus	64543	6.5	3746	3.9	136	3280	1.14	(1.11 to 1.18)	66.3	72.5	274482	4.3
Small Intestine	3470	0.4	377	0.4	141	330	1.14	(1.03 to 1.27)	61.8	70.5	26766	7.7
Soft Tissue including Heart	5762	0.6	565	0.6	106	505	1.12	(1.03 to 1.22)	54.3	67.1	53287	9.2
Thyroid	45600	4.6	4037	4.2	76	3621	1.12	(1.09 to 1.15)	46.8	62.8	529731	11.6
Ovary	32863	3.3	2218	2.3	98	2075	1.07	(1.03 to 1.12)	58.4	66.7	227119	6.9
Breast	392959	39.7	36668	38.1	90	34495	1.06	(1.06 to 1.08)	59.3	70.9	4085949	10.4
Corpus and Uterus, NOS	75508	7.6	9191	9.6	120	8728	1.05	(1.04 to 1.08)	61.3	71.1	767038	10.2
Colon and Rectum	98690	10.0	10292	10.7	130	9821	1.05	(1.03 to 1.07)	65.9	73.8	792524	8.0
Stomach	8992	0.9	661	0.7	130	634	1.04	(0.97 to 1.13)	64.6	73.3	51021	5.7
Myeloma	11404	1.2	726	0.8	129	727	1.00	(0.93 to 1.08)	65.9	71.0	56264	4.9
Melanoma of the Skin	44660	4.5	4565	4.7	89	4574	1.00	(0.97 to 1.03)	52.3	67.5	515156	11.5
Bones and Joints	1605	0.2	116	0.1	71	121	0.96	(0.8 to 1.15)	46.8	62.9	16450	10.2
Brain and Other Nervous System	8102	0.8	287	0.3	55	316	0.91	(0.81 to 1.02)	48.6	59.1	51860	6.4

References

1. Overview of the SEER Program <https://seer.cancer.gov/about/>.
2. Appendix D, Race And Nationality Descriptions From the 2000 U.S. Census Bureau and National Center for Health Statistics (https://seer.cancer.gov/...als/2018/SPCSM_2018_AppendixD.pdf-129K). .
3. SEER Program Coding and Staging Manual 2018 (https://seer.cancer.gov/manuals/2018/SPCSM_2018_maindoc.pdf - 1.4M).
4. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 13 Registries (excl AK), Nov 2019 Sub (1992-2017) - Linked To County Attributes - Total U.S., 1969-2018 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission. Accessed June 1, 2020-Oct 16, 2020.
5. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 13 Registries (excl AK), Nov 2019 Sub (1992-2017) for SMRs - Linked To County Attributes - Total U.S., 1969-2018 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission. Accessed June 1, 2020-Aug 25, 2020.
6. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. eds. SEER Cancer Statistics Review, 1975-2017. https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020. Bethesda, MD: National Cancer Institute; 2020.
7. Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. *Blood*. 2010;116(20):e90-98.
8. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 9 Registries, Nov 2019 Sub (1975-2017) - Linked To County Attributes - Total U.S., 1969-2018 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission. Accessed June 1, 2020-Aug 25, 2020.
9. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). *New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000*. National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD, 2006.
10. Johnson CH, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards BK. *The 2007 Multiple Primary and Histology Coding Rules*. National Cancer Institute, Surveillance, Epidemiology and End Results Program. Bethesda, MD, 2007.
11. UNSCEAR. AnnexA: Epidemiological Studies of Radiation and Cancer. Vol I. New York, NY: United Nations; 2006. Report of the United Nations Scientific Committee on the Effects of Atomic Radiation. UNSCEAR 2006 report.
12. National Center for Health Statistics. National Vital Statistics System. 2020, <https://www.cdc.gov/nchs/nvss/deaths.htm>.
13. U.S. Department of Health and Human Services. *Smoking Cessation. A Report of the Surgeon General*. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2020.
14. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer--Viewpoint of the IARC Working Group. *The New England journal of medicine*. 2016;375(8):794-798.

15. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Alcoholic drinks and the risk of cancer. Available at dietandcancerreport.org. Accessed on Oct 10, 2020.
16. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens--Part B: biological agents. *Lancet Oncol*. 2009;10(4):321-322.
17. Yasui Y, Liu Y, Neglia JP, et al. A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. *Am J Epidemiol*. 2003;158(11):1108-1113.
18. Rostgaard K. Methods for stratification of person-time and events - a prerequisite for Poisson regression and SIR estimation. *Epidemiol Perspect Innov*. 2008;5:7.
19. Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 8.3.6.